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Materials and Methods 
All chemicals used in this project were from Sigma (UK) unless otherwise stated. 
The pictures were created using Coot (Emsley and Cowtan, 2004), Procheck 







Glycosyltransferases (GTs) are an enzyme superfamily responsible for the synthesis 
of glyconjugates by transferring the sugar moiety from an active donor to a specific 
acceptor, usually a protein or a polysaccharide. The glyconjugates, such as 
glycolipids and glycoproteins, play vital roles in physical maintenance of tissue 
structures, immune recognition and other biological activities. Understanding their 
catalytic mechanisms is therefore critical. There are two kinds of reaction defined 
based on the stereochemistry of the product carbohydrate moiety compared to the 
donor: retaining and inverting. Whilst the mechanism of inverting GTs is well-
known, the catalytic process of retaining GTs is as yet unclear. 
Glycosyltransferase family 6 (GT6), according to the Carbohydrate Active Enzyme 
(CAZy) database, is a retaining GT family which catalyses the transfer of α-
galactose (α-Gal) or α-N-acetyl-galactosamine (α-GalNAc) to the 3-OH group of a 
β-linked Gal or GalNAc in an acceptor substrate. Most GT6s from vertebrates 
require a metal ion for their activity. The metal ion-dependence is linked to the 
AspXaaAsp (DXD) motif which is conserved among these enzymes. However, 
analysing sequences of GT6s from bacteria showed that the DXD motif was 
substituted by an AsnXaaAsn (NXN) sequence. One of two CAZy family 6 
glycosyltransferases, BoGT6a from Bacteroides ovatus, which catalyses the transfer 
of GalNAc from UDP-GalNAc to the saccharide acceptor and UDP-GalNAc 
hydrolysis, was kinetically and structurally studied. This enzyme is fully active in 
the absence of metal ions. The structure of BoGT6a is strikingly similar to its 
mammalian homologues such as GTA, GTB and α-1,3-galactosyltransferase, but it 
has a shorter N-terminal region and a NXN motif instead of a DXD motif. This 
suggests that the substitution of the DXD motif with the NXN may affect the 
catalytic mechanism of the enzyme. 
The structure of the enzyme in complex with its acceptor molecule 2’-fucosyllactose 
was obtained at 3.0 Å. Comparison of the X-ray crystallographic structures of 
BoGT6a in its native and acceptor bound forms demonstrated the conformational 
changes of the enzyme associated with acceptor binding. It also elucidated the 
impact of acceptor binding on enzyme conformation and the structural relationship 




Structural snapshots of the BoGT6a Glu192Gln (E192Q) mutant processing its 
donor UDP-GalNAc were also obtained. The interactions between the enzyme and 
the donor provide an insight into the mechanistic role of the NXN motif and nearby 
amino acid residues in BoGT6a’s metal-independent activity. Moreover, the high 
flexibility of the enzyme conformation when it interacts with the ligands provides a 
general picture of how the enzyme processes UDP-GalNAc. 
Together, these structures illustrate how a significant divergence in catalytic 
properties can be accommodated by minor structural adjustments, and propose a role 
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1.1 Protein crystallography 
Structural biology has developed dramatically since the first protein structure was 
solved at 6 Å resolution (Kendrew et al., 1958). There are now a wide range of 
techniques such as X-ray crystallography, Nuclear magnetic resonance (NMR) 
spectroscopy, and electron microscopy (EM) available to scientists. The knowledge 
of accurate molecular structures enriches our understanding of the fundamentals of 
biochemistry, such as reaction mechanisms. It is also a prerequisite for structure 
based functional studies which assist in the development of effective therapeutic 
agents and drugs.  
X-ray crystallography is the most conventional and common technique in 
determination of protein structures. More than 89 % of structures deposited in the 
protein data bank (PDB) (Berman et al., 2000) have been solved using this technique 
(May 2014). 
The wavelength of X-rays, 1-2 Å, is comparable to the carbon-carbon (C-C) bond 
length, 1.5 Å, making them a powerful tool for providing atomic information about 
protein structures. X-rays are diffracted off the many identical and regularly ordered 
protein molecules in a crystal, and the X-ray diffraction data is processed by 
computer to generate maps of electron density. Crystallographers can interpret the 
protein structure from these. A drawback of crystallography is that crystallisation is a 
difficult and time-consuming process. Nonetheless, this technique has become more 
powerful due to both improved software and hardware.  
A standard crystallography process begins with protein production, including 
expression and purification. Once a sufficient quantity of high quality protein has 
been obtained, crystallisation can be performed either manually or automatically by 
usage of robots. This is the most crucial step because without a crystal there is, of 
course, no crystallography. A good quality crystal will give high resolution 
diffraction data, using either an in-house X-ray source or the synchrotron source. The 
diffraction data can then be processed by various specialised programs to derive the 
structure of the protein. An outline of this process is given in Figure 1. 





Figure 1. A general process of protein structure determination by using 
crystallography. The protein we are interested in is expressed in its required form with a 
high yield. It is then purified to be sufficiently homogenous and pure for crystallisation. 
Crystallisation may be performed robotically or manually. Diffraction data of the target 
crystals may be collected using an in-house X-ray source, or the synchrotron source. The 
final result, which is the structure of the target protein, is achieved by data processing on 
computers. 
1.1.1 Preparation of protein 
The first step of the protein structure determination process is producing an adequate 
supply of pure protein (Figure 1). Limited protein sources, which were mainly 
isolated directly from the original hosts, proved a barrier to crystallisation; this was 
particularly challenging for human proteins. However, once recombinant DNA 
technology had been applied to protein production, it became significantly easier to 
produce the necessary quantities of pure protein. The protein structure database has 
grown rapidly, and there were 100326 available structures in PDB at the time when 
the thesis was written (May, 2014). 
Applications of various expression systems enable researchers to obtain their target 
proteins either from prokaryotes or eukaryotes. Each system has its own advantages 




and disadvantages, which are summarised in table 1. Escherichia coli still remains 
the most popular expression system used in crystallography because of their low-
cost, short life cycle, high yield and ease of genetic manipulations.  
A commonly used E. coli strain in laboratories is BL21 (λDE3) Codon plus RIL/RP. 
This strain contains the T7-RNA polymerase promoter for faster protein translation, 
disabled lon and ompT proteases for new protein protection, and argU, ileY, leuW 
and proL tRNA genes which recognise some rare codons such as AGG, AGA, AUA, 
CUA and CCC (Terpe, 2006, Kane, 1995). Proteins expressed in E. coli are 
occasionally in inclusion bodies, which are frequently incorrectly folded and 
aggregated. Hence insolubly expressed proteins first need to be solubilised, refolded, 
purified, concentrated and buffer exchanged to be homogeneous, pure, soluble, and 
stable at a high concentration before the crystallisation process.  
Many purification techniques can be applied depending on the target protein’s 
characteristics, such as affinity chromatography, size exclusion chromatography (or 
gel filtration), ion exchange chromatography, and hydrophobic interaction 
chromatography. 
Affinity chromatography (AC) is the most varied and dominant chromatographic 
method for purification of a specific protein. It is based on highly specific biological 
interactions between two molecules, such as interactions between enzyme and 
substrate (such as between glutathione S-transferase and glutathione), receptor and 
ligand (such as between histidine-tagged proteins and metal ions), or antibody and 
antigen (such as antibodies binding to protein A or protein G). In a typical AC 
process, the sample is applied under conditions that favour specific binding to the 
ligand. Elution is performed specifically, using a competitive ligand, or non-
specifically, by changing the pH, ionic strength, or polarity. The high selectivity of 
AC enables many separations to be achieved with high purity in a single step. When 
higher purity is required, one or more additional purification steps may be required, 
such as size exclusion chromatography.  
 
 




Table 1. Advantages and drawbacks of protein expression systems (Sodoyer, 2004) 
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Size exclusion chromatography (SEC) is usually the last step in the purification 
process. It improves the purification result by separating protein samples based on 
molecular size. A crude protein sample is applied to a column of porous resin. 
Proteins of different size pass through the column at different rates. Larger 
molecules take a shorter route through the column and thus are released from the 
column earlier than smaller molecules which penetrate into the porous resin and so 
have a longer retention time. The resolution of SEC depends on the size of the pores 
in the resins and the length of the column. The resolution of SEC is greater with finer 
resins and longer columns.  
Generally, purification is a multistep process. Depending on the characteristics of the 
target protein and the impurities present, one or more of the methods listed above are 
carefully selected. These are then used in different combinations to maximise the 
purity of the target protein. The purity of the protein can be analysed using protein 
gel electrophoresis or modern techniques such as Dynamic Light Scattering and 
Mass Spectrometry.  
Dynamic Light Scattering (DLS) is a spectroscopic technique generally used to 
determine the size distribution of protein molecules in solution. It is also a good 
indicator for any contaminants or heterogeneity of the protein sample. Mass 
spectrometry (MS) is another powerful tool in protein crystallisation. It can be used 
for analysing the expression of recombinant protein, assessing the purity of a 
preparation, or checking for heavy atom derivatives (during the structure 
determination process). It also gives information on the nature of a protein construct, 
for example the mass, whether it is in complex with its substrate(s) or in its apo 
form, whether it is monomeric or oligomeric. (Cohen, 1996, Carte et al., 2000).  
When the final protein is homogeneous, active, pure and stable in a suitable buffer at 
the required concentration (5-20 mg/ml), it will be ready for crystallisation trials.  
1.1.2 Crystallisation  
The principles of crystal growth have been intensely investigated for many years and 
the theoretical and practical aspects of crystallisation of molecules such as salts or 
small organic compounds are well established nowadays. However, although the 




crystallisation of macromolecules such as protein, DNA and RNA is proving to be 
theoretically similar to small molecules, much work remains mainly based on trial 
experiments (McPherson, 1999). Three major stages of crystal formation are 
common to all systems; nucleation, growth, and cessation of growth.  
A classical explanation of crystal nuclei formation and growth can be illustrated by a 
phase diagram (Figure 2). The solubility curve divides the concentration space into 
two areas - the undersaturated and supersaturated zones (Russo Krauss et al., 2013). 
Each point on this curve corresponds to a concentration at which the solution is in 
equilibrium with the precipitating agent. In the soluble area, the solution is 
undersaturated and crystallisation will never take place. Above the solubility curve 
line is the supersaturation zone which is divided into three regions, namely 
metastable zone, labile zone and precipitation zone, based on the level of protein 
supersaturation.  
 
Figure 2. Crystallisation phase diagram. Schematic representation of a two-dimensional 
phase diagram illustrating the change of protein concentration against precipitating agent 
concentration. The concentration space is divided by the solubility curve into three areas 
corresponding to the unsaturated state, the saturated state (or metastable zone) and the 
supersaturated state of a protein solution. The supersaturated area comprises the labile zone 
and the precipitation zone (Russo Krauss et al., 2013). 




Crystal nuclei form and growth occurs in the labile zone in which protein 
concentration is just at intermediate supersaturation. The precipitation zone is where 
the protein concentration is so high that molecules immediately separate from the 
solution to form amorphous aggregates. The region of the labile zone near to the 
precipitation zone is where nucleus formation happens too fast, causing the 
formation of many microcrystals, sometimes they can be confused with precipitate. 
The last zone, the metastable zone, is where crystal growth is supported but nucleus 
formation cannot occur.  
Based on this diagram, the general strategy of crystallisation is bringing the protein 
gradually from the soluble zone to the labile zone in order to obtain a single nucleus 
or a few nuclei. During nucleus formation, the solution will return to the metastable 
region. No more nuclei occur and the existing ones grow to bigger crystals at a 
decreasing rate, helping to avoid defect formation, until equilibrium is reached. 
However, in practice, it is difficult to identify these ideal conditions because each 
protein behaves differently in different solutions and a single experimental parameter 
change can concurrently influence several aspects of a crystallisation experiment.  
Modern techniques have provided a clearer understanding of the crystallisation 
process. For example, atomic force microscopy (AFM) has proved a powerful tool in 
observing the general phenomenon of crystal growth (McPherson et al., 2003). 
However, these high-tech methods are expensive and only available in a few 
crystallography laboratories. Crystallisation is often considered the main hurdle of 
protein structure determination. Obtaining suitable single crystals is the least 
understood step in the X-ray structural analysis of a protein. Protein crystallisation is 
mainly a trial-and-error procedure in which the most general crystallisation strategy 
is to bring the protein to a point only slightly above its saturation point as slowly as 
possible. 
1.1.2.1 Crystallisation techniques 
There are many crystallisation techniques that have been developed based on the 
principle that protein solubility decreases gradually until reaching a solid phase 
(crystal). Conventional and popular methods that have been employed by 




crystallographers include batch, dialysis, vapour diffusion and free interface 
diffusion (FID). Although these methods differ, they all share the overarching aim of 
bringing the protein to the nucleation and metastable zone (Figure 3). Recently the 
gel crystallisation technique, already successfully applied to small molecules, has 
been developed for macromolecule crystallisation. The counter-diffusion in gel 
approach, introduced by Garcia-Ruiz (2003), appears particularly powerful as a 
method to produce many high quality crystals suitable for X-ray diffraction work.  
 
Figure 3. A simplified protein crystallisation phase diagram. The different routes of 
reaching nucleation and metastable zones for the four main crystallisation techniques 
(picture adapted from the review of Russo Krauss et al. (2013)). 
The most popular technique in crystallisation is vapour diffusion in which the 
protein is brought into the nucleation zone by slowly increasing both protein 
concentration and precipitant concentrations simultaneously (Figure 3). The increase 
is caused by water evaporation and diffusion from the droplet containing a mixture 
of protein and reservoir solution into the reservoir solution. This technique is widely 
used because it is easy to manipulate conditions and apply high-throughput 




screening, as well as optimisation of crystallisation conditions (Russo Krauss et al., 
2013). The technique consists of the hanging drop method, the sitting drop method 
and the sandwich drop method. Each method has different advantages and 
disadvantages, which are discussed below.  
The hanging drop method is a simple approach in which a 2-6 µl droplet of protein 
and reservoir solution is placed on a cover slip. The cover slip is inverted such that 
the drop is facing the reservoir solution in a well and the well is sealed with grease 
(Figure 4A). The equilibrium rate in this method is highest among three methods 
because of the large surface area of the drop exposed to the reservoir solution. This 
method is mainly used in the optimisation stage of crystallisation procedure. Its 
disadvantages are difficulty in automation and incapacity in working with large 
volumes of sample. These drawbacks are overcome by the other methods.  
The sitting drop method, in which the mixture of protein and reservoir solution is 
placed on a small bridge inside the well containing reservoir solution, can be used 
with a large volume of sample (Figure 4B). The biggest advantage of this method is 
that the whole procedure can be performed automatically by a robot, which is 
popular in all structural biology laboratories for crystallisation screening.  
The last method in this technique, the sandwich drop method, is less popular than the 
other two, but in some cases, when crystallographers need to slow down the 
equilibration process, this method is a good choice. Because the droplet is placed 
between two cover slips (Figure 4C), the surface area of the drop is reduced, leading 
to a slower water vapour diffusion rate from the drop to the reservoir solution and as 
a consequence, better protein crystals can sometimes be produced. 
 





Figure 4. Vapour-diffusion technique. (A) hanging drop method, (B) sitting drop method, 
and (C) sandwich drop method (Russo Krauss et al., 2013). 
1.1.2.2 Screening and optimizing crystallisation 
To obtain protein crystals, crystallographers generally go through two steps: (i) 
screening crystallisation conditions to identify which chemical, biochemical and 
physical conditions can produce some crystalline material, which is sometimes 
insufficient for diffraction data collection, and (ii) optimizing crystallisation based 
on the “hits” obtained from previous steps to achieve superior crystals which are 
suitable for diffraction data collection.  
1.1.2.2.1 Screening 
Protein crystallisation mainly relies on screening techniques with assistance from 
robots. Most of the robots commercially available nowadays are very practical for 
crystallisation condition screening purpose because they can handle nanolitre scale 
volumes of samples and eliminate human errors in repeating hundreds of 
experiments. Typical experiments when working with a robot involve setting up 96-
well plates, enabling the analysis of 96 conditions simultaneously.  To set up a 96 




well plate only ~20 µl of protein, depending on dropsize, is required and the protein 
concentration usually ranges from 1-20 mg/ml.  
The choice of which solution conditions to screen has been greatly simplified over 
the years. One source of solution conditions is The Biological Macromolecular 
Crystallisation Database, which is a free online collection of published successful 
crystallisation conditions for biological macromolecules 
(http://wwwbmcd.nist.gov:8080/bmcd/bmcd.html) (Gilliland et al., 1994). In 
practice, however, one of the many commercial screening kits is used, based on the 
sparse matrix approach first proposed by Jancarik & Kim (Jancarik and Kim, 1991). 
These cover most of the efficient precipitants and pH, as well as a variety of other 
useful solution conditions, and can be purchased in ready-to-use form (for example, 
see http://www.hamptonresearch.com).  
If crystals are not produced, the screens are usually moved to a cold room and 
allowed to re-equilibrate. Ultimately, if crystals still do not appear, the purity of the 
protein is often the first thing to be considered. Purification steps need to be 
improved to get a higher level of purity. The buffer used during protein purification 
can also be considered for protein activity, solubility and stability. One can also try 
to improve protein surface interactions by mutating one or more residues, which may 
make crystallisation more favourable. For example, surface lysine methylation 
(SLM), in which lysine residues are chemically methylated, can be used to improve 
the probability of protein crystallisation (Sledz et al., 2010).  
If crystals are produced during the screening trials, they can be used directly for X-
ray analysis if their quality meets requirements for diffraction data collection, or 
further optimisation is conducted to improve their size and diffraction quality. 
1.1.2.2.2 Optimisation 
Optimisation involves varying the chemical and physical parameters around those of 
the reagent mixture that yielded your crystals and searching crystallisation parameter 
space by small increments away from the starting point.  




During nucleation, if a high level of supersaturation occurs, then nuclei formation 
happens quickly. This leads to crystals of poor quality, such as being too small, of 
high mosaicity or having clusters of needles. In such cases, either reducing the level 
of supersaturation or seeding a metastable, supersaturated protein solution with 
crystals from earlier trials can be tried. There are two general seeding methods, 
namely micro seeding in which microcrystals are used as seeds, and macro seeding, 
in which a single crystal of a size 5-50 µm is used as a seed (Bergfors, 2003).  
One disadvantage of seeding with microcrystals is that the number of seeds is 
uncontrollable. It is possible that too many nuclei will be introduced into the fresh 
supersaturated solution and plenty of crystals may appear, but none of them may be 
suitable for X-ray diffraction analysis. In practice, microcrystals from a parent 
solution are serially diluted between 10-2 and 10-7 to obtain the optimum amount of 
nuclei (Bergfors, 2003). Once seeds are ready, micro seeds can be introduced into 
the new drop in many different ways, such as using a seeding wand which is dipped 
into the microcrystal diluted solution to take seeds and then touched, stirred, or 
streaked across the surface of the new drop.  
In macro seeding, crystals used as seeds should be large enough to be manipulated 
and transferred under a microscope. Like micro seeding, controlling the number of 
seeds is still a problem in this technique because there may be microcrystals 
adhering to the surface of the seed crystal. To avoid this, the macro seeds should be 
washed thoroughly by passing them through a sequence of intermediate transfer 
solutions. The washing step not only removes microcrystals but also improves the 
surface of the seed crystals and as consequence, new growth patterns may be induced 
when they are transferred to new protein solution (McPherson and Gavira, 2014). 
One important thing that should be considered is that the new solution must be 
supersaturated with respect to protein, but not extremely so, in order to ensure slow 
and ordered growth. It is usually recommended to start with the same condition of 
reservoir solution but lower protein concentration because protein concentration is 
linearly related to its solubility (Bergfors, 2003).  
Seeding is often a useful technique for initiating the growth of crystals or inducing 
nucleation and growth at a lower level of supersaturation than might otherwise 




spontaneously occur. This technique is also used with poor crystals of the target 
protein or even with oils and precipitates (Bergfors, 2003, Gavira et al., 2011) . In 
some cases, seeds can be heterogeneous or epitaxial nucleants, such as fibres, animal 
hairs, epoxide coatings, and nanoscale etched surfaces of graphite and silicon 
(McPherson, 1999). 
The final step, prior to the X-ray data collection, is to know how to manipulate or to 
prepare these crystals for a proper and successful data collection, either at a 
synchrotron or using an in-house X-ray source.  
1.1.2.3 Cryo protection and crystal mounting 
The traditional method of mounting crystals involves direct mounting in a fine glass 
capillary, which contains a droplet of the reservoir solution along with the crystal, 
onto the goniometer head. The advantage of this method is that the orientations of 
crystals are controlled and crystals do not dry out. However, the amount of mother 
liquor in the capillary can adversely affect crystal diffraction and handling the glass 
capillary need to be done with care and requires practice. Popular nowadays, due to 
its ease of manipulation, is the small loop which is large enough to maintain a thin 
layer of mother liquor around the crystal. With various sizes (50-200nm) and types 
(round loops or mesh loops) available, it is easy to find a loop suitable for the target 
protein crystal.  
Through many experiments, crystallographers found that very low temperatures can 
reduce radiation damage of crystals during the data collection process. Liquid 
nitrogen has been a good source for producing such low temperatures (100 Kelvin) 
for collection of crystal diffraction data. When performing experiments at this 
temperature, the formation of ice around the cooled crystal can reduce the order of 
crystal blocks of the crystal, increasing its moisacity. This problem, which can be 
identified as a ice-ring on the diffraction image at around 3.9 Å, reduces the quality 
of crystal diffraction data. Thus crystals are frequently flash cooled in the presence 
of cryoprotectants such as glycerol, PEG or even the mother liquor itself when it 
contains a high precipitant concentration. Searching for a good cryoprotectant is an 
empirical task, since each protein reacts differently to different cryoprotectants.  




1.1.3 Diffraction data collection 
Diffraction data collection is the process of capturing the scattering of X-rays by the 
electrons in the molecules constituting the target crystal. The X-ray beams come 
from an X-ray generator, at the heart of which is an X-ray tube, rotating anode or 
particle storage ring. 
 
Figure 5. Diagram of a diffraction data collection process. 
X-ray generators use a high voltage to accelerate electrons released by a hot cathode 
to a high velocity. These high velocity electrons collide with a metal target, the 
anode. Collisions with these incoming electrons displace electrons in the target 
material from lower to higher level orbitals. An X-ray photon is created when these 
electrons spontaneously return to the stable lower orbital. 
 X-ray tubes are composed of a water-cooled anode made of the target metal, 
whereas rotating anode tubes use a water-cooled rapidly rotating metal disk as an 
anode.  Rotating anodes can create X-rays more than ten times as powerful as tubes 
with fixed anodes because they increase the metal surface exposed to the powerful 
electron bombardment from the cathode, reducing heat dissipation which is not as 
effectively reduced by water in the X-ray tubes. The particle storage rings are 
however the most powerful X-ray source, in which electrons circulate at velocities 
near the speed of light, driven by energy from radio-frequency transmitters and 
maintained in circular motion by powerful magnets. A charged body like an electron 
emits energy when forced into curved motion, and in accelerators, the energy is 




emitted as X-rays. The intensity of X-rays is increased by wigglers which cause 
additional bending of the beam. The synchrotron source is not only powerful, which 
reduces data collection time, but also convenient due to the focusing mirror systems 
and monochromators which can produce powerful monochromatic X-ray at 
selectable wavelengths.  
In a typical data collection experiment, a crystal is positioned in a beam of 
monochromatic X-ray radiation and the scattered rays are collected by a detector 
(Figure 5). X-rays passing through the crystal will cause the electrons of the 
molecules to oscillate. These oscillating charges then emit X-ray radiation of the 
same wavelength in all directions. Only scattered rays obeying Bragg’s law that 
constructively interfere with each other can produce a diffraction pattern on a 
detector.  
According to Bragg’s law, an X-ray that reflects from the surface of a substance has 
travelled less distance than an X-ray which reflects from a plane of atoms inside the 
crystal. The penetrating X-ray travels down to the internal layer, reflects, and travels 
back over the same distance before being back at the surface. The distance travelled 
depends on the separation of the layers d and the angle   at which the X-ray enters 
the material (Figure 6). 
 
Figure 6. Diagram illustrates Bragg’s law. 
For this wave to be in phase with the wave which reflected from the surface it needs 
to have travelled a whole number of wavelengths while inside the material, which 
can be expressed in an equation 









    
  
(eq. 1) 
When n is an integer (1, 2, 3 etc.) the reflected waves from different layers are 
perfectly in phase with each other and produce a reflection on diffraction data. In 
other words, the waves that are not in phase will interfere destructively. 
According to Bragg’s law (eq. 1), the diffracted X-rays are only affected by the 
crystal structure or in other words, the geometry (size and shape) of the crystal unit 
cell, and the wavelength of the X-rays.  
Firstly, the shape and the symmetry of the unit cell define the directions of the 
diffracted beams. The larger and higher the symmetry of the unit cell, the more 
diffracted beams or reflections can be observed. Secondly, the effectiveness of 
interference of the diffracted rays in each direction, and therefore the intensity of 
each diffracted ray, depends on the arrangement of all the atoms within the unit cell. 
In other words, the intensity of each individual reflection depends on the positions of 
all atoms in the unit cell. It is, therefore, not possible to solve only a selected, small 
part of the crystal structure without modelling the rest of it, in contrast to other 
structural techniques such as NMR or extended X-ray absorption fine structure 
spectroscopy which can describe only part of the molecule. 
The entirety of a crystal can be described by its unit cell. Because a crystal is 
composed of periodically organised, highly similar, structural motifs it is described 
as a three dimensional lattice where each lattice point is a motif.  
In mathematical description, because the X-ray is characterised as a wave, which can 
be described by a periodic function, a simple wave in one dimension is written in the 
form 
                    (eq. 2) 
Where      specifies the vertical height of the wave at any horizontal position  ,    
the amplitude of the wave,   its frequency, and   its phase.  




This equation can also be written in complex form 
                                (eq. 3) 
or 
         
        (eq. 4) 
with          . 
To describe a complicated wave in one dimension, the sum of simple waves is used. 
This sum is called a Fourier sum and each simple wave equation in the sum is called 
a Fourier term 
                    
 




        
 
   
         
(eq. 6) 
 Although the equation does not show the phase   of the wave, this value is implicit 
in the combination of the cosine and sine functions and specified by the values of   
and  .  
The Fourier sum is also applied to a three dimensional wave which has its own three 
frequencies  ,  , and   in each dimension  ,   and   respectively 
                 
             
   
 
(eq. 7) 
Like the wave in one dimension, for each possible set of values  ,  , and  , the 
associated wave has amplitude      and the implicit phase     . 




In crystallography, each atom   at a position             in a unit cell will give a 
scattering ray, called an atomic structure factor   , which has its own amplitude      
and frequencies  ,  , and   in the three directions  ,   and   or also the indices of 
specific reflection in the reciprocal lattice 
        
              (eq. 8) 
Since the unit cell represents all the information of a crystal, diffraction data of a 
crystal received at the detector is a collection of all diffracted X-rays from all atoms 
in the unit cells. Each diffracted ray is a complicated wave, the sum of diffractive 
contributions from all atoms in the unit cell. For a unit cell containing n atoms, the 
structure factor     , which describes the diffracted ray producing a reflection with 
reciprocal lattice indices hkl on the detector, is the sum of all the atomic scattering 
   values in a unit cell in the direction defined by  ,  , and   
          
 
   
               
(eq. 9) 
In general, the aim of crystallography is to obtain the mathematical function whose 
graph is the molecular electron density map, enabling interpretation of the desired 
structure. X-rays are scattered from the electrons of all the atoms of the crystal. The 
diffraction obtained is thus a representation of the clouds of electrons in the 
molecules of the crystal, called electron density (Rhodes, 2006). In other words,      
can be written as the sum of contributions from each volume element of electron 
density in the unit cell. By making the size of the volume element infinitesimally 
small, we obtain in the limit the following integral 
                  
                   








               




where the integral over V, the unit cell volume, is just shorthand for the integral over 
all values of  ,  , and   in the unit cell. Each volume element contributes to      
with the phase determined by its coordinates        , just as the phase of atomic 
contributions depend on atomic coordinates. This equation means that      is the 
Fourier transform of          on the set of real lattice planes         (Rhodes, 
2006). Since the Fourier transform is reversible, equation (eq. 11) can be written as 
         
 
 
        
              
   
 
(eq. 12) 
This equation is a sum rather than an integral because      represents a set of 
discrete functions.  
Considering      as a vector,      can be written in the form 
             
      (eq. 13) 
where      is the phase angle of the complex structure factor     .  
Equation (eq. 12) can thus be rewritten as 
         
 
 
          
                    
   




          
                     
   
 
with              
(eq. 14) 
 




From equation (eq. 14), the electron density can be obtained from      , which is 
characterised by its own amplitude        and phase      at each set of  ,  , and  .  
However, only reflection amplitudes can be obtained from the measured intensities 
of reflections (             ) and no direct information about reflection phases is 
provided by the diffraction experiment. This is called the “phase problem” in 
crystallography. 
Several methods are used in protein crystallography to determine the phases. 
Typically, they lead to an initial approximate electron-density distribution in the 
crystal, which can be improved in an iterative fashion, eventually converging at a 
faithful structural model of the protein. 
1.1.4 Data analysis/structure determination 
The primary result of an X-ray diffraction experiment is a map of electron density 
within the crystal. This electron distribution is usually interpreted in (chemical) 
terms of individual atoms and molecules after the phase problem is solved. The 
result of model building is a model of which atoms are in agreement with both the 
electron density map. The atomic model is ‘refined’ by varying all model parameters 
to achieve the best agreement between the observed reflection amplitudes (Fobs) and 
those calculated from the model (Fcalc). The final structure is validated to check its 
stereochemical quality before being published on the PDB. 
1.1.4.1 X-ray data processing 
Two separate pieces of information can be found in the reflections of the diffraction 
images. The first comes from the geometrical arrangement of the reflections, which 
gives all the information about the crystal lattice and the symmetry of the crystal. 
During indexing the spots have to be found, identified with integer numbers (h, k, l = 
Miller Indices) and the crystal geometry has to be determined accurately so that the 
intensities can be integrated accurately and the space that has to be modelled later is 
defined accurately. This step will provide crystallographers with information about 
the space group and unit cell dimensions. A diffraction experiment involves 
measuring a large number of reflection intensities. Because crystals have symmetry, 




some reflections are expected to be equivalent and thus have identical intensity. The 
average number of measurements per individual, symmetrically unique reflection is 
called redundancy or multiplicity. Because every reflection is measured with a 
certain degree of error, the higher the redundancy, the more accurate the final 
estimation of the averaged reflection intensity. The spread of individual intensities of 
all symmetry-equivalent reflections, contributing to the same unique reflection, is 
usually described by the residual Rmerge (sometimes called Rsym or Rint) (Wlodawer et 
al., 2008).  
        
                      
            
 
(eq. 15) 
where        is the j
th
 intensity measurement of reflection hkl, and        is the 
average intensity from multiple observations. 
If the value of the overall Rmerge is too high, the data should be truncated to lower 
resolution. This value should be smaller than 10 %. The intensities of the reflections 
are the actual experimental data of a crystallography experiment. Therefore 
integration is a crucial step during data processing. An intensity value (I) and a 
background value (σI) are determined and saved. Several errors can occur and have 
to be accounted for: reflections can be hidden in the background, the signal can be 
saturated and reflections can be hidden by the backstop of the detector. Badly 
measured reflections should be excluded from the analysis. This is generally done 
using automatic integration programmes.  
The second comes from the intensity of the reflection which gives information about 
the contents of the crystal. Unfortunately the second part of information, which is the 
one that we are actually interested in, is only partial - we lack the phases.  
The final step of data processing is scaling. During scaling the integrated values of 
the different images collected during the diffraction experiment are combined into 
one set of structure factors and normalised, also according to symmetry.  




1.1.4.2 Phase determination 
1.1.4.2.1 Experimental phasing 
The phase problem was conventionally solved using additional experimental 
information from a number of derivatives of the native crystals which were made by 
soaking in one or more solutions containing heavy atoms such as Hg, Pt, and Au. 
The additional scattering of the heavy atoms results in a difference in intensity of the 
observed reflections, which is exploited to obtain phase estimates. This approach is 
known as Multiple Isomorphous Replacement (MIR).  
A major drawback of this method is that the derivative crystals may have different 
unit cell dimensions compared to the native crystal. This obstacle is overcome by the 
Single or Multi-wavelength Anomalous Diffraction (SAD or MAD) method, 
although the anomalous signals obtained from these methods are much smaller than 
the isomorphous signal from the MIR method. These methods provide one or more 
datasets from the same crystal containing suitable anomalous scatterers. The phases 
are calculated from the wavelength-dependent quantitative differences in the 
anomalous scattering contribution of certain atoms contained in the crystal. In 
anomalous scattering methods, the intensity differences between Friedel pair 
reflections hkl and –h-k-l (the so-called Bijvoet differences) are used to calculate 
phase estimates. The continuous tunability of synchrotron radiation sources makes 
them convenient to exploit yet another signal: dispersive intensity differences 
between data collected at different wavelengths.  
1.1.4.2.2 Direct methods 
Direct methods have been developed for solving the phase problem in the structure 
determination of small molecules, and have also used in protein structure 
determination as an assistive tool complementary to isomorphous replacement, and 
anomalous diffraction. However, this technique is limited to use with small proteins 
and high resolution data (up to 1.2 Å). 
1.1.4.2.3 Molecular replacement 
A much more common way of phasing in protein crystallography is molecular 
replacement (MR). The MR method has been based on the properties of the 




Patterson function which corresponds to a map of position vectors between each pair 
of atoms in the structure. The Patterson map is a vector map, with peaks at the 
positions of vectors between atoms in the unit cell. The vectors in the Patterson map 
can be divided into two categories, including intramolecular vectors (from one atom 
in the molecule to another atom in the same molecule) and intermolecular vectors 
(from one atom in the molecule to another atom in the other molecule). The 
intramolecular vectors depend only on the orientation of the molecule, not on its 
position in the unit cell, while the intermolecular vectors depend on both the 
orientation of the molecule and its position. The MR process typically consists of 
two steps: rotation and translation, using a known homologous structure as a starting 
model to determine the location of the target protein in the unit cell. The rotation 
function finds the orientation of the reference molecule in the target unit cell by 
exploiting the intramolecular vectors. Once the orientation of the reference molecule 
is known, the translation function then finds its position by exploiting the 
intermolecular vectors. The phases of the correctly placed model are used as starting 
phases for map reconstruction. This is a quick and common technique in protein 
structure determination, but model phase bias can be substantial because the phases 
dominate the electron density reconstruction (Rupp, 2010). Replacement is to be 
understood as “positioning” of the search probe in the crystal structure, not as 
“substitution”.   
In practice, the program Phaser (McCoy et al., 2007) is a popular tool for MR which 
requires an mtz file and a reference model. An mtz file contains necessary 
information, such as magnitude of each reflection, symmetry operations, and cell 
dimensions. A reference model should share at least 30 % sequence identity with the 
target structure. The user needs to provide the number of molecules in an asymmetric 
unit, the molecular weight or protein sequence, and percentage sequence identity 
with the model. The result includes a log file, a new mtz file and an initial structure 
of the target protein. Phaser uses a Log Likelihood Gain (LLG), the difference 
between the likelihood of the model and the likelihood calculated from a Wilson 
distribution as the scoring function (McCoy et al., 2007). The LLG can be used to 
compare different models against the same data set, which higher LLG better model. 
A success of MR is evaluated by a LLG of 40 or greater. In addition, the solution is 




also judged using the Z-scores, including the rotation function Z-score (RFZ) and the 
translation function Z-score (TFZ), which indicate the number of standard deviations 
above or below the mean for particular LLG score. The Z-score is useful in the case 
that there are many ambiguous solutions found due to a low signal-to-noise value of 
the search. An acceptable solution should have TFZ above 5. 
1.1.4.3 Model building 
After an electron density map has been obtained from initial phasing and density 
modification techniques, interpretation of this map in terms of a protein model is 
required. In this process prior knowledge of the amino-acid sequence as well as the 
known structural characteristics of protein molecules are of great importance. An 
atomic model of the structure has to be built into the electron density map. The 
correct building of the structure and its refinement is used to improve the 
(approximate) phases obtained earlier. 
1.1.4.4 Refinement 
After the initial phasing and building, the model of a protein is generally far from 
perfect. To improve the phases and also the interpretation of the electron density 
map, refinement methods are a very important step in the interpretation of the 
diffraction data. After refinement additional rebuilding rounds are normally needed. 
Refining is achieved through adjustment of the atomic coordinates to fit the 
diffraction data better. The first quality indicator for the structure is the R-factor 
which measures how the calculated diffraction by the structure fits to the observed 
intensity data. For a group of reflections h, the R-factor is described as a ratio 
   
                   
        
 
(eq. 16) 
where        are the observed structure factor amplitudes and         are 
amplitudes calculated from the current model. The R-factor falls towards zero as the 
observed and calculated structure factor amplitudes agree more closely. The progress 
of refinement can be analysed by monitoring the R-factor and ensuring that it 




continues to fall. However, the refinement procedure may make adjustments which 
reduce the value of R-factor, by modelling the noise in data, without any 
improvement of the model.  To avoid this problem, a factor called Rfree is used. Rfree 
is calculated using the same equation as the R-factor, but it is calculated from a small 
fraction of reflections (typically 5%) that are excluded from refinement. The 
reduction of Rfree is thus an unbiased estimate of the improvement of the model. The 
Rfree is typically about 1.2 times the R-factor.  
Two methods are widely used in refinement: Non-crystallographic symmetry 
restraints (NCS) and simulated annealing. Both methods use restraints to how an 
atomic model should behave, for example bond distances, angles and torsions and 
temperature factors (B-factors). In NCS each atom of equivalent molecules in an 
asymmetric unit is treated using the same restraints, increasing the data-parameter 
ratio (Kleywegt, 1996, Headd et al., 2014). There are however some local 
conformational differences among equivalent molecules of the model, such as 
disordered loops and active site regions; manually checking and building each 
residue of the protein model still necessary. In simulated annealing the structure is 
"heated" to allow all atoms of the structure rearrange themselves randomly in a 
liquid phase and then is cooled gradually. During cooling stage, all atoms arrange 
themselves again to obtain their lowest energy state. This process can improve both 
the accuracy and variability of the final refined structure (Brunger and Adams, 
2002). 
1.1.4.5 Validation 
A model stays a model even if at high resolution and if it fits the electron density 
very well. There are many potential sources of error (experimental or due to wrong 
interpretation) during the structure solution process. Validation methods detect 
inconsistencies in the final model based on information that was not used during the 
refinement process, making validation a compulsory step in protein structure 
determination.  
At the same time validation thus can be seen as an additional step of the refinement 
process. This additional step can be done during final refinement steps if the 




validation indicates that something really does not seem right with the structure, 
which is a good suggestion to improve the structure quality.  
When a structure is submitted to a database, an additional validation process is 
performed. The Protein Data Bank suggests some common programs to validate the 
structures before submission, such as MolProbity (Chen et al., 2010), which is useful 
for checking geometrical criteria such as torsion angle, side chain rotamers, and Cβ 
deviations; Procheck (Laskowski et al., 1993), which works on the stereochemical 
quality of protein structure; and other programs with similar functions.  
  





Glycosyltransferases (GTs, Enzyme Commission number (EC) 2.4.x.y) are enzymes 
responsible for the synthesis of glycoconjugates by transferring an activated sugar 
residue from a donor either to an appropriate acceptor molecule or to an aglycone for 
chain initiation and elongation. The donors can be nucleotide-sugars, lipid phosphate 
sugars or phosphate sugars and the acceptors can be lipids, proteins, heterocyclic 
compounds, or other carbohydrate residues. There are three classification systems for 
GTs based on their properties, namely sequences, structures and the stereochemistry 
of the transferred sugar moiety in the final product. The wide range of donors and 
acceptors for glycosyltransferases results in significant diversity; enzymes from the 
same family may have different donors or acceptors, causing inaccuracy or 
unreliability in GTs function and structure prediction from sequence information. 
Much research has been carried out to find out more about the relationship between 
structure and function of GTs which may give insights into GTs evolution as well as 
their catalytic activities.  
The GT family classification available on the Carbohydrate Active enZymes (CAZy) 
database is based on sequence (Lombard et al., 2014). This system was first 
proposed by Campbell et al. and then modified by Coutinho et al. (Campbell et al., 
1997, Coutinho et al., 2003). A sequence-based classification spreads GTs in many 
families, which reflects the diversity of their acceptors and donors. For some 
researchers, GTs may be grouped based on their common acceptors, for example the 
galactosyltransferase family, and the sialyltransferase family (Hennet, 2002, Audry 
et al., 2011).  
In contrast, three dimensional structures of GTs are well-conserved. Only two 
different folds (GT-A and GT-B) have been identified in solved crystal structures up 
until 2007. A new fold (GT-C) has been reported recently in a structural study of 
GTs utilising a lipid-phosphate donor substrate (Henrissat et al., 2008).  
Additionally, GTs are also classified by the configuration of the anomeric functional 
group of the glycosyl donor molecule and of the resulting glycoconjugate. All known 
glycosyltransferases can be divided into two major types: retaining GTs, which 




transfer a sugar residue with the retention of anomeric configuration, and inverting 
GTs, which transfer a sugar residue with the inversion of anomeric configuration 
(Lairson et al., 2008, Golovin et al., 2005, Kabsch and Sander, 1983). 
1.2.1 Classification of glycosyltransferases 
1.2.1.1 Based on sequences 
GTs have been classified into families by amino acid sequence similarities (Coutinho 
et al., 2003, Velankar et al., 2005, Campbell et al., 1997) (available at 
http://afmb.cnrs-mrs.fr/CAZY). At the time of writing (May, 2014), the database 
comprises more than 140868 known and putative GT sequences that have been 
divided into 95 families (denoted as GTx). These numbers will be likely to increase 
with the discovery of new GT genes.  
Significant deviations in the number and function of GTs are observed among 
families. A few families comprise a large number of sequences from various sources 
with diverse functions. The best known example is the family GT2 which is recorded 
in the CAZy database with more than 42997 sequences, and members found in a 
wide range of species including animals, plants, yeasts, and bacteria. These enzymes 
cover at least 14 distinct GT functions that have already been characterised, such as 
cellulose synthesis, chitin synthesis, mannose transfer, glucose transfer, galactose 
transfer, rhamnose transfer, and other functions. In contrast, other families are 
monofunctional and contain only a few sequences, for example the GT6 family 
which only catalyse N-acetylgalactosamine (GalNAc) or galactose (Gal) transfer 
(Breton et al., 2006). 
The sequence-based classification system is supposed to incorporate both structural 
and mechanistic features within each family (Coutinho et al., 2003), however, the 
system is only well applied to glycoside hydrolases because they have a good 
correlation of sequence with enzyme mechanisms (inverting or retaining) and once 
established for a member of a family, the mechanism can be safely extended to all 
other members of that family (Davies and Henrissat, 1995). In contrast it is tricky to 
apply this to the GT families due to similarities at the sequence level between the 
inverting and retaining families (Franco and Rigden, 2003, Liu and Mushegian, 




2003). Different families which have different catalytic mechanisms (retaining or 
inverting) may have similarities in their sequence, such as the retaining GT27 family 
(related to the animal polypeptide-α-GalNAc transferase) and the inverting GT2 
family (Breton et al., 1998a). In addition, enzymes in one family can be either 
inverting or retaining. For example, the GT52 family, which comprises both 
inverting (α2,3-sialyltransferase) and retaining (α2-glucosyltransferase) enzymes.  
The prediction of the function of a putative GT based on sequence similarity is also 
difficult because there are many examples of closely related sequences having 
different catalytic activity, even within a monofunctional family. A good example 
are histo blood group A and B transferases (belonging to the GT6 family), which 
differ by only four amino acids but utilise different glycosyl donors UDP-GalNAc 
(uridine diphospho N-acetyl galactosamine) and UDP-Gal for the A transferase and 
the B transferase respectively (Yamamoto et al., 1995). Consequently, it is unreliable 
to predict the functions of members belonging to a large polyfunctional family based 
on sequence.  
1.2.1.2 Based on structures 
According to the CAZy database, GTs are classified into 94 different families based 
on sequence interrelationships (Coutinho et al., 2003). There are, however, only two 
general folds (GT-A and GT-B) and a proposed fold (GT-C) found in the published 
structures of GTs at present. The GT-A fold, first observed in the SpsA from 
Bacillus subtilis (Charnock and Davies, 1999), and the GT-B fold, first reported in β-
glucosyltransferase structure (Breton et al., 2006), adopt Rossmann-like folds that 
are typical of nucleotide-binding proteins.  
The general characteristics of a GT-A structure comprises an open twisted β-sheet 
surrounded by α-helices on both sides which are tightly associated, and hence appear 
as one domain with a continuous central β-sheet (Figure 7A). They also contain an 
AspXaaAsp motif (DXD motif) which is linked to the metal-dependent catalytic 
mechanism of most glycosyltransferases. However, this motif is not a signature of 
either the GT-A fold or glycosyltransferases because there are some non 




glycosyltransferases which also contain this motif and some GT-A fold enzymes do 
not have this motif in their sequence (Lairson et al., 2008).  
On the other hand, the GT-B fold consists of 2 β/α/β domains which interact and face 
each other with the active-site being located in the resulting cleft, and a bound metal 
ion, which is not essential for activity (Figure 7B). The new fold, GT-C, was found 
recently in the structure of oligosaccharyltransferase STT3 from Pyrococcus 
furiosus, which adopts a novel structure with a central, mainly α-helical domain 
surrounded by three β-sheet-rich domains (Figure 7C) (Lairson et al., 2008, Igura et 
al., 2008). 
 
Figure 7. Three different folds of glycosyltransferases. (A) GT-A fold, displayed by SpsA 
from Bacillus subtilis (PDB ID 1QGQ) (Charnock and Davies, 1999), (B) GT-B fold, 
presented by bacteriophage T4 β-glucosyltransferase (PDB ID 1BGT) (Vrielink et al., 1994, 
Coutinho et al., 2003), and (C) GT-C fold , exhibited by the C-terminal soluble domain of 
Pyrococcus furiosus STT3 (PDB ID 2ZAG) (Igura et al., 2008). All structures are shown in 
cartoon representation and are coloured by secondary structure with helices in red, sheets in 
yellow and loops in green. The picture was created using Pymol. 




1.2.1.3 Based on the anomeric configuration of glycosyltransferase product 
Based on the configuration of the product, GTs are divided into 2 classes: retaining 
GTs which retain the anomeric configuration of the monosaccharide from the donor 
in the product and inverting GTs which invert the stereochemistry of the sugar 
moiety in the product.  
 
Figure 8. Scheme of either inversion or retention of the anomeric stereochemistry with 
respect to the donor sugar (Lairson et al., 2008). 
1.2.1.3.1 Inverting glycosyltransferases 
The GT-A fold inverting GTs cause an inverted stereochemistry of the anomeric 
moiety of the donor via a single oxocarbenium ion-like transition state by using a 
single displacement SN2-like reaction (Lairson et al., 2008). In these enzymes, an 
active-site side chain serves as a base catalyst to deprotonate the incoming 
nucleophile of the acceptor, allowing direct SN2-like displacement of the activated 
phosphate leaving group (Figure 9). The catalytic base residue is either Asp or Glu, 
the position of which is conserved in the catalytic site of enzymes from GT2 (SpsA) 
(Charnock et al., 2001), GT7 (β4-galactosyltransferase (Gal-T1)) (Gastinel et al., 
1999), GT13 (N-acetylglucosaminyltransferase (GnT-I)) (Unligil et al., 2000), GT14 
(leukocyte type core 2 β1,6-N-acetylglucosaminyl-transferase (C2GnT-L)) (Pak et 
al., 2006), GT31 (β1,3-N-acetylglucosaminyltransferases (Mfng) (Jinek et al., 2006) 
and GT43 (glucuronyltransferase (GlcAT-P)) (Kakuda et al., 2004, Ohtsubo et al., 




2000) families. The importance of these residues was demonstrated by mutagenesis 
studies of Sinorhizobium meliloti glucosyltransferase ExoM from GT2, in which 
activity of the enzyme was abolished when the Asp187 (positioned at the conserved 
location in the active site) was mutated (Garinot-Schneider et al., 2000). Inverting 
GTs in general promote catalysis by features that help to promote leaving-group 
departure. In the GT-A fold GTs, a DXD motif-bound divalent metal ion is typically 
positioned to interact with the diphosphate moiety of the sugar nucleotide donor. The 
additional negative charge that develops on the UDP leaving group during bond 
breakage is electrostatically stabilised by the positively charged metal ion. The metal 
ion serves as an acid catalyst initiating a sequential ordered mechanism in which 
nucleotide sugar binding is followed by loops closing and acceptor binding (Zhang 
et al., 2001). This motif is observed in a majority of GT-A fold GTs which require 




 for their activity. However, there are some 
exceptions which are metal independent in catalytic mechanism, namely 
sialyltransferases from GT42 and C2GnT-L from family GT14. These enzymes use 
tyrosyl hydroxyls or basic amino acids to compensate for the positive charge of the 
metal ion. This mechanism is also observed in the GT-B fold GTs, explaining their 
metal-independent activities. 
1.2.1.3.2 Retaining glycosyltransferases 
Unlike inverting GTs, the catalytic mechanism of retaining GTs is not clearly 
understood. There are two proposed mechanisms, the double-displacement 
mechanism and the internal return (SNi-like) mechanism (Figure 10). The first 
mechanism involves formation of a covalent intermediate with inversion of the 
anomeric configuration of the donor sugar followed by hydrolysis of the 
intermediate with another inversion (Gastinel et al., 2001). However, neither 
structural nor kinetic data agreed with this mechanism (Lairson et al., 2004, Boix et 
al., 2001). Even though many experiments using mutant enzymes are able to identify 
a range of intermediates, the only intermediate that could be trapped was an amino 
acid distant from the active site (Lairson et al., 2004). In addition, based on the 
structural data, only a few retaining GTs have amino acids which have their side 
chains suitably positioned in the active site to act as a nucleophile in such a 
mechanism. 




An alternative mechanism is an SNi-like mechanism in which the nucleophile attacks 
from the same face as the leaving group departs. This mechanism was first proposed 
for retaining glycosyltransferases by Persson et al. (2001) when they studied α-
Galactosyltransferase LgtC from Neisseria meningitidis in which stable donor and 
acceptor substrate analogues were observed bound to the active site. The researchers 
suggested that a SNi-like mechanism occurred involving a direct attack on the C1 
atom of UDP-Gal by the acceptor molecule itself concurrent with cleavage of the 
glycosidic bond and direct transfer of the Gal moiety to the disaccharide acceptor 
without the formation of a glycosyl enzyme intermediate. The enzyme, therefore, 
was proposed to orient substrates in close proximity, stabilise the oxocarbenium ion-
like species and activate the leaving group, leading to the reduction of transition state 
energy. The theory was supported recently through the structural and kinetic study of 
trehalose-6-phosphate synthase (OtsA). In this study, the ternary complex of OstA 
and UDP-Glc suggests the transition state occurs when a hydrogen bond is formed 
between the leaving group oxygen of UDP and the nucleophile mimic of the sugar 
moiety. In addition, the results of kinetic isotope effect experiments and the linear 
free energy relationships of a range of substrates implicate both the leaving group of 
the donor and the acceptor nucleophile during the transition state and suggest a front-
side, SNi-type mechanism (Lee et al., 2011). 





Figure 9. Reaction mechanism proposed for inverting glycosyltransferases. Inverting GT reactions are suggested to occur in single displacement 
with formation of an oxocarbenium-ion transition state. A catalytic amino acid serves as general base (noted as B) that deprotonates the nucleophile 
OH-group of the acceptor (HOR) and the negative charge on the departing phosphate can be stabilized by metal (noted as M) as shown in the figure 
(for metal binding GT-A enzymes) or positive amino acids or helix dipole (for GT-B enzymes) (Breton et al., 2012). 
 





Figure 10. Reaction mechanism proposed for retaining glycosyltransferases. (A) illustrates the double displacement mechanism. (B) illustrates 
the internal return (SNi-like) mechanism. ROH is noted for an acceptor and R′ an active donor (Breton et al., 2012). 
 




1.2.2 Glycosyltransferase family 6 
Glycosyltransferase family 6 consists of α-1,3-galactosyltransferase (EC 2.4.1.87); 
α-1,3 N-acetylgalactosaminyltransferase (EC 2.4.1.40); α-galactosyltransferase (EC 
2.4.1.37) and globoside α-N-acetylgalactosaminyltransferase (EC 2.4.1.88) (CAZy 
database). These enzymes catalyse the stereochemistry-retaining transfer of α-
galactose (αGAL) or N-acetylgalactosamine (GalNAc) from a specific donor UDP-
α-D-galactose (UDP-Gal) or UDP-N-acetyl-D-galactosamine (UDP-GalNAc) to the 
3-OH group of a β-linked Gal or GalNAc of an acceptor. This family was researched 
through their representatives, including the histo-blood group A and B GTs (GTA 
and GTB), the α1-3-galactosyltransferase (α3GT), Forssman α1-3 GalNAc-
transferase (FS), isogloboside 3 synthase (iGb3S) and their homologues from other 
vertebrates and prokaryotes (Hennet, 2002). 
1.2.2.1 Functions 
This family is interesting due to the antigenic effects of their products on human 
immune systems. The most well characterised GT6 members are GTA and GTB, 
which are responsible for the ABO blood group system classification. In humans, the 
ABO locus located on chromosome 9 consists of 3 alleles, A, B and O. GTA and 
GTB are encoded by A and B alleles at the ABO locus respectively. Their respective 
products, A or B histo-blood group antigens, are formed by the transfer of a Gal or 
GalNAc to the Gal moiety of their specific acceptor H antigen, which is recognised 
with a fucose molecule attached to the C2 position of the Gal moiety (Figure 11). 
Non-functional products of various O alleles are not able to catalyse Gal/GalNAc 
transfer to H antigen to produce either A or B histo-blood group antigen (Yamamoto, 
2000, Yamamoto et al., 1990). In nature, there exist at least four H antigens on 
glycolipids and glycoproteins that are recognised by GTA and GTB. The most 
common are the type I H antigen (α-L-Fucp-(1→2)-β-D-Galp-(1→3)-β-D-GlcNAcp-
OR where R as either glycoprotein or glycolipid) and the type II H antigen (α-L-
Fucp-(1→2)-β-D-Galp-(1→4)-β-D-GlcNAcp-OR). Less common are the type III H 
antigen (α-L-Fucp-(1→2)-β-D-Galp-(1→3)-α-D-GalNAcp-OR) and the type IV H 
antigen (α-L-Fucp-(1→2)-β-D-Galp-(1→3)-β-D-GalNAcp-OR) (Hakomori, 1999)  
(Figure 11).  





Figure 11. Chemical structure of 4 types of H antigen acceptors of the human ABO(H) 
Blood Group A and B Glycosyltransferases. Picture created using ChemDraw. 
Understanding the ABO polymorphism in humans prevents many fatal transfusions 
from occurring due to incompatible blood transfusion. ABO variety also helps 
human immune system resist bacterial and viral pathogens. ABO glycans were 
detected on membrane protein 120 of HIV derived from cells transfected with ABO 
cDNA. Virus carrying the A histo-blood group antigen was neutralised in fresh 
human sera from B and O histo-blood group cells and vice versa (Neil et al., 2005). 
This finding suggests that interaction between ABO sugars and the envelope of HIV 
is a barrier to HIV transmission between individuals of different ABO types. A 
similar result was also recorded with the measles virus (Preece et al., 2002). 
Antibodies of ABO antigens can inhibit the transmission of Severe Acute 
Respiratory Syndrome coronavirus (SARS-coV) by interrupting the interaction 
between the glycosylated SARS-coV spike (S) protein and angiotensin-coverting 
enzyme 2 as its receptor on the host cell surface (Guillon et al., 2008). Both the 
presence of ABO antigens on virus envelopes and the protection of ABO antibodies 




against virus transmission were reported as two main driving forces in ABO genetic 
evolution (Seymour et al., 2004).  
Unlike ABO genes of which both active and inactive products are produced in 
humans, the α3GT, FS and iGb3S genes do not encode any protein because of 
frameshift and missense mutations (Koike et al., 2002).  
α3GT is an enzyme that catalyses the transfer of galactose from UDP-α-D-Galactose 
as donor substrate to the acceptor N-acetylglucosamine forming an α-1,3 linkage 
with β-galactosyl groups in glycoconjugates, also known as α-Gal epitopes. The 
enzyme is neither expressed in humans nor in apes and old world monkeys (Galili et 
al., 1987, Galili et al., 1988). Only partial sequences, similar to the α3GT gene of 
non-primate mammals have been detected in the human genome and are thought to 
correspond to pseudo genes, due to multiple deletions leading to premature 
translation stops (Lanteri et al., 2002). Complete loss of expression of this gene in 
old world primates enables the production of significant amounts of natural 
antibodies toward α-Gal epitopes (Galili et al., 1987). These antibodies are strongly 
active in the presence of complement, which is thought to be an effective way to 
prevent infection by pathogenic microorganisms that expose α-Gal epitopes. 
However, α-Gal epitopes are also found in many other species, such as pigs, rats, and 
chickens, and this has been a major barrier against xenotransplantation (Galili, 
2001).  
FS transfers a GalNAc to a glycolipid, the globotetraosylceramide (Haslam and 
Baenziger, 1996). From species to species, the Forssman gene seems to be active or 
inactive. Mouse and chicken are Forssman positive, whereas rat and pigeon are 
Forssman negative. In nonprimates, Forssman antigen is synthesised by FS. In 
humans, Forssman glycolipid is not detected, but the precursor globoside is, 
suggesting that human tissues lack Forssman synthase activity. Forssman 
glycolipids, normally found only on RBCs of selected nonprimate mammals, are 
strongly expressed on human Apae RBCs. Apae RBCs, first described in 1987, 
expresses only part of the normal A antigen and the anti-A present in the serum does 
not have an anti- Apae component (Stamps et al., 1987). Recently, analysing genetic 
polymorphisms in the human FS gene (GBGT1) showed that this gene can alter the 




enzymatically inactive human protein to its active nonprimate counterpart, 
implicating the Forssman antigen as a new histo-blood group system with potential 
implications for contribution to variable host susceptibility to microbial pathogens. 
(Svensson et al., 2013).  
The last functional member of the GT6 family, iGb3S, transfers a Gal on 
lactosylceramide that is involved in the isoglobo-series glycolipid pathway. This 
gene is a pseudogene in human which is not able to produce a functional enzyme, but 
is active in several other mammals (Keusch et al., 2000a). This supports the idea of a 
selection pressure exerted against the expression of Gal(α-1,3)Gal and GalNAc(α-
1,3)Gal antigens in humans. (Iso)globo-series glycolipids often function as receptors 
for pathogens like bacteria, viruses and toxins (Karlsson, 1995). It is possible that the 
suppression of Gal(1-3)Gal-related epitopes may give an advantage for the 
respective hosts toward various microbes and toxins (Hennet, 2002). The rat gene 
encoding the iGb3 synthase enzyme has been isolated by an expression cloning 
strategy (Keusch et al., 2000b). The rat iGb3 synthase protein shares about 39% 
identity with the other α3GalTs and with the Forssman α-1,3-GalNAc transferase 
(Haslam and Baenziger, 1996).  
1.2.2.2 Structures 
All characterised vertebrate GT6 members are type II transmembrane proteins 
localised in the Golgi apparatus, with a cytoplasmic domain, a transmembrane 
domain of about 20 amino acids, and a C-terminal catalytic domain (Hennet, 2002). 
The N-terminal cytoplasmic domain of mammalian GTs was reported as a signal for 
localisation of anchored Golgi GTs (Tu and Banfield, 2010). Although the sequences 
of GT6 members are diverse, their three dimensional structures are highly conserved 
and belong to the GT-A fold with an α/β/α Rossmann-like motif which is often 
observed for nucleotide binding proteins.  
The first crystal structure of this family was the catalytic domain (residues 80 – 368) 
of apo-form bovine α3GT (PDB ID 1FG5) first reported in the tetragonal crystal 
form (form I), P41212, at 2.8 Å by Gastinel et al. (Gastinel et al., 2001). The overall 
structure of the enzyme consists of 10 β-strands, 6 α-helices and 6 310-helices which 




form the GT-A fold with a central core of twisted β-sheet of 8 β-strands surrounded 
by 4 long α-helices. The central β-sheet can be divided into two main regions which 
create a cleft between them. The first region runs from Val129 to Met224, defining 
the N-terminal subdomain and is made up of a β-strand core (3 β-strands) and 
surrounded by two long α-helices. This subdomain accommodates the nucleotide 
moiety of the donor substrate binding site. The second portion of the central β-
strands consists of 2 parallel β-strands flanked by 2 anti-parallel β-strands with 2 
long helices on each side. There is a small β-sheet region parallel to the central β-
strand comprising 2 short anti-parallel β-strands. The structures of α3GT in complex 
with UMP (PDB ID 1G8O) and Hg-UDP-Galactose (PDB ID 1G93) were also 
reported at 2.3 Å and 2.5 Å respectively (Gastinel et al., 2001). 
 The higher resolution (1.53 Å) structure of bovine α3GT in complex with UDP and 
Mn
2+
 was solved in a monoclinic form (form II), P21, giving a detailed picture of  
bovine α3GT interacting with its donor substrate (Boix et al., 2001). This structure is 
similar to that of the form I, which displays Rossmann-like domain in overall 
structure, but the catalytic site and C-terminus are strikingly different. In general, the 
structure in form II is more ordered with a 3 times lower average B factor and 
displays the C-terminal region from residues 357-368 which was disordered in the 
form I structure. This region acts as a lid over the active site of the enzyme, which is 
a deep tunnel inside the molecule, with the presence of a UDP moiety and a Mn
2+
 
ion (Boix et al., 2001). The UDP moiety orientation is similar to those of UDP-Gal 
or UMP in form I and also interacts with the Asp225XaaAsp227 motif. These 
regions underwent a significant conformational change caused by the interactions 
between the enzyme and the ligand UDP.  
The crystal structures of the catalytic domains (residues 63–354) of the cloned GTA 
and GTB were solved to 1.80 and 1.65 Å resolution, respectively, and of the catalytic 
domain of the GTA and GTB in complex with the H-antigen disaccharide and UDP 
to 1.35 and 1.32 Å resolution, respectively (Patenaude et al., 2002). The topology of 
GTA and GTB resembles the α3GT transferase structure in which the polypeptide 
chain is organised in two domains separated by a 13 Å cleft containing the active site 
and all four critical amino acid residues. These four residues are the only difference 
in sequence between GTA and GTB, namely Arg/Gly 176, Gly/Ser 235, Leu/Met 




266 and Gly/Ala 268 respectively. The conserved DXD motif of this family, defined 
by residues Asp211, Val212 and Asp213, is also found in the active sites of these 
enzymes (Yamamoto et al., 1990, Patenaude et al., 2002).  
Although Forssman antigens were discovered in 1980s and have been intensely 
researched, the Forssman synthase and iGb3 synthase structures have not yet been 
reported. Sequence alignment of the 4 GT6 representative enzymes, including 
Forssman glycolipid synthase (Haslam and Baenziger, 1996), isogloboside 3 
synthase (Keusch et al., 2000b), GTA and GTB (Yamamoto et al., 1990), and bovine 
α3GT (Boix et al., 2001), showed 44% to 55% identity with a few insertions or 
deletions in the regions corresponding to secondary structures, which suggested they 
should have similar overall structures to those reported for bovine α3GT, GTA and 
GTB (Heissigerova et al., 2003). They do however utilise different acceptors; hence, 
some key residues may play different roles in acceptor binding interactions. 
1.2.2.3 Interactions with substrates 
Crystal structures of bovine α3GT in substrate free form and substrate bound form 
show a contiguous flexible loop at the end of the C-terminal region, residues 358 – 
368, and an internal loop from residues 188 to 199 that undergoes a conformational 
change to a more rigid structure when the enzyme interacts with substrates (Boix et 
al., 2001, Jamaluddin et al., 2007). Like bovine α3GT, the substrate bound complex 
structures of GTA and GTB also undergo a conformational change related to 
enzyme-ligand interactions (Qasba et al., 2005, Soya et al., 2009). Previous kinetic 
and structural studies on the blood group GTs suggest that the UDP-sugar donor 
substrate binds first to an “open” form of the enzyme (Alfaro et al., 2008, Kamath et 
al., 1999). Reorganisation of an internal flexible loop (residues 176–188 in 
GTA/GTB which corresponds to residues 188 – 199 in bovine α3GT) concomitant 
with donor binding generates a “semiclosed” state and creates an acceptor binding 
site. Upon binding of the acceptor substrate, the enzyme adopts a “closed” 
conformation in which the final nine C-terminal amino acid residues (residues 345 – 
354 in GTA/GTB corresponding to residues 358 – 368 in bovine α3GT) become 
ordered by forming hydrogen bonds to both UDP and  the acceptor  (Alfaro et al., 
2008, Boix et al., 2001). Such extensive conformational rearrangements during the 




enzyme catalytic cycle are characteristic of GTs in general and have been observed 
for many other enzymes in this family (Qasba et al., 2005). 
Looking into the details of the interactions between residues and substrates, 
regardless of the diverse donor and acceptor substrate specificity of the members of 
the GT6 family, the reported structures of the GT6 members display a conserved 
structure-function relationship. There are nine different amino acid regions 
containing conserved residues which are categorised based on their roles in substrate 
interactions (Figure 12) (Heissigerova et al., 2003). LBR-A (residues 133-139, 
numbered relative to bovine α3GT) interacts with uridine and the ribose ring; LBR-B 
(residues 199-201) interacts with the ribose ring and Gal or GalNAc of UDP-Gal; 
LBR-C (residues 225-227, with the conserved DXD motif) interacts with Mn
2+
, 
phosphates, and Gal or GalNAc; LBR-D (residues 247-250) interacts with the 
acceptor substrate; LBR-E (residues 278-282) and LBR-F (residues 314-317) 
interact with Gal or GalNAc of the donor substrate, LBR-G (residues 340-343), 
LBR-H (residues 356-361) and LBR-I (residues 365-367) interact with the acceptor 
and the phosphate atoms of the donor (Figure 13).  
LBR-A, LBR-B and LBR-C showed high conservation, especially the DXD motif of 
LBR-C, which is obviously important in the vertebrate GT6 catalytic activity. The 
important role of this motif in the GT6 family was shown clearly in structures of the 
family members in complex with their donor substrate, in which both Asp residues 
of the DXD motif not only interacted with the Mn
2+
 through coordinate bonds but 
also the phosphate group (Boix et al., 2001, Patenaude et al., 2002). GTA, GTB and 
bovine α3GT were all found to bind weakly or not at all to their donor and acceptor 
substrates in the absence of Mn
2+
 (Soya et al., 2009, Zhang et al., 2001). Mutation of 
either Asp residue in the DXD motif caused bovine α3GT to be inactive (Zhang et 
al., 2001).   
The flexible LBR-H and LBR-I loops in the C-terminal region contain two 
conserved residues, Lys359 and Arg365 (numbering relative to bovine α3GT) which 
were considered to form the lid of the nucleotide sugar binding site (Boix et al., 
2001, Heissigerova et al., 2003). As these regions react with the donor substrate on 
binding, they may play an important role in enzyme activity. In the structures of 




bovine α3GT wild type in complex with UDP, both Lys359 and Arg365 make 
contacts with UDP through phosphate groups (Boix et al., 2001) and their 
substitutions result in a significant reduction in the enzyme catalytic activity. The 
activity of the mutants Lys359Arg or Arg365Lys was reduced 30-fold whereas the 
mutant Lys359Ala or 4 C-terminal end residue truncated form (including Arg365) 
caused a major loss in enzyme activity (about 350-fold or 150-fold reduction in kcat 
respectively) (Jamaluddin et al., 2007). However, the affinity of these mutants for 
the substrate UDP-gal was increased (in case of Lys359Arg and Lys359Ala) or 
slightly increased (about 2-fold in case of Arg365Lys). This finding suggests that 
Lys359 and Arg365 are important, although not essential, for activity and appear to 
have a principal role in transition state stabilisation, mediated through interactions 
with the UDP leaving group, as opposed to (ground-state) substrate binding. 
Two more important regions are LBR-D and LBR-E which contain the only 4 
different residues between GTA and GTB. These residues are supposed to be 
responsible for specificity of the donor recognition where two of the four critical 
amino acids serve to differentiate between the two sugar-nucleotide donors. In detail, 
GTB can easily prohibit bulkier A donor (UDP-GalNAc) as the floor of the active 
site cleft contains the larger critical residues Met 266 and Ala 268 that restrict the 
space available to UDP-donor sugar moieties. In contrast, the smaller critical 
residues Leu 266 and Gly 268 in GTA form a larger active site cleft that would be 
inappropriate for the smaller donor UDP-Gal (Patenaude et al., 2002). The other 
residues are not positioned to directly interact with the donor. The residue 
Gly/Ser235 affected the conformation of the aliphatic tail of the acceptor in the 
structures of GTA and GTB in complex with their UDP-sugar donors and H antigen, 
suggesting it may play a role in H antigen structure recognition (Patenaude et al., 
2002). Interestingly, mutant Arg176Gly of GTA did not show any GTB activity but 
increased GTA activity although the affinity for the substrates was reduced. Mutant 
Gly176Arg of GTB showed higher affinity for UDP-Gal than the wild type GTB but 
the catalytic efficiency was unchanged (Lee et al., 2005, Alfaro et al., 2008).  





Figure 12. Multiple alignment of amino acid sequences of GT6 family representatives. α3GalT is the bovine α3GalT (GenBank accession number 
J04989), Forss-S is the canine Forss-S (U66140), GTA is human GTA (J05175), GTB is human GTB (AF134414), and iGB3S is rat iGb3 (AF248543). 
Secondary structure elements of α3GalT are indicated above the sequences and numbered as in Boix et al. (2001). Identical amino acids have a black 
background and conservatively-substituted ones a grey background. Regions involved in ligand binding are boxed. The stars indicate the four amino acids 
that are different between GTA and GTB sequences (Heissigerova et al., 2003). 




Structural studies of these mutants showed that Arg/Gly176 had no interaction with 
either substrate or the other residues of the enzyme and was partially or fully 
disordered in all structures. This finding, combined with the kinetic assays, suggests 
that this residue only contributes to substrate turnover in the way smaller side chains 
with a higher range of dihedral angles can enhance the rate of product release and 
substrate exchange (Alfaro et al., 2008). In bovine α3GT, mutagenic analysis of 
His280, corresponding to Met/Leu266 in GTA/GTB, also exhibited the key role of 
this residue in donor substrate recognition through the H-bond between the residue 
and the 2-OH of the sugar moiety of the donor substrate (Zhang et al., 2003). 
The LBR-F defined as W314H/QD/EE317 (numbering relative to bovine α3GT) is 
well conserved in the GT6 family. The residues in this region directly contact the 
donor and acceptor substrates, suggesting that it can play a crucial role in the 
catalytic mechanism of the GT6 enzymes. Glu317 of bovine α3GT or Glu 303 of 
GTA/GTB was considered as a catalytic nucleophile because of its close proximity 
to the C1 of the sugar moiety of the UDP-sugar donor (Gastinel et al., 2001, 
Patenaude et al., 2002).  However, the higher resolution structure of bovine α3GT in 
complex with UDP displayed an H-bond between Glu317 and 4-OH of the Gal 
moiety of the acceptor (Boix et al., 2001). Regardless of the debated catalytic 
mechanism of the GT6 members, the interactions of this residue with the substrate as 
well as the significant reduction in activity of its mutations such as Glu317Gln, 
Glu317Ile and Glu317Ala of bovine α3GT or Glu303Ala of GTA/GTB show that the 
residue is crucial for the enzyme activity (Zhang et al., 2003, Monegal and Planas, 
2006, Patenaude et al., 2002).  
 





Figure 13. Nine conserved ligand binding regions (LBRs) of GT6a family. (A) Location 
of nine LBRs on a representative of GT6a family, bovine α3GT (PDB ID 1K4V). LBR-A 
(residues 133-139) is coloured in green, LBR-B (residues 199-201) in cyan, LBR-C 
(residues 225-227) in magenta, LBR-D (residues 247-250) in yellow, LBR-E (residues 278-
282) in orange, LBR-F (residues 314-317) in hot pink, LBR-G (residues 340-343) in green 
cyan, LBR-H (residues 356-361) in purple blue, and LBR-I (residues 365-367) brown.  
Protein is shown in cartoon representation. The black arrow points out the C-terminus and 
the red arrow the N-terminus. (B) The active site of model bovine α3GT in complex with 
UDP-Gal and LacNAc. Interacting residues are shown as line, labelled and coloured 
according to which LBR they belong to. The protein is shown in cartoon representation in 
grey. The ligands are shown as stick in pink. The figure was created using Pymol.  




Kinetic assays, in which the mutant Asp316Asn was inactive while the Asp316Glu 
mutation reduced the catalytic rate 3-fold, showed that the negative charge of the 
residue Asp316 (in the case of bovine α3GT) is necessary for catalytic activity 
because with different side chain size but the same charge, Asp316Glu still retains 
enzyme activity, while the loss of the hydroxyl group in the case of Asp316Asn 
resulted in an inactive enzyme (Tumbale et al., 2008). In contrast, both the change in 
charge (His319Glu) and size (His319Tyr) of His319 ruined the enzyme activity. 
However, the size of this residue is more important than its charge because the 
mutant His319Ala activity was only 2-fold reduced compared to the wild type. The 
size effect was also observed on His315 where the mutant His315Arg resulted in 
more than 450-fold activity reduction. The impact of these residues on the enzyme 
activity could reflect their proximity to Glu317 (Tumbale et al., 2008). 
1.2.2.4 Catalytic mechanism 
Belonging to the retaining GT-A glycosyltransferases, for which the catalytic 
mechanism is as yet unclear, the enzymatic activities of GT6 members have been 
greatly investigated. The two postulated mechanisms for retaining GTs are the 
double displacement and the SNi mechanisms.  
The double displacement mechanism was supported by the first crystal structure of a 
GT6 member. At a modest resolution of 2.5 Å, the O of the potential nucleophile 
Glu317 was 3.8-4 Å from C1 of the Gal moiety of UDP-Gal. Although not within 
covalent bond distance, this could be sufficiently close when the enzyme changed its 
conformation in the substrate bound state (Gastinel et al., 2001). Following this 
theory, Patenaude also suggested that Glu303 of GTA and GTB could be a candidate 
nucleophile when he solved the structures of these enzymes with and without their 
substrates (Patenaude et al., 2002).  
However, this proposal was not accepted because the limited resolutions of the 
structures of bovine α3GT exhibited insufficient electron density at the link between 
Glu317 and the Gal moiety. In addition, in the higher resolution structures, there was 
no electron density observed between the sugar moiety of UDP-Gal and Glu317, and 
the mutant Glu317Gln activity was reduced but not sufficiently to support the theory 




that Glu317 was the catalytic nucleophile (Zhang et al., 2003). Glu317 is important 
for catalysis by bovine α3GT, reflected in the 30000-fold reduction in catalytic 
efficiency for Gal transfer to lactose (230-fold for transfer to water) in the Gln 
mutant and is positioned to act in stabilising a transition state in which the galactose 
has oxocarbenium ion character in a single displacement SNi mechanism, suggesting 
that the enzyme can follow the SNi mechanism (Boix et al., 2002, Zhang et al., 
2003).  
Nonetheless, the question of the retaining GT mechanism and the GT6 family in 
particular was raised again when the cavity of the inactive mutant Glu317Ala of 
bovine α3GT was successfully rescued by azide which acted as a nucleophile to give 
β-D-galactosylazide (Monegal and Planas, 2006). This finding supported the double 
displacement mechanism although it did not exclude the alternative SNi mechanism.  
In addition, glycosyl-enzyme intermediates for mutants of GTA and GTB detected 
by mass spectrometry were reported recently (Soya et al., 2011). In an attempt to test 
the possibility of Glu303 as a catalytic nucleophile in GTA and GTB activity, the 
mutant Glu303Cys of both GTA and GTB was made to increase its nucleophilicity.  
As expected, a peak corresponding to the weight of glycosyl-enzyme was detected. 
In addition, when the glycosyl-enzyme was incubated with a disaccharide acceptor, a 
trisaccharide product was detected, suggesting these mutants can catalyse the 
transfer following the double displacement mechanism (Soya et al., 2011).  
Since the recent results were obtained with the modified GT6 enzymes were not 
definitive evidence for either mechanism, the debate remains open. 
1.2.3 Glycosyltransferase from Bacteroides ovatus 
Bacteroides ovatus is one of the commensal intestinal microbes found in the human 
gut that is responsible for the pathology of inflammatory bowel disease in humans 
(Saitoh et al., 2002).  This gram-negative bacterium has two genes encoding GT6 
glycosyltransferases BoGT6a and BoGT6b, namely ZP_02064961.1 and 
ZP_02066673.1 respectively. The activity and structure of the former have been 
characterised, while the latter has only been studied at the sequence level. Thus, 
knowledge of glycosyltransferases from Bacteroides ovatus is from BoGT6a.  




1.2.3.1 Characteristic features 
BoGT6a (EC 2.4.1.40) is a 263 aa protein containing a N-terminal catalytic domain 
and a C-terminal membrane-associated, hydrophobic domain (Brew et al., 2010). 
This enzyme has the same donor substrate specificity as GTA which catalyses the 
stereochemistry-retaining transfer of GalNAc from the donor UDP-GalNAc to the 
acceptor 2’-fucosyllactose (FAL) or its homologues (Figure 14). Like its mammalian 
homologues, BoGT6a is also able to catalyse the hydrolysis of its donor substrate 
UDP-GalNAc with a higher rate than that of glycosyltransferase (Tumbale and 
Brew, 2009).  
 
Figure 14. Chemical diagram illustrating the GalNAc transfer from UDP-GalNAc to 
FAL catalysed by BoGT6a. Diagram was created by using Chemdraw. 
In the sequence of the enzyme, the DXD motif which is conserved among GT6 
vertebrate members and supposed to interact directly with the metal ion is replaced 
by a NXN sequence (Asn95Ala96Asn97) (Figure 15). The NXN sequence is also 
observed in other bacterial GT6 member (Figure 16). 





Figure 15. DNA sequence and Protein sequence of BoGT6a. The 17 C-terminal residues 
are highlighted in cyan and the NAN in pink. 
 
DNA sequence 
atg aga att ggt ata tta tat atc tgt act ggc aaa tat gac att ttt tgg aaa gac ttt tat cta agc 
gca gaa cgt tat ttt atg caa gac caa tct ttc att atc gag tat tat gta ttt act gat agt cct aaa 
cta tat gac gaa gaa aac aac aaa cat att cac cgg atc aaa caa aag aat tta gga tgg cct gac 
aac aca tta aaa cgt ttc cat ata ttc ctt cgt atc aag gaa cag tta gag cga gaa acc gac tat 
cta ttt ttc ttc aat gcc aat ctc tta ttc acc agt cct att ggc aaa gaa att cta cca cca tca gat 
agt aac gga tta cta gga act atg cac cct gga ttc tac aat aaa ccg aac tcc gaa ttt aca tac 
gag cga aga gat gct tct act gcc tat atc cca gag gga gaa ggt cga tat tat tac gct gga ggg 
ctt tca ggt gga tgt aca aag gcc tac ttg aaa ctc tgc aca aca att tgc tca tgg gtt gac aga 
gat gcc aca aac cat ata ata cca att tgg cac gac gaa tct cta atc aat aaa tac ttt tta gat aat 
cca cca gct att aca ttg tcc cct gca tat cta tac cca gaa ggt tgg ctc ctt cct ttt gaa cca ata 
atc ctc att cga gac aaa aat aaa ccc caa tat ggc ggg cat gaa tta ttg cga aga aaa aac tct 
tta tgg gaa agg att aag cta atc tgc caa aaa ttt aaa tcg gct gat tag  
Protein sequence  
M R I G I L Y I C T G K Y D I F W K D F Y L S A E R Y F M Q D Q S F I I E Y 
Y V F T D S P K L Y D E E N N K H I H R I K Q K N L G W P D N T L K R F H 
I F L R I K E Q L E R E T D Y L F F F N A N L L F T S P I G K E I L P P S D S 
N G L L G T M H P G F Y N K P N S E F T Y E R R D A S T A Y I P E G E G R 
Y Y Y A G G L S G G C T K A Y L K L C T T I C S W V D R D A T N H I I P I 
W H D E S L I N K Y F L D N P P A I T L S P A Y L Y P E G W L L P F E P I I 
L I R D K N K P Q Y G G H E L L R R K N S L W E R I K L I C Q K F K S A D 
Stop 
 





Figure 16. Sequence alignment of GT6 members from both vertebrates and bacteria. 
The substitution of the DXD motif by the NXN motif is marked. Picture created using 
ClustalX (Larkin et al., 2007). 
As expected, the structurally conservative substitutions of Asn95 and Asn97, 
corresponding to Asp225 and Asp227 of bovine α3GT, with Asp indicated that the 
Asn95Asp mutation had a large effect on catalytic activity (more than 4000-fold 
reduction in kcat and 30-fold increase in the KM for UDP-GalNAc) much greater than 
the corresponding substitution for Asn97 (about 8-fold reduction in kcat and 10-fold 
increase in KM for FAL). This finding suggested that this Asn95Asp substitution 
perturbed the interaction of the enzyme with the donor substrate while Asn97 was 
not involved in donor binding. However, structural studies are needed to determine 
the role of this region in donor substrate binding (Tumbale and Brew, 2009).  
The residue Glu192 of BoGT6a corresponds to the key residue Glu317 of bovine 
α3GT and Glu303 of GTA/GTB, both of which have considerable importance in 
catalytic activity of GT6 enzymes (Patenaude et al., 2002, Zhang et al., 2003). 
Mutagenesis of the corresponding residue of BoGT6a, Glu192, to Gln results in a 
10-fold greater reduction of kcat (more than 22,000-fold reduction) than that produced 
by the same substitution for the corresponding residue, Glu317, of α3GT (Zhang et 
al., 2003), indicating that Glu192 is a key residue in catalysis in BoGT6a.  
Although the sequence of the C-terminal region of BoGT6a differs significantly 
from those of mammalian GT6 members, alanine scanning indicated that Arg229, 
Lys231, Arg243 and Arg244 were well conserved among bacterial GT6s and belong 
to LBR-H and LBR-I which are involved in the C-terminal conformational change 
induced by the substrate binding. Mutagenesis of these residues indicated that the 




Lys231Ala mutation had the greatest adverse effect on the enzyme activity (more 
than 200-fold kcat reduction compared to 3-fold reduction for Arg229Ala and 10-fold 
for Arg243Ala/Arg244Ala), which was similar to the effect of the Lys359Ala 
mutation for bovine α3GT (Jamaluddin et al., 2007, Tumbale and Brew, 2009). The 
Arg243 corresponds to Arg365 of bovine α3GT, but the insignificant effect on the 
BoGT6a suggested its role in the cavity of the enzyme may not be as necessary as 
the role of Arg365 in bovine α3GT activity. 
Finally Ala155 of BoGT6a corresponding to Leu/Met266 in GTA/GTB or His280 in 
bovine α3GT was expected to be involved in the donor recognition specificity. 
Kinetic assays of the mutant Ala155Met indicated that the enzyme affinity to both 
UDP-GalNAc and UDP-Gal was reduced about 8-fold and 3-fold respectively, but 
the catalytic rate of the enzyme with UDP-Gal was increased 5-fold while the 
enzyme almost lost its activity with UDP-GalNAc (more than 400-fold reduction) 
(Tumbale and Brew, 2009). This result supports the importance of Ala155 in the 
donor substrate specificity of BoGT6a. 
Based on the knowledge of the GT6 family, the mutagenesis of key residues in 
BoGT6a that correspond to those that have key roles in catalysis and substrate 
binding in its mammalian homologues proved that BoGT6a has the same structure-
function relationships as mammalian GT6s do. However, BoGT6a retained its 
activity in the presence of EDTA, which completely inhibited activity of bovine 
α3GT which requires Mn2+. Increasing the concentration of Mn2+ did not enhance 
the enzyme catalysis, proving that a metal ion is not required for its catalytic activity 
(Tumbale and Brew, 2009). Sequence alignment showed that the DXD motif, which 
is well conserved in GT-A glycosyltransferase, was replaced by NXN in bacterial 
glycosyltransferases (Figure 16). This raised a question about the impact of the NXN 
substitution on BoGT6a metal-independent activity as well as the catalytic 
mechanism of BoGT6a in particular and GT6 family members in general. 
1.2.3.2 Native structure 
The active domain (1-246) of BoGT6a was expressed with an N-terminal His-tag. 
The protein was expressed by E. coli BL21 (DE3) cells and purified by affinity 






-NTA Super Resin (Qiagen) (Tumbale and Brew, 2009). 
The structure of BoGT6a in substrate free form was solved by MR at 3 Å resolution, 
consisting of 10 β-strands, 4 α-helices and three 310 helices following the GT-A fold 
with a Rossmann-like domain (Thiyagarajan et al., 2012) (Figure 17). The only 
remarkable structural difference is its short N-terminal region which supposedly 
relates to localisation of mammalian glycosyltransferase in the Golgi (Tu and 
Banfield, 2010) (Figure 18). 
 
Figure 17. Secondary structure of BoGT6a apo form. The image was sourced from 
RCSB source (Velankar et al., 2005, Golovin et al., 2005, Kabsch and Sander, 1983). 





Figure 18. N- and C- terminus of BoGT6a apo form (PDB: 4AYL) (a), GTA (PDB: 
1ZI1) (b), and bovine α3GT (PDB: 1GX4) (c). The N-terminal extension in GTA and 
α3GT are marked. The manganese ions in GTA and α3GT are shown as purple spheres 
(Thiyagarajan et al., 2012). 
As is the case for its mammalian homologues, BoGT6a also contains 2 flexible 
loops, namely an internal mobile loop (from residue 126 to residue 151) and a 
flexible C-terminus (from residue 234 to residue 246) which were disordered in its 
apo form structure. These regions are absent in the apo form structure, resulting in a 
structure consisting of two regions, namely region 1 from Met1 - Y126 and region 2 
from Arg151 - Pro234 (Figure 17).  
There are only two ions presenting in the structure, Cl
-
 located near a loop between 
Met 29 and Phe 34, and Ca
2+
 interacting with C-terminal residues Glu 216, Asp 230 
and Asn 232; there is no metal ion observed in the active site of BoGT6a (Figure 
18). This is consistent with its metal-independent activity (Thiyagarajan et al., 2012). 
A superposition of the structure of BoGT6a with the structure of bovine α3GT (PDB 
1K4V) showed positions of 9 conserved LBRs observed in previous published 
structures of GT6 family; LBR-A includes residues 7-13, LBR-B residues 70-72, 
LBR-C residues 95-97, LBR-D residues 122-125, LBR-E residues 153-157, LBR-F 
residues 189-192, LBR-G residues 215-218, LBR-H residues 231-236, LBR-I 
residues 243-245 (Figure 19). 





Figure 19. Positions of nine conserved LBRs on the BoGT6a apo form structure (PDB 
4AYL). LBR-A is coloured in green, LBR-B in cyan, LBR-C in magenta, LBR-D in yellow, 
LBR-E in orange, LBR-F in hot pink, LBR-G in green cyan, and LBR-H in purple blue. The 
protein is shown in cartoon representation. The black arrow points out the C-terminus and 
the red arrow the N-terminus. Picture created using Pymol.  
The striking structural similarity to GT6 enzymes led to the proposal that the 
difference in the activity of GT6 members with respect to metal ions could be caused 
only by the change of individual residues in the active site. Investigating this requires 
structural studies of BoGT6a in complex with its donor substrate, UDP-GalNAc, and 
its acceptor substrate, FAL, which will provide an insight into how key residues 
interact with the ligands and their roles in the enzyme activity. 
1.2.3.3 Catalytic mechanism 
The catalytic mechanism of BoGT6a is not well-understood just like all vertebrate 
GT6 members. This is true even with the two proposed mechanisms: the SNi 
mechanism and the double displacement mechanism.  
In the SNi mechanism BoGT6a is said to play a role as a coordinator, orientating the 
donor substrate, UDP-GalNAc and the acceptor substrate (FAL), bringing them close 
to each other (Figure 20A). At an approximate distance the lone pair on the oxygen 
atom of FAL attacks the C1 of the GalNAc moiety of UDP-GalNAc, breaking its 




bond with UDP moiety and forming a bond between C1 of GalNAc and O3 of FAL. 
The configuration of GalNAc remains as the α conformation without the presence of 
the glycosyl enzyme intermediate.  
In the double displacement mechanism the bond between C1 of GalNAc moiety and 
UDP moiety is broken by an attack from the lone pair on the oxygen atom of the 
hydroxyl group of Glu192. This attack leads to a formation of glycosyl-enzyme 
intermediate and the conformation of GalNAc moiety changes to the β conformation. 
The glycosyl-enzyme intermediate undergoes a nucleophilic attack by the oxygen 
atom of the FAL acceptor substrate forming a bond between C1 of GalNAc and O3 
of FAL to give the final product. This second nucleophilic attack changes the 
conformation of GalNAc back to α conformation (Figure 20B). 
Currently, there has been only one successful attempt at trapping a glycosyl-enzyme 
intermediate of GTA and GTB mutant Glu303Cys (Soya et al., 2011). There is no 
structural evidence of a glycosyl-enzyme intermediate reported. One of the reasons 
may be that the native GT6 members catalyse their reaction at a high rate meaning 
that, the intermediate is not stable enough to be observed by crystallography. A 
structural study of both the native form and the mutant form of BoGT6a (with 
reduced activity) in a complex with its donor and acceptor substrate may illustrate 
the mechanism of BoGT6a in particular. This may be applied to other GT6 members.  





Figure 20. Proposed mechanisms for BoGT6a catalytic activity. (A) the SNi mechanism. (B) the double displacement mechanism. R1 is noted for 
UMP and R2 for the acceptor FAL. The diagram was created using ChemDraw. 




1.3 Aims and objectives 
1.3.1 Aims 
The main goal of this project was to elucidate the possible role of the substitution of 
Asp-X-Asp motif in the metal- independent catalytic mechanism of BoGT6a.  In 
particular, structural studies of BoGT6a with its potential donor UDP-GalNAc and/or 
acceptor FAL were undertaken to determine whether the mutated residues perturbed 
the interaction between enzyme and donor substrate, or if mutated residues changed 
the active site structure of the enzyme. In addition, structural characterisation of the 
BoGT6a Glu192Gln (BoGT6a E192Q) mutation was performed to analyse the 
impacts of key residues on the catalytic activity of the enzyme itself, and of the GT6 
family in general.  
   
1.3.2 Objectives 
1. Determine the structure of native BoGT6a in complex with the donor (UDP-
GalNAc) and/or acceptor (2’-fucosyllactose). 
 
2. Determine the structure of BoGT6a E192Q, which showed a significant 






Structure of BoGT6a  
in complex with  
2’-fucosyllactose 




2 Structure of BoGT6a in complex with its acceptor substrate 2’-
fucosyllactose 
2.1 Methods 
The truncated form of BoGT6a, which lacked 17 residues at the C-terminal end and 
terminated at Asn246, was expressed and purified as described by Tumbale et al. 
(2009). This C-terminal truncated form has been shown to be fully active and was 
provided to us by our collaborator Professor Keith Brew, Florida Altantic University, 
USA.. This form is referred to as BoGT6a native protein throughout the thesis and 
the mutants are derived from it. 
Crystals and diffraction data of BoGT6a in complex with FAL were obtained by our 
former colleague Dr. Amit Sundriyal. The crystal of BoGT6a·FAL diffracted to 2.67 
Å resolution and 200 images were collected at Diamond Light Source, but the 
resolution was cut off at 3 Å such that the Rmerge is acceptable. The dataset was 
indexed using HKL2000 (Otwinowski and Minor, 1997) in space group P21. The 
mtz file was derived from the scale file obtained from HKL2000 by using the import 
scale file function in CCP4i (Winn et al., 2011). 
Phaser version 2.3.0 (McCoy et al., 2007) in CCP4i version 6.2.0 (Winn et al., 2011) 
was used to calculate phases for the BoGT6a•FAL complex data. The MR method 
was used (using the fully refined native BoGT6a structure as the starting model) in 
space group P21 with four molecules in the asymmetric unit. The missing loop (from 
residue 127 to residue 150) in the native BoGT6a structure was built based on its 
clear electron density. Clear electron density was observed for the acceptor substrate 
FAL and the ligand was inserted into the structure. Further refinement and model 
building were carried out using PHENIX.refine version 1.7.1_743 (Adams et al., 
2010) and COOT (Emsley and Cowtan, 2004) (for model building). 5% of 
reflections were used to calculate Rfree, and refinement and model building continued 
until the R/Rfree factors reached 18.07/26.19 and acceptable Ramachandran values 
were achieved. In spite of the moderate resolution, the structure is highly ordered 
and the information about the structural changes due to acceptor molecule 
recognition is quite evident in all four copies of the protein in the asymmetric unit. 





The crystal belonged to the monoclinic space group P21. The Matthew’s coefficient 
and solvent content were calculated from the unit cell dimensions and the molecular 
weight of BoGT6a using Matthews_Coef (Matthews, 1968, Winn et al., 2011, 
Kantardjieff and Rupp, 2003). Solvent content was calculated to be 47% with a 0.7 
probability across all resolution ranges (P(tot)) with 4 molecules per asymmetric 
unit. The phase problem was solved by MR method using the Phaser with the native 
BoGT6a structure as the search model. The resulting structure had 4 chains with 
LLG and TFZ values of 2217 and 38.2 respectively. Each chain contained only the 
first 230 residues of BoGT6a. The missing region from 127 to 150 which was not 
observed in the native BoGT6a due to its disorder was clearly visible in the electron 
density map of the complex BoGT6a•FAL (Figure 21).  
After a number of cycles of refinement, clear difference density was visible for both 
the flexible region at the C-terminus and ligand of each chain, and so these were 
built into the structure (Figure 22 and Figure 23). Refinement was performed to 
improve quality of the structure until R and Rfree got 18.07 and 26.19 respectively. 
96.7 % of residues are in the favoured region of the Ramachandran plot and 3.3 % 









Figure 21. Electron density map observed in BoGT6a•FAL structure (chain B as 
representative) before and after the flexible loop from residue 126 to 151 was built. (A) 
BoGT6a•FAL without residues 126 – 151, and (B) BoGT6a•FAL with residues 126 – 151. 
Protein is shown in yellow for chain B without the loop, and green for chain B with the loop. 
Residues are noted in 1 letter abbreviation, showing the loop position. The 2Fc-Fo map is 
contoured in blue at 1σ, and the Fc-Fo map in green (positive) and red (negative) at 3 σ. 
Picture created using Pymol. 





Figure 22. Electron densities of C terminus (of chain B as representative) in the 
BoGT6a•FAL. (A) the different densities of C terminus after phasing with BoGT6a apo 
form as starting model. (B) shows the final electron densities fitted well with the end of the 
C terminus. Protein is shown in yellow for chain B without the end of the C terminus, and 
green for chain B with the end of the C terminus. Residues are noted in 1 letter abbreviation, 
showing the C terminus. The 2Fc-Fo map is contoured in blue at 1σ, and the Fc-Fo map in 
green (positive) and red (negative) at 3 σ. Picture created using Pymol. 





Figure 23. Electron densities of FAL (of chain B as representative) in the BoGT6a•FAL 
structure. (A) the difference electron density of FAL at the active site after phasing with 
BoGT6a apo form as starting model. (B) shows how FAL moiety was supposed into the 
difference electron density. (C) shows the final electron density fitted well with the FAL 
moiety. Protein is shown in yellow for chain B without FAL, and green for chain B with 
FAL. FAL is shown in pink. Residue Trp189 is noted in 1 letter abbreviation, showing the 
active site of BoGT6a. The 2Fc-Fo map is contoured in blue at 1σ, and the Fc-Fo map in green 
(positive) and red (negative) at 3 σ. Picture created using Pymol. 




Table 2. Data collection and refinement results for BoGT6a•FAL structure 
 Space group Monoclinic, P 21 
Number of molecules per asymmetric unit 4 
Cell dimensions 
a= 70.9 Å, b=93.9 Å, c=75.5 Å, 
β=93.8o 
Resolution range (Å) 70.7 – 3.0 (3.2 – 3.0) 
Rp.i.m. (outer shell) 0.07 (0.29) 
I/σI (outer shell) 9.3 (2.6) 
Completeness (outer shell) % 94.1 (93.7) 
Total no. of reflections 72365 
Unique no. of reflections 18641 













A: 30.5, B: 35.2, C: 41.7, D: 38.8 
36.2 
RMSD 







Number of protein atoms 
Number of ligand atoms 
A: 1928, B: 1961, C: 1945, D: 1973 
132 






PDB ID 4AYJ 
 




The final structure consists of 4 molecules in an asymmetric unit (Figure 24). There 
are 231 residues in chain A, 235 residues in chain B, 233 residues in chain C, and 
236 residues in chain D. The topologies of all the four subunits are similar to each 
other, with an r.m.s.d value of 0.41 Å for chain A and chain B, 0.39 Å for chain A 
and chain C, and 0.47 Å for chain A and chain D (calculated by using the program 
COOT).  
 
Figure 24. Crystal structure of BoGT6a in complex with FAL. The 4 molecules in an 
asymmetric unit are coloured by chain. The flexible loop from residue 126 to residue 151 
(loop 1) of each chain is coloured in red. Ligands are shown as stick in pink. Picture created 
using Pymol. 
The structure of the complex consists of 10 β-strands, 4 α-helices and 2 310-helices 
as calculated by STRIDE (Heinig and Frishman, 2004) (Figure 25). Its general 
structure is similar to the BoGT6a apo form which follows the GT-A fold and is 
strikingly similar to those of other enzymes in the GT6 family, with a central β sheet 
made of 8 β-strands surrounded by 4 α-helices. The structure can be divided into two 




domains (Figure 25). The first domain beginning from Met1 to Phe94 is comprised 
of a central β sheet composed of 3 N-terminal β-strands (β1, β2, and β3) and two 
surrounding α-helices (α1, and α2). The other domain, from Asn95 to Pro234, 
consists of a β-sheet composed of 2 anti-parallel β- strands (β4 and β7) and 2 parallel 
β-strands (β6 and β8), at the centre, two long α-helices (α4 and α5) on one side, and 
then a pair of anti-parallel β-strands (β5 and β10). The loop region from residue 
Tyr127 to Gly150 (loop 1), which is absent in the structure of the apo form of 
BoGT6a due to a lack of visible electron density, can be seen clearly in the structure 
of the complex as a large loop (Figure 24).  
 
Figure 25. Secondary structure of BoGT6a in complex with FAL. Protein is shown in 
cartoon representation and coloured by secondary structure. Two domains are distinguished 
by a purple dash line. N terminus and C terminus are noted. The ligand is shown as stick in 
pink. Picture created using Pymol. 





The conformation of the region from residue Met1 to Tyr126 in the BoGT6a•FAL 
complex is similar to that of the same region in BoGT6a apo form, with an r.m.s.d 
value of 0.54 Å. In contrast, the conformation of the region from Ala151 to Lys231 
of the BoGT6a•FAL complex is quite different from that of native BoGT6a, with an 
r.m.s.d value of 1.74 Å (calculated using the program COOT). This region contains 
the loop from residue 181 to 192 (loop 2) and the C-terminal region from residue 
229 to 231 (C-term) (Figure 26). This suggests that the C terminal region, loop 1 and 
loop 2 could play important roles in BoGT6a catalytic activity. In addition, the 
interaction between the residues of this region and FAL stabilises the loop 
conformation, also pointing to its importance in catalytic activity.   
 
Figure 26. Overall structure comparison between of BoGT6a•FAL compared to 
BoGT6a in substrate free form. Proteins are shown in cartoon representation in yellow for 
BoGT6a apo form and in green for BoGT6a•FAL, residue 1-2, 125-126, 151-152 and 226-
236 are marked in red for BoGT6a apo form and in dark blue for BoGT6a•FAL. FAL is 
shown as stick and coloured in magenta. The C-termini and N-termini are labelled. Two 
flexible loops which were changed significantly are circled. Picture created using Pymol. 




Analysing the packing of molecules in the BoGT6a•FAL showed there were two 2-
fold axes. The first one is the axis between residues Pro221 of molecule A and 
molecule B. The second axis is the axis going through between residues Pro221 of 
chain D and chain C (Figure 27A). Each chain interacts with FAL at the C-terminus 
region. The packing arrangement of the four chains means that in each pair (A and 
B, C and D) the acceptor substrate binding sites face each other (Figure 24).  
 
Figure 27. Symmetry in BoGT6a•FAL complex crystal packing. (A) Rotation operation 
applied to the structure of BoGT6a•FAL. Protein displayed in cartoon representation in 




which the first 10 residues of each chain are coloured in green for chain A, cyan for chain B, 
yellow for chain C and magenta for chain D. Pro221 and Lys128 are shown as sticks and 
coloured following the chain that they belong to. The first residue, Met1, in all chains is 
contoured as red sticks. (B) Symmetry between chain B (in cyan) and chain D (in magenta). 
Protein shown in stick-ball model, and the distances between residues Y126 and E223 
displayed as red dashes. The picture was created using Pymol. 
There are 4 cysteine residues in BoGT6a sequence. Cys9 belonging to LBR-A is 
buried in the active site of BoGT6a. The other cysteines, Cys162, Cys170 and 
Cys174 belong to helix α7 in which only Cys162 and Cys174 are exposed on the 
protein surface (Figure 28).   
 
Figure 28. Surface of BoGT6a•FAL structure. Protein is shown in cartoon representation 
and coloured by chain. Surface of all residues are coloured in light blue, except those of 4 
cysteine residues. Cysteine residues are shown as stick and surface in yellow. There are only 
surfaces of Cys162 and Cys174 exposing on the surface of the protein. FAL moieties are 




shown as pink sticks. The others are buried in the core of the protein. Picture created using 
Pymol. 
However, as these exposed Cys belonging to a helix which is high ordered, they may 
highly be involved in stabilising the alpha helix rather than forming any disulphide 
bridge between molecules. This agrees with the finding reported by Tumbale et 
al.(2009) that BoGT6a is active in a monomer form (Tumbale and Brew, 2009). In 
addition, regardless to the appearance as two dimers in an asymmetric unit, buried 
surface analysis of both the complex structure with and without ligand using PISA 
(Krissinel and Henrick, 2007) indicates that the dimer interface results from the 
packing of the crystal and does not pertain to a biological unit. Of the 4 chains, chain 
A has the lowest B factor value and hence this chain was used as a representative 
molecule of the BoGT6a•FAL complex for further analysis. 
The disordered region between Tyr126 and Gly150 observed in the native BoGT6a 
structure appears to be ordered when it interacts with FAL. This region forms a large 
loop (loop 1) which is responsible for acceptor binding (Figure 26). Residues 
His122, Lys128, and Glu132 from this loop along with Trp189 and Glu192 form 
hydrogen bonds with FAL (Figure 29). The acceptor binding site also has many 
hydrophobic residues (Trp189, Trp218, Pro215, Ile228, Pro123, Phe125 and Tyr153) 
which are important in accommodating and maintaining the correct orientation of the 
acceptor molecule (Figure 29). Sequence alignments have indicated that Tyr126 of 
BoGT6a corresponds to residue Tyr172 of GTA and bovine α3GT, and that residue 
Gly150 corresponded to residue Gly196 of GTA and bovine  α3GT (Tumbale and 
Brew, 2009). This means that the disordered loop in BoGT6a corresponds to the 
internal flexible loop in its mammalian homologues (residues 176–188 in 
GTA/GTB, and residues 188 – 199 in bovine α3GT) but it is larger with 24 residues. 
In addition, loop 2 (residue Ala181 – Glu192) also underwent a conformational 
change in which Trp189 was brought into the acceptor binding site, suggesting that 
the loop conformation and its residues could play an important role in the activity of 
the enzyme (Figure 30). This is expected because residues 189-192 belong to LBR-F 
which is a region directly interacting with both donor and acceptor substrates 
(Heissigerova et al., 2003). 





Figure 29. Interactions between BoGT6a and its acceptor substrate, FAL in the acceptor binding site. (A) Interactions of BoGT6a and FAL in 
the acceptor binding site. The Protein is shown in cartoon representation, and interacting residues and FAL as stick-ball. The interacting residues 
from chain A are coloured in green, the residues from chain B in cyan, and FAL in magenta. The possible hydrogen bonds are shown as blue dashes. 
The image was created using Pymol. (B) Ligplot of BoGT6a-FAL (chain A as representative) interactions with key residues. FAL is shown in 
purple, interacting residues in orange, and hydrophobic interacting residues in red colours. Hydrogen bonds are shown as green dashes. Image 
created using Ligplot (Wallace et al., 1995).  






Figure 30. Stereo view showing conformational change of individual residues in the acceptor binding site of BoGT6a in complex with FAL 
compared to those of BoGT6a in substrate free form. Proteins are shown in cartoon representation in yellow for BoGT6a apo form and in green 
for BoGT6a•FAL. FAL is shown as stick and coloured in pink. The interacting residues are shown as stick-ball model and coloured following the 
protein colours as above. The picture was created using Pymol. 




The orientations of the C-terminal residues of BoGT6a in complex with FAL are 
almost completely opposite to those in the BoGT6a apo form. The C-terminal region 
in the complex structure tends to cover the active site of the enzyme, while in the apo 
form of the structure the C-terminal region appears more open (Figure 26, Figure 
30). This conformation is in agreement with those observed in other GT6 members 
where substrate binding also induces a conformational change of the C-terminal 
region. However, strong electron density was only observed for residues up to 
Lys231. Further residues which were observed in other chains were highly flexible 
(average B factor values of residues from 231 to the end of C-terminus in chain B, C 
and D vary from 47 to 72 Å
2
) and there is a missing region at the C-terminus (from 
Gly237 to Asn246), suggesting that the end of the C-terminal region is still highly 
mobile due to the lack of interactions between it and the acceptor substrate. In other 
words, it does not participate in acceptor binding. 
When stored in the absence of a reducing agent, BoGT6a was observed as a 
disulphide-linked dimer (approximately 60 kDa) on SDS-PAGE. This resulted in 
protein aggregation and a reduction in enzyme activity (Tumbale and Brew, 2009). 
However, as discussed above, no disulphide bonds were observed in the structure of 
BoGT6a in complex with FAL. There were hydrophobic interactions between the 4 
chains of the complex structure, namely residue Leu219 of chain B interacts with 
residue Asn127 of chain A (the same as in chain D and chain C), residue Glu223 and 
Pro221 of chain A interact with residue Glu216 and Gly217 of chain D respectively 
(the same as in chain C and chain B). In addition, there are hydrophobic interactions 
occurring symmetrically between chain A and chain C, and chain B and chain D 
(Figure 27B). Residues Glu132 and Lys128 of chain B also interact with the ligand 
of chain A (also in chain D and chain C) (Figure 29). However the protein is fully 
active as a monomer (Tumbale and Brew, 2009), and the distance between Lys128 
of chain B and the O5’ of FAL is too small to have a biological role. PISA analysis 
also indicated that the close contact between chain A and chain B, which solvent 
accessible area interface is 3.0% and 3.2% respectively, is not a biological contact, 
resulting instead from crystal packing. The same result was obtained for chain C and 
chain D which their solvent accessible area interface were 3.0% and 2.8% 
respectively. 




Comparing the acceptor binding sites of the GT6 members, represented by GTA 
(PDB 1ZI3), GTB (PDB 1ZI1), bovine α3GT (PDB 1GX4) and BoGT6a in complex 
with FAL, shows a high conservation in both composition and conformation. The 
acceptor binding sites contain many similar residues such as Trp189, Thr134, 
Tyr153, His122, and Glu192 (BoGT6a numbering) (Figure 31), suggesting that the 
conformation of the acceptor binding site is conserved in the GT6 family, regardless 
of metal-independence or dependence. This also suggests that the metal ion is mainly 
involved in donor, rather than acceptor, binding.  
In addition, comparing the acceptor pockets of these GT6 members illustrates 
structural conservation of many hydrophobic residues. For example, Trp189 
corresponds to Trp314 of bovine α3GT and Trp300 of GTA and GTB. Pro123 and 
Phe125 are conserved in GTA and GTB (Pro234 and Phe236 respectively), but are 
replaced by larger hydrophobic residues (Ala248 and Trp250 respectively) in α3GT 
(Figure 31).  
Previous structural studies have shown that Trp314 of bovine α3GT forms mainly 
hydrophobic interactions with the β-galactosyl moiety of the acceptor. The N of its 
indole ring is also within H-bonding distance of O6 of the glucose moiety of the 
acceptor substrate, lactose (Boix et al., 2002, Zhang et al., 2004). The mutant 
Trp314Tyr, lacking the N of the indole ring, displays a 30 fold decrease in its 
glycosyltransferase activity. This is in spite of the fact that both the acceptor and 
donor substrates retain the same orientations in the active sites and that affinity for 
the acceptor is 2 fold greater (Boix et al., 2002, Zhang et al., 2004). The mutation 
did not however affect the hydrolysis activity (Zhang et al., 2004). This means that 
this residue plays a more important role in acceptor binding than in donor binding. 
These findings suggested that this residue plays a role in stabilising the bisubstrate 
transition state for the transfer of galactose to the carbohydrate, rather than to the 
water molecule. Such an important role explains why this Trp residue is well 
conserved among GT6 members.    
 





Figure 31. Acceptor binding pocket among GT6 family members showing the 
conserved residues and interactions. (a) BoGT6a in complex with FAL; (b) GTA in 
complex with H-antigen (PDB id: 1LZI); (c) GTB in complex with H-antigen (PDB id: 
1LZJ); (d) α3GT in complex with LacNAc (PDB id:1GX4). Water molecules are shown as 
cyan spheres. Picture created using Pymol. 
The bovine α3GT mutant Trp250Phe displays slightly increased transferase as well 
as hydrolysis activity. However, the affinity of the mutant for UDP-Gal is 
significantly reduced (approximately 10 fold) and the affinity for the acceptor, 
lactose, is also slightly decreased in the transferase reaction. Conversely, there was 
no noticeable change in substrate affinity in the hydrolysis reaction (Zhang et al., 
2004). The activity of the bovine α3GT mutant Trp250Tyr, was also affected in the 
same way; with a smaller increase in glycosyltransferase activity and a larger 




increase in hydrolysis activity. In addition, both the mutants of bovine α3GT did not 
exhibit any selectivity between Lac and LacNAc (Zhang et al., 2004). This suggests 
that the residue Trp250 only has a role in providing hydrophobic interactions with 
the carbohydrate substrate, helping the enzyme to accommodate it, but not in the 
catalytic activity of the enzyme. This also explained the differences observed at this 
position among GT6 members. The substitution of Trp250 in bovine α3GT by 
Phe125 in BoGT6a and Phe236 in GTA/GTB does not affect the activities of the 
enzymes as long as they are able to maintain hydrophobic interactions with the 
acceptor substrates.  
Bovine α3GT was not able to accommodate an acceptor with a fucosyl derived 
substrate as GTA/GTB and BoGT6a were. In the acceptor binding site, a bulky 
residue, Trp356, forms hydrophobic interactions with the Gal moiety of its acceptor. 
BoGT6a and GTA/GTB have Ile228 and Ala343 respectively at this position (not 
shown in the figure as the small size makes it very difficult to see). These are smaller 
residues and hence are able to accommodate an additional sugar moiety or larger 
acceptor substrate (Figure 31).  
The Trp356Thr mutation in bovine α3GT reduced the glycosyltransferase activity by 
10 fold. This corresponds with an approximately 10-fold reduction in acceptor 
affinity. In contrast, although the affinity for the UDP-Gal substrate was reduced 2 
fold, the hydrolysis capability of the mutant was reduced 16 fold. This finding also 
suggests that hydrophobic residues play an important role in the acceptor binding 
site.  
In summary, in spite of a major functional divergence from vertebrate GT6s in 
having metal-independent catalytic activity, BoGT6a is strikingly similar to its 
mammalian homologues and also utilises precisely equivalent residues for binding 
acceptor substrates. This suggests the metal ion only affects the donor substrate 
binding of GT6 members through the interactions with the DXD motif. The 
conservation of a high density of hydrophobic residues allows these enzymes to 
accommodate carbohydrate substrates, but the difference in the sizes of these 
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3 Structure of BoGT6a E192Q in complex with its donor substrate UDP-
GalNAc 
3.1 Introduction  
One of the main aims of this project was to shed light into the structural basis of the 
BoGT6a catalytic mechanism. Previous structural studies on GT6 members indicate 
that Glu317 is a potential catalytic nucleophile of bovine α3GT, and Glu303 is a 
potential catalytic nucleophile of GTA and GTB (Gómez et al., 2013, Gómez et al., 
2012, Soya et al., 2011, Monegal and Planas, 2006). Both of these belong to LBR-F, 
and may be involved in a double displacement mechanism. These residues are highly 
conserved in the GT6 family, and their derived mutants show a significant reduction 
in their activity (Zhang et al., 2003, Patenaude et al., 2002). 
Superposition of the structure of BoGT6a with those of its homologues shows that 
Glu192, which corresponds to Glu317 of bovine α3GT, can be a catalytic 
nucleophile in BoGT6a catalytic activity. Kinetic assay of BoGT6a E192Q has 
shown that glycosyl transferase activity of this mutant is reduced by a factor of 
30000 compared to that of wild type enzyme, implicating its importance in enzyme 
activity (Tumbale and Brew, 2009).  
To understand more about the role of Glu192 in BoGT6a catalytic activity, 
crystallisation attempts of the E192Q mutant, in complex with substrates, were 
performed. This chapter describes the crystallisation, structure determination and 
analysis of this mutant with its active donor substrate UDP-GalNAc bound in the 
active site. In addition, the donor bound complexes of the mutant explain how the 
residues of BoGT6a function in the absence of metal ions. 
3.2 Methods 
3.2.1 Protein preparation 
The protein BoGT6a E192Q, was received from Professor Keith Brew, Florida 
Atlantic University, USA, in a number of different buffers at concentrations ranging 
from 0.3-0.4 mg/ml (Table 3). The protein from each batch needed to be 




concentrated and this was achieved by centrifugation at 4 
o
C, 4000 rpm for cycles of 
45 minutes using a Thermo Scientific Heracus Megafuge 16R Centrifuge, until the 
concentration reached about 8 mg/ml. An Amicon Ultra-15 MW3000 (Millipore) 
was utilised during this process. Protein concentration was calculated using a 
Nanodrop 2000c spectrophotometer (Thermo Scientific) to measure the absorbance 
at 280 nm with an absorbance coefficient of 1.4 for 1 mg/ml, calculated using 
ExPASy – ProtParam (Expert Protein Analysis System) tool (Gasteiger et al., 2003). 




1a 20mM Tris-HCl, 0.5M NaCl, 1mM DTT, pH 7.5 0.33 
 1b 20mM Tris-HCl, 0.5M NaCl, 1mM DTT, pH 7.9 0.40 
 2 20mM Tris-HCl, 0.5M NaCl, 150mM DTT, pH 7.9 0.36 
 3a 




20mM Tris-HCl, 0.1M NaCl, 2mM DTT, 10mM 
EDTA, pH 7.0 
0.30 
 4 
20mM Tris-HCl, 0.1M NaCl, 2mM DTT, 10mM 
EDTA, pH 7.0 
0.27 
 
To make the complex of BoGT6a E192Q with the donor substrate UDP-GalNAc, the 
concentrated protein was incubated with UDP-GalNAc at a final concentration of 10 
mM at room temperature.  
For the complex of BoGT6a E192Q with both the donor UDP-GalNAc and the 
acceptor 2’-fucosyllactose (FAL), the concentrated protein was mixed with UDP-
GalNAc and FAL simultaneously, both at a final concentration of 10 mM at room 
temperature.  
All the complexes were incubated at 4 
o
C overnight prior to the crystallisation trials. 





A Phoenix crystallisation robot (Art Robbins Instruments) was used to set up 
commercial crystallisation screens using 96-well Intelli-plates ®. Screens used 
included: Structure screen I & II, Clear Strategy Screen I, Clear Strategy Screen II, 
PACT premier, and Proplex (Molecular Dimensions). The sitting drop vapour 
diffusion method was used with a drop size of 0.2 µl and a 1:1 ratio of protein: 




Subsequently, crystallisation was scaled up to 24-well plates to optimise the initial 
“hits” from the 96-well screens. During crystallisation optimisation, incubation time 
for the complex of BoGT6a E192Q with UDP-GalNAc was reduced to 1 hour at 
room temperature prior to crystallisation. Precipitant concentrations, as well as the 
type of PEG and buffer used were varied, but parameters such as pH, incubation 
temperature, protein concentration and the ratio of protein to reservoir solution were 
kept constant. Crystals obtained from both screening and optimisation were analysed 
at Diamond Light Source (Didcot, Oxon-UK). 
3.2.3 Structure determination 
Diffraction datasets for the complexes were collected at Diamond Light Source 
(Didcot, Oxon, UK) at 100 K. Cryo cooling was achieved by stabilising the crystals 
(prior to X-ray data collection) in 25%v/v Glycerol. Datasets were processed 
automatically by XIA2 (Winter, 2010) available at Diamond Light Source.  
Three datasets were used to determine structures of BoGT6a E192Q in complex with 
its donor substrate UDP-GalNAc. The first was dataset 2, which was processed at 
3.50 Å in space group P21. The second was dataset 4, which was processed at 3.42 Å 
in space group P212121. The last was dataset 5, which was processed at 2.78 Å in 
space group P212121.  
Phases for the BoGT6a E192Q-UDP-GalNAc complex at 2.78 Å were calculated by 
the MR method (using the native BoGT6a structure as the starting model) with four 
molecules per asymmetric unit using Phaser (program version 2.5.0) in PHENIX 




software suite (version 1.8.0). The missing loop (residues 126 – 150) in the BoGT6a 
structure was built based on the observed electron density map. Electron density was 
only observed for α-GalNAc (noted as GalNAc), and so only GalNAc, rather than 
UDP-GalNAc, was inserted into the structure. Further refinement and model 
building were performed using the PHENIX software suite and COOT. This 
structure is henceforth referred to as BoGT6a E192Q-GalNAc or form I structure. 
Chain A of the BoGT6a E192Q•GalNAc structure without the GalNAc moiety was 
used as a starting model for phase calculation of the other datasets. As in the 
BoGT6a E192Q.GalNAc structure, there are 4 molecules per asymmetric unit in the 
protein structure from dataset 4, whilst there are 16 molecules per asymmetric unit in 
the protein structure from dataset 2. UDP-GalNAc, UDP and GalNAc were inserted 
into the protein structures based on their observed electron densities. Final structures 
were achieved after several refinement cycles using PHENIX software suite and 
COOT. The structure obtained from dataset 4 was named BoGT6a E192Q•UDP-
GalNAc structure in orthorhombic form or form II structure, and the structure from 
dataset 2 is referred to as BoGT6a E192Q•UDP-GalNAc structure in monoclinic 
form or form III structure. 
3.3 Results 
3.3.1 Crystallisation 
The BoGT6a E192Q protein was not stable in buffer at pH 7.5 and pH 7.9 which 
caused precipitation during transportation. This led to a limited protein source for 
crystallisation screens. The crystallisation screens for the complexes derived from 
these proteins did not provide any hits, only precipitation. The BoGT6a E192Q 
protein from batch 3b was more stable and some “hits” were obtained from its 
crystallisation screens (Table 4).  
Although BoGT6a E192Q was co-crystallised with 10mM of UDP-GalNAc and with 
10 mM of both UDP-GalNAc and FAL, only crystals of BoGT6a E192Q in complex 
with UDP-GalNAc were obtained from the commercial screens. The crystallisation 
trials for the ternary complex only showed aggregation and precipitation. Lower 
protein concentration (6 mg/ml) was tried but the result was not improved. As the 




protein source was limited, the priority was to use BoGT6a E192Q to set up 
crystallisations for the donor bound complex, as this had yielded some “hits” during 
the condition screening experiments. 
Table 4. Crystallisation screen results for BoGT6a E192Q batch 3b in complex with 
UDP-GalNAc 
Name of commercial screen and 
Condition 
Crystal form 
Crystal Strategy Screen I MD1-31 (D3) 
0.2M MgCl2 
0.1M sodium cacodylate, pH6.5 
10% PEG 8000 + 10% PEG 1000 
 
Crystal Strategy Screen I MD1-31 (C2) 
0.2M Li2SO4 
0.1M sodium cacodylate, pH6.5 
25% PEG 2000 MME 
 
Structure Screen 1 & 2 HT-96 MD1-30 
(G2) 
0.2M (NH4)2SO4 
0.1M MES, pH 6.5 
30% PEG 5000 MME 
 




Name of commercial screen and 
Condition 
Crystal form 
ProPlex screen HT-96 MD1-42 (E12) 
0.2M (NH4)2SO4 
0.1M MES, pH 6.5 
20% PEG 8000 
 
Crystal Strategy Screen II HT-96 MD1-32 
(E6) 
0.2M Ca(CH3COO)2 
0.1M Tris-HCl, pH 7.5 
15% PEG 4000 
 
 
Most of the hits were of insufficient quality for mounting, except for one cluster of 
bar-shaped crystals. These appeared after 1 month of incubation at 16 
o
C in a well 
solution containing: 20% PEG 3350, 0.1M Na citrate, pH 5.0, 20% PEG 8000 from 
the Proplex crystallisation screen (Molecular Dimensions Ltd., UK). These crystals 
diffracted to 2.78 Å (Dataset 5, Table 5). Unfortunately, attempts at repetition and 
optimisation of this condition did not yield any good crystals.  
Based on the hits obtained (Table 4), modified crystallisations were set up manually 
in 24-well plates using the vapour diffusion, hanging drop method. Analysis of the 
hit conditions indicated that the complex of BoGT6a E192Q and UDP-GalNAc 
tended to form crystals with Li2SO4 or (NH4)2SO4 at pH 5.6 and pH 6.5.  Different 
PEGs, including PEG 4000, PEG 3500, PEG 6000 and PEG 8000, and different 
buffers at pH 5.5 and pH 6.5 were tried. 0.2 M of either Li2SO4 or (NH4)2SO4 in 0.1 
M Bis Tris, pH 5.5 and 20 % PEG 3350 provided potential conditions for the 
complex, which produced many bar-shaped crystals diffracting to between 3.30 Å to 
4.03 Å. Two representatives of the crystals from these conditions, which gave 




sufficient quality diffraction data for protein structure determination are shown in 
Table 5 (Dataset 2 and Dataset 4).   
Table 5. Crystallisation conditions of the diffracted crystals of BoGT6a E192Q in 
complex with UDP-GalNAc  
Conditions Pictures Results 
0.2M Li2SO4 
0.1M Bis Tris, pH 5.5 





0.1M Bis Tris, pH 5.5 




0.1M Na citrate, pH 5.0 










3.3.2 Structure determination 
The diffracting crystals from both screening and optimisation provided 8 datasets in 
total at different resolutions. Diffraction data, which were automatically indexed by 
XIA2 at Diamond Light Source, are summarised in Table 6. Only data collected at 
greater than 3.50 Å resolution; datasets 2, 4 and 5, were used because resolution 
lower than this is not useful for accurate depiction of substrate conformation.  
Diffraction dataset 2 was collected at station I04, Diamond Light Source, using a 
ADSC Q315 detector with data collection parameters: λ = 0.9795 Å, Δ φ = 1.0 o, and 
exposure = 2 seconds (Figure 32). 128 images were collected for this dataset. The 
highest resolution of these data was 3.35 Å, but it was processed at 3.50 Å for the 
best Rmerge value (Table 6). 
Diffraction datasets 4 and 5 were collected at station I04-1, Diamond Light Source, 
using a Pilatus 2M detector with data collection parameters: λ = 0.9200 Å, Δ φ = 1.0 
o
, and exposure = 3 seconds (Figure 33 and Figure 34). 150 images were collected in 
total for each dataset. The datasets were processed at their highest resolutions: 3.42 
Å for dataset 4 and 2.78 Å for dataset 5 (Table 6). 





Figure 32. Diffraction image from the crystal of BoGT6a E192Q in complex with UDP-
GalNAc that diffracted to 3.50 Å (dataset 2). The inset represents a portion of the image 
zoomed in to show the highest resolution spots. 






Figure 33. Diffraction image from the crystal of BoGT6a E192Q in complex with UDP-
GalNAc that diffracted to 3.42 Å (dataset 4). The inset represents a portion of the image 
zoomed in to show the highest resolution spots.  





Figure 34. Diffraction image from the crystal of BoGT6a E192Q in complex with UDP-
GalNAc that diffracted to 2.78 Å (dataset 5). The inset represents a portion of the image 
zoomed in to show the highest resolution spots. 












Cell dimensions Rmerge 
Completeness 
(%) 
1_1 50 3.91 P2 
a = 177.2 Å, b = 79.9 Å, c = 178.8 Å 
β = 94.4 o 
0.067 69.20 
1_2 100 3.91 P2 
a = 177.0 Å, b = 79.8 Å, c = 178.6 Å 
β = 94.4 o 
0.119 93.50 
2 128 3.50 P21 
a = 176.7 Å, b = 79.7 Å, c = 179.1 Å 
β = 95.2 o 
0.134 98.00 
3 150 3.75 P212121 
a = 80.1 Å, b = 119.8 Å, c = 131.7 Å 
α = β = γ = 90.0 o 
0.087 99.70 











Cell dimensions Rmerge 
Completeness 
(%) 
4 150 3.42 P212121 
a = 80.1 Å, b = 120.2 Å, c = 131.8 Å 
α = β = γ = 90.0 o 
0.085 97.60 
5 150 2.78 P212121 
a = 80.1 Å, b = 115.6 Å, c = 126.1 Å 
α = β = γ = 90.0 o 
0.095 97.70 
6 120 3.81 P21212 
a = 120.1 Å, b = 130.2 Å, c = 79.3 Å 
α = β = γ = 90.0 o 
0.122 94.30 
7 250 4.03 P21 
a = 176.1 Å, b = 79.8 Å, c = 178.3 Å 
β = 95.0 o 
0.238 99.40 
8 200 3.30 P21212 
a = 382.4 Å, b = 79.3 Å, c = 114.0 Å 
α = β = γ = 90.0 o 
0.182 95.60 




3.3.2.1 Structure of BoGT6a in complex with GalNAc (form I) 
The processed results of dataset 5 were used to determine the structure of BoGT6a in 
complex with UDP-GalNAc. Matthews_Coef indicated that there were 4 molecules 
per asymmetric unit with a solvent content of 51.17 %. The MR method using 
Phaser version 2.5.3 in PHENIX was thus set as 4 components in an asymmetric unit 
with a 4-copy search. Chain A of the BoGT6a•FAL structure without the FAL 
moiety was used as a starting model. The solution gave a structure consisting of 4 
molecules per asymmetric unit with LLG 4198 and TFZ 32.7. 
Each molecule had difference strong electron density for a continuous structure from 
residue Met1 to Asp230. As expected, there was also difference electron density at 
the active site and the C-terminal region in each chain (Figure 35A, Figure 36A). 
The C-terminal regions were built based on their electron densities in each chain to 
get the final structure with 236 residues for chain A and chain B, 237 residues for 
chain C, and 235 residues for chain D (Figure 35B and C).  
Although the difference density was observed in the active site of all 4 molecules, it 
was not sufficient for building the whole donor substrate, UDP-GalNAc, only 
individual GalNAc moieties. GalNAc moieties were added based on the positive 
electron density (Figure 36). The occupancies were different in the four chains: 0.65 
in chain A, 0.70 in chain B, 0.77 in chain C, and 0.81 in chain D. This was due to 
their flexibility in the active sites. Since this structure was obtained from a crystal 
grown from the solution of BoGT6a E192Q in complex with UDP-GalNAc, the 
residue Glu192 in each chain was changed to Gln192, even though the electron 
density was not sufficient to distinguish between residue Gln and residue Glu 
(Figure 36). Water molecules were built into the structure during refinement cycles. 
Refinement was performed using the Refine program in PHENIX with NCS 
restraints and Coot until the values of R and Rfree reached 23.14 and 27.35 
respectively. 96.1 % of residues in this structure lie in the favoured region of the 
Ramachandran plot. Further crystallographic statistics are summarised in Table 7. 
The final structure, named BoGT6a E192Q•GalNAc structure (form I), has 4 
molecules per asymmetric unit, each with GalNAc moieties in their active sites 
(Figure 37). 






Figure 35. Electron densities of C-terminal region (of chain A as representative) of BoGT6a E192Q in complex with donor substrate derived 
from dataset 5. (A) the difference densities of the end residues of C-terminus (after Lys231) after phasing with the structure of chain A of 
BoGT6a•FAL as a starting model. (B) shows the end residues of the C terminus built based on the positive difference electron density map. (C) 
shows the final electron densities fitted well with the end of the C-terminal region. Protein was shown as line which was coloured in yellow for the 
structure after the first search and in green for the final structure. The 2Fo-Fc map is contoured at 1σ and coloured in blue. The Fo-Fc is contoured at 3 
σ and coloured in green for positive electron density and in red for negative electron density. Residues are noted in 1 letter abbreviation. The picture 
was created by using Pymol. 





Figure 36. Electron densities of ligand (of chain A as representative) in the structure BoGT6a E192Q in complex with donor substrate 
derived from dataset 5. (A) the different densities appeared in the active site of BoGT6a E192Q after phasing with the structure of chain A of 
BoGT6a•FAL as a starting model. (B) shows the final electron densities fitted well with GalNAc moiety. Protein is shown as line which is coloured 
in yellow for the structure after the first search and in green for the final structure. The ligand is shown as line in magenta. The 2Fo-Fc map is 
contoured at 1σ and coloured in blue. The Fo-Fc is contoured at 3 σ and coloured in green for positive electron density and in red for negative 
electron density. Residues are noted in 1 letter abbreviation, showing the active site of the enzyme. The picture was created by using Pymol. 
 
 





Figure 37. Crystal structure of BoGT6a in complex with β-GalNAc from the orthorhombic crystal form (form I). (A) 4 chains in a 
asymmetric unit. Protein is shown in cartoon representation and coloured by chain. The ligands are shown as orange sticks. (B) one chain as 
representative. Protein is shown in cartoon representation and coloured by secondary structure. The ligand is shown as stick in violet and labelled as 
GalNAc. Red arrow indicates the C-term, and black arrow the N-term. Picture created using Pymol. 




3.3.2.2 Structure of BoGT6a in complex with UDP-GalNAc (form III) 
The first datasets obtained were actually dataset 1 and dataset 2, but only dataset 2 
was at a resolution sufficient for protein structure determination, 3.50 Å. Automatic 
indexing by XIA2 at Diamond Light Source showed that the crystal belonged to 
spacegroup P21 with Rmerge 0.134 and 98 % completeness. The Matthew’s coefficient 
and solvent content calculated from the unit cell dimensions and the molecular 
weight of BoGT6a without His-tag weight (Mw 29000) using MATTHEWS_COEF 
indicated that the unit cell contained 16 molecules per asymmetric unit with a 
solvent content of 54.66 %. Although the unusually high number of molecules in the 
asymmetric unit suggested that the symmetry of the crystal could be higher than P21, 
Pointless gave the probability of P21 as 95 %. Furthermore, attempts to manually 
index dataset 2 in P212121, C222 or C2221 using Imosflm failed at the scaling step.  
The processed data from XIA2 was used for further analysis. The MR method using 
Phaser (program version 2.3.0) in CCP4i (version 6.2.0) was applied to solve the 
phase problem with BoGT6a in complex with FAL using chain A of the structure 
without FAL as a starting model. Although the first search was set with 16 molecules 
per asymmetric and 16 copies search, the search failed to find a complete solution. A 
partial solution with only 15 molecules in the asymmetric unit was found with LLG 
and TFZ values of 12443 and 48.2 respectively. A second search was performed 
with all parameters was set as in the first search but only 1 copy search. This gave 1 
molecule with LLG 158 and TFZ 9.3. Similar searching steps were repeated in 
which each step was set with 1 copy search each time utilising the solution from the 
previous search. After each search, one more molecule in the asymmetric unit was 
found and the LLG value was increased. However, the last search for 16
th
 molecule 
failed as the first search had, even though there was difference electron density 
visible for one more molecule in the asymmetric unit (Figure 38).  
MR was performed again with Phaser program in PHENIX using the same processed 
data from XIA2, again setting 16 chains in the asymmetric unit and 16 copy search 
with chain A of the structure of BoGT6a•FAL without FAL moiety as a starting 
model. Unlike the CCP4i result, the solution from PHENIX was completed with 16 
molecules found and there was no large difference electron density in the map, 




except for the ligands in the active site and the C-terminal region of each chain. The 
values of LLG and TFZ were 12268 and 24.4 respectively. Each chain of the model 
also had continuous structure from Met1 to Lys231, and the residue Glu192 was kept 
as in the starting model. The first refinement gave R and Rfree values of 25.43 and 
30.22 respectively.  
 
Figure 38. Electron densities for missing molecules in asymmetric unit after MR 
searching using Phaser_MR program in CCP4i version 6.2.0. (A) two difference electron 
densities appeared in the map after 14 searches. (B) one difference electron density presents 
in the map after 15 searches. The maps are set at 80 Å diameter. The 2Fo-Fc map is 
contoured at 1σ and coloured in blue. The Fo-Fc is contoured at 3 σ and coloured in green for 
positive electron density and in red for negative electron density. The picture was created by 
using Coot. 




By the time the solution was found using PHENIX, datasets 4 and 5 had been 
collected. After solving the structure of BoGT6a E192Q•GalNAc from dataset 5, 
chain A from this structure, without the GAL moiety, was used as the starting model 
for phasing of dataset 2. The structure must be a better starting model than 
BoGT6a•FAL structure because it derived from the same protein and donor 
substrate. Its conformation was expected to be more similar to the target structure. 
The full solution also found 16 molecules per asymmetric unit but the values of LLG 
and TFZ were slightly higher than the previous search with BoGT6a•FAL as 
searching model; 13278 and 25.7 respectively. Although the general topology of the 
structures and the crystal packing from both searches were similar, the structure 
found by the MR method with BoGT6a•GalNAc as a starting model was used for 
further analysis. This was because not only were the LLG and TFZ values better, but 
each chain also had a longer C-terminal region, ending at Tyr236, as in the model. 
Since the mutant structure was used as the search model, each chain of the resulting 
structure also contained the E192Q mutation. The first refinement improved the R 
and Rfree values, which were 25.78 and 29.77 respectively.  
Like the BoGT6a•GalNAc structure, there was also positive difference electron 
density present in the active sites and the C-terminal regions of all chains, but these 
densities were not consistent in all chains. At the C-terminal region, chains A, B, C, 
D, I, J, K, and L did not have sufficient positive electron density to build further, 
whilst the other chains (E, F, G, H, M, N, O and P) had larger densities (Figure 39). 
Residues of the C-terminus were added to each chain based on their electron 
densities. After a few refinement cycles, chains A, B, C, D, I, J, K and L ended with 
Tyr236. Chains E, F, G, H and M ended at Lys245, chains N and P at 243, and chain 
O at Glu240. In addition, a small amount of positive electron density was visible at 
the N-termini of chains A, B, C, D, E, F, G, H, and K. In accordance with  the 
sequence of BoGT6a, residues of the His-tag were added and the final structure 
contained residue His0 and Ser-1 in chains A, B, C, H, and only His0 in chains D, E, 
F, G and K (Figure 40).  
 





Figure 39. The electron density maps of the C-terminal region (of chain E as 
representative) of the structure BoGT6a in complex with UDP-GalNAc (derived from 
dataset 2) before and after the missing residues were built. (A) the electron density of the 
C-terminal region before the 9 end residues were added. (B) the electron density of the final 
C terminus. The protein is showed as stick and coloured in yellow for the structure before 
residues were added, and in green for the final structure. The 2Fo-Fc map is contoured at 1σ 
and coloured in blue. The Fo-Fc is contoured at 3 σ and coloured in green for positive 
electron density and in red for negative electron density. Residues are noted, in 1 letter 
abbreviation, to show the differences between two structures. Picture created using Pymol. 





Figure 40. The electron density maps of the N terminus (of chain A as representative) 
of the structure BoGT6a in complex with UDP-GalNAc (derived from dataset 2) before 
and after the missing residues were built. (A) the electron density of the N-terminus 
before His0 and Ser-1 were added. (B) the electron density of the final N terminus. The 
protein is showed as stick and coloured in yellow for the structure before residues were 
added, and in green for the final structure. The 2Fo-Fc map is contoured at 1σ and coloured 
in blue. The Fo-Fc is contoured at 3 σ and coloured in green for positive electron density and 
in red for negative electron density. Residues are noted, in 1 letter abbreviation, to show the 
differences between two structures. Picture created using Pymol. 




The electron densities in the active sites had three different configurations. The first 
configuration, configuration A, was a big continuous component seen in chains E, F, 
G, H, O and P (Figure 41). The second, found in chains A, B, C, D, I, J, K and L, 
included two smaller components, the distance between which was comparable to 
the size of each component. This was called configuration B (Figure 42). The last 
configuration also contained two smaller components, but they were closer together. 
This configuration, configuration C, was found in chains M and N (Figure 43).  
The whole UDP-GalNAc moieties were placed into all active sites according to the 
electron density. However, after refinement, UDP-GalNAc only fitted in electron 
density appearing in the active site of chain E, F, G, H, O and P (Figure 41B and C). 
Negative electron densities appeared in chain A, B, C, D, I, J, K, L, M and N where 
UDP-GalNAc had been added into the separated electron densities (Figure 42B, 
Figure 43B). UDP-GalNAc moieties of those chains were hence replaced with 
separate UDP and α-GalNAc moieties in chain A, B, C, D, I, J, K and L (Figure 
42C). Although the resolution of the electron density map was not good enough to 
distinguish between α configuration and β configuration, the GalNAc moieties were 
set as α-GalNAc (noted as GalNAc) because BoGT6a is a retaining 
glycosyltransferase and so its product must be in the same configuration as that of 
the GalNAc in UDP-GalNAc.  
Interestingly, in the active sites of chain M and chain N that had electron density in 
form C, the GalNAc moieties appeared to be in close proximity, about 1.3 Å, to 
residue Gln192. The oxygen atoms of the hydroxyl groups of the C1 atoms of the 
GalNAc moieties were deleted and links between the nitrogen atoms of the amino 
group and the C1 were created. GalNAc moieties appeared in β configuration 
(abbreviated as NGA) when they linked to Gln192, and in α configuration when they 
were free in the active site (Figure 43C). 
After completing the missing C-terminal regions, the N-terminal regions and the 
substrates in the active sites, there was still some positive difference electron density 
remaining around the chains. Some glycerol moieties, some water molecules and one 
SO4
2-
 ion were added to the structure (Figure 44, Figure 45, Figure 46). 





Figure 41. The conformation A of the electron densities that appeared in the active sites of the complex BoGT6a E192Q•UDP-GalNAc 
(derived from dataset 2). (A) shows the positive difference electron densities that appeared in the active site of chain E (as representative). (B) 
shows the electron density map of the active site of chain E resulted from the first refinement round after UDP-GalNAc (short as UD2) was added in 
to the structure. (C) shows the electron density map of the active site of chain E of the final structure. The protein is showed as stick and coloured in 
yellow for the structure before UD2 was added, in orange when UD2 was added and in green for the final structure. The 2Fo-Fc map is contoured at 
1σ and coloured in blue. The Fo-Fc is contoured at 3 σ and coloured in green for positive electron density and in red for negative electron density. 
Residues are noted, in 1 letter abbreviation, to indicate the active site of the enzyme. Picture created using Pymol. 





Figure 42. The conformation B of the electron densities that appeared in the active sites of the complex BoGT6a E192Q•UDP-GalNAc 
(derived from dataset 2). (A) shows the positive difference electron densities appearing in the active sites of chain A (as representative). (B) shows 
the electron density map of the active site of chain A resulted from the first refinement round after UDP-GalNAc (short as UD2) was added in to the 
structure. Negative electron density appeared between UDP and GalNAc moiety. (C) shows the electron density map of the active site of chain A of 
the final structure which the UD2 was replaced by separated UDP and α-GalNAc (noted as GalNAc). The protein is showed as stick and coloured in 
yellow for the structure before UD2 was added, in orange when UD2 was added and in green for the final structure. The 2Fo-Fc map is contoured at 
1σ and coloured in blue. The Fo-Fc is contoured at 3 σ and coloured in green for positive electron density and in red for negative electron density. 
Residues are noted, in 1 letter abbreviation, to indicate the active site of the enzyme. Picture created using Pymol. 
 





Figure 43. The conformation C of the electron densities that appeared in the active sites of the complex BoGT6a E192Q•UDP-GalNAc 
(derived from dataset 2). (A) shows the positive difference electron densities appearing in the active sites of chain M (as representative). (B) shows 
the electron density map of the active site of chain M resulted from the first refinement round after the UDP-GalNAc (short as UD2)  moieties were 
added in to the structure. Negative electron density appeared at the bonds between UDP and GalNAc moieties. (D) shows the electron density map 
of the active site of chain M of the final structure which UDP-GalNAc was replaced by separated UDP and β-GalNAc (noted as NGA). The protein 
is showed as stick and coloured in yellow for the structure before UD2 was added, in orange when UD2 was added and in green for the final 
structure. The 2Fo-Fc map is contoured at 1σ and coloured in blue. The Fo-Fc is contoured at 3 σ and coloured in green for positive electron density 
and in red for negative electron density. Residues are noted, in 1 letter abbreviation, to indicate the active site of the enzyme. Picture created using 
Pymol. 
 






Figure 44. Electron density of PEG in chain A of the structure BoGT6a E192Q in 
complex with UDP-GalNAc derived from the dataset 2. (A) shows electron density map 
before PEG was added to the structure. (B) shows electron density map of the final structure 
which PEG was added to the structure. Protein is shown as line in yellow for the structure 
before PEG was added and in green for the final structure. The 2Fo-Fc map is contoured at 
1σ and coloured in blue. The Fo-Fc is contoured at 3 σ and coloured in green for positive 
electron density and in red for negative electron density. Residues are noted, in 1 letter 
abbreviation, to indicate the location of PEG. Picture created using Pymol. 
 





Figure 45. Electron density of glycerol in chain A (as representative) of the structure 
BoGT6a E192Q in complex with UDP-GalNAc derived from the dataset 2. (A) shows 
electron density map before glycerol (noted as GOL) was added to the structure. (B) shows 
electron density map of the final structure which GOL was added to the structure. Protein is 
shown as line in yellow for the structure before PEG was added and in green for the final 
structure. The 2Fo-Fc map is contoured at 1σ and coloured in blue. The Fo-Fc is contoured at 
3 σ and coloured in green for positive electron density and in red for negative electron 
density. Residues are noted, in 1 letter abbreviation, to indicate the location of GOL. Picture 
created using Pymol. 





Figure 46. Electron density of SO4
2-
 ion in chain B of the structure BoGT6a E192Q in 
complex with UDP-GalNAc derived from the dataset 2. (A) shows electron density map 
before SO4
2-
 ion (noted as SO4) was added to the structure. (B) shows electron density map 
of the final structure which SO4
2-
 was added to the structure. Protein is shown as line in 
yellow for the structure before SO4
2- 
ion was added and in green for the final structure. The 
2Fo-Fc map is contoured at 1σ and coloured in blue. The Fo-Fc is contoured at 3 σ and 
coloured in green for positive electron density and in red for negative electron density. 
Residues are noted, in 1 letter abbreviation, to indicate the location of SO4
2-
 ion. Picture 
created using Pymol. 




Improving Ramachandran values and fitting residues into the electron density was 
performed during a few refinement cycles until the R/Rfree values reached 
22.53/24.94 and 93.6 % of residues were in the favoured region of the 
Ramachandran plot. More crystallographic statistics are shown in Table 7. The final 
structure was named BoGT6a E192Q•UDP-GalNAc structure in monoclinic form 
with 16 molecules in the asymmetric unit (Figure 47). Of these, 6 chains (E, F, G, H, 
O and P) had UDP-GalNAc (configuration A) in their active sites. 8 chains (A, B, C, 
D, I, J, K and L) had UDP and α-GalNAc (configuration B) in their active sites, 
whilst 2 chains (M and N) had UDP and β-GalNAc (configuration C) in their active 
sites (Figure 47, Figure 48).  
 
Figure 47. Crystal structure of the BoGT6a E192Q in complex with the donor UDP-
GalNAc from the monoclinic crystal form (form III). The protein is shown in cartoon 
representation. The molecules with intact UDP-GalNAc are coloured in yellow, the 
molecules with UDP-GalNAc and α-GalNAc in green, and the molecules with UDP-
GalNAc and β-GalNAc in magenta. The ligands are shown as orange sticks. Each chain is 
labelled as their name. Picture created using Pymol. 






Figure 48. Comparison of the overall structure of representative molecules in the BoGT6a E192Q in complex with the donor UDP-GalNAc 
form III structure. (A) shows the molecule with intact UDP-GalNAc. (B) shows the molecule with UDP and α-GalNAc. (C) shows the molecule 
with UDP and β-GalNAc. Protein is shown in cartoon representation and coloured by secondary structure. The ligand is shown as stick in violet and 
labelled. UDP-GalNAc is noted as UD2, α-GalNAc as GalNAc and β-GalNAc as NGA. Red arrows indicate the C-termini, and black arrows the N-
termini. Picture created using Pymol. 
 




3.3.2.3 Structure of BoGT6a in complex with UDP-GalNAc (form II) 
As was the case for dataset 5, dataset 4 was processed automatically by XIA2 
program in P212121, but with lower resolution (3.42 Å). The cell content analysis 
result from Matthews_Coef program in CCP4i indicated that there were also 4 
molecules per asymmetric unit with a solvent content of 55.06 %. MR using Phaser 
program in PHENIX with chain BoGT6a•FAL without FAL moiety as a starting 
model found 4 molecules after one search. The values of LLG and TFZ were 2597 
and 13.8 respectively.  
Since the quality of this dataset was lower than that of dataset 5, dataset 5 was given 
priority for processing. When the structure of BoGT6a E192Q•GalNAc was solved, 
dataset 4 was analysed again, using BoGT6a E192Q•GalNAc without GalNAc as a 
starting model. The searching experiment also gave a solution with 4 molecules per 
asymmetric unit, but the values of LLG and TFZ were slightly different. Although 
the TFZ value was lower (9.6 compared to 13.8), the solution from this search was 
used for further analysis because the LLG was significantly higher (2764 compared 
to 2597) and the resulting structure had a longer C-terminal region (terminating at 
Tyr236 instead of Lys231 as in BoGT6a•FAL) (Figure 49). The first refinement 
result also gave slightly improved values of R and Rfree, 28.08 and 37.65 
respectively, compared to 29.32 and 38.95 from the first refinement with the 
previous Phaser result using BoGT6a•FAL without the FAL moiety as the searching 
model. 
Like the starting map of the other structures, there was positive difference electron 
density in the active sites and the C-terminal regions of all chains. At the C-termini, 
there was also a difference in the length of each chain. Chains A and C had larger 
difference electron densities than those of the other chains. After missing residues 
were added into the structure using Coot and several rounds of refinement were 
performed using Refine in PHENIX, the final structure consisted of 241 residues in 
chain A, 238 residues in chain B, 240 residues in chain C, and 236 residues in chain 
D (Figure 49, Figure 50).  
 





Figure 49. Electron density map of a long C terminus in the structure of BoGT6a 
E192Q•UDP-GalNAc derived from the dataset 4. (A) shows the positive difference 
electron density map of the C terminal region of chain A (as representative) after using MR 
method with the structure of BoGT6a E192Q•GalNAc without GalNAc as a searching 
model. (B) shows the electron density map of the C terminus of the final structure. The 2Fo-
Fc map is contoured at 1σ and coloured in blue. The Fo-Fc is contoured at 3 σ and coloured in 
green for positive electron density and in red for negative electron density. Residues Tyr236 
and Leu245 are noted, in 1 letter abbreviation, to indicate the difference between two 
structures. Picture created using Pymol. 





Figure 50. Electron density map of a short C terminus in the structure of BoGT6a 
E192Q•UDP-GalNAc derived from the dataset 4. (A) shows the positive difference 
electron density map of the C terminal region of chain B (as representative) after using MR 
method with the structure of BoGT6a E192Q•GalNAc without GalNAc as a searching 
model. (B) shows the electron density map of the C terminus of the final structure. The 2Fo-
Fc map is contoured at 1σ and coloured in blue. The Fo-Fc is contoured at 3 σ and coloured in 
green for positive electron density and in red for negative electron density. Residues Tyr236 
and Gly238 are noted, in 1 letter abbreviation, to indicate the difference between two 
structures. Picture created using Pymol. 
Unlike the structure of BoGT6a E192Q in complex with UDP-GalNAc in 
monoclinic form, the positive densities in the active sites of this structure had only 
two of the three configurations found in the previous donor bound BoGT6a E192Q 
map. Configuration A was seen in chain A and chain C and configuration B in chain 




B and chain D. UDP-GalNAc moieties were added into the chain A and chain C 
active sites, and UDP and α-GalNAc moieties were added into chain B and chain D 
(Figure 51, Figure 52).  
 
Figure 51. The conformation A of the electron densities that appeared in the active sites 
of the complex BoGT6a E192Q•UDP-GalNAc (derived from dataset 4). (A) shows the 
positive electron densities appearing in the active site of chain A (as representative). (B) 
shows the electron density map of the active site of chain A of the final structure. The 
protein is showed as line and coloured in yellow for the structure before UDP-GalNAc 
(noted as UD2) was added and in green for the final structure. The 2Fo-Fc map is contoured 
at 1σ and coloured in blue. The Fo-Fc is contoured at 3 σ and coloured in green for positive 
electron density and in red for negative electron density. Residues are noted, in 1 letter 
abbreviation, to indicate the active site of the enzyme. Picture created using Pymol. 





Figure 52. The conformation B of the electron densities that appeared in the active sites 
of the complex BoGT6a E192Q•UDP-GalNAc (derived from dataset 4). (A) shows the 
positive electron densities appearing in the active site of chain B (as representative). (B) 
shows the electron density map of the active site of chain B of the final structure with UDP 
and α-GalNAc (noted as GalNAc). The protein is showed as line and coloured in yellow for 
the structure without ligands and in green for the final structure. The 2Fo-Fc map is 
contoured at 1σ and coloured in blue. The Fo-Fc is contoured at 3 σ and coloured in green for 
positive electron density and in red for negative electron density. Residues are noted, in 1 
letter abbreviation, to indicate the active site of the enzyme. Picture created using Pymol. 
After several cycles of refinement, the final values of R and Rfree were 28.35 and 
31.41 respectively and 92.7 % of residues were in the favoured region of the 
Ramachandran plot. Other crystallographic statistics are listed in Table 7. The final 




structure was called BoGT6a E192Q•UDP-GalNAc structure in orthorhombic form 
with 4 molecules per asymmetric unit, with 2 chains (A and C) having UDP-GalNAc 
in their active sites and 2 chains (B and D) having UDP and α-GalNAc (Figure 53). 
 
Figure 53. Crystal structure of BoGT6a E192Q in complex with the donor UDP-
GalNAc in orthorhombic crystal form (form II). (A) 4 chains in a asymmetric unit. 
Protein is shown in cartoon representation and coloured by chain. The ligands were shown 
as orange sticks. (B) shows chain A and (C) chain B as representatives. Protein is shown in 
cartoon representation and coloured by secondary structure. The ligands are shown as stick 
in violet and labelled. UDP-GalNAc is noted as UD2, α-GalNAc as GalNAc. Red arrow 
indicates the C-terminus, and black arrow the N-terminus. Picture created using Pymol. 














Ligands used in 
crystallisation 
UDP-GalNAc UDP-GalNAc UDP-GalNAc 







Space Group P 212121 P 212121 P 21 
No. of molecules/a.u 4 4 16 
Cell dimensions 
a= 80.1, b= 115.6, 
c= 126.1 Å 
a= 80.1, b= 120.1, 
c= 131.8 Å 
a=177.0, b= 79.8, 
c= 179.1 Å, 
β= 95.2° 
Resolution range (Å) 
67.6 –2.8 (2.9 – 
2.8) 
88.8 –3.4 (3.6 – 
3.4) 
88.0 –3.5 (3.6 – 
3.5) 
Rmerge (outer shell) 0.10 (0.71) 0.09 (0.54) 0.13 (0.50) 
I/σI (outer shell) 15.0 (2.3) 13.5 (2.8) 7.4 (2.1) 
Completeness (outer 
shell) % 
97.7 (99.5) 97.6 (99.8) 98 (99.0) 
Total no. of 
reflections 
158394 93516 168581 
Unique no. of 
reflections 
29475 17402 61949 
Redundancy (outer 
shell) 
5.4 (4.9) 5.4 (4.6) 2.7 (2.6) 
Wilson B-factor (Å
2
) 45.73 93.61 76.41 





41.19 82.25 71.38 

































































RCSB-PDB codes 4cjb 4cjc 4cj8 





Although both BoGT6a native form and BoGT6a E192Q were set up with the donor 
substrate, UDP-GalNAc, only the BoGT6a E192Q complex formed crystals. This 
could be as a result of the slow catalytic activity of the mutant (22000 fold reduction 
compared to the native enzyme). All bovine α3GT and human GTA/GTB are 
reported to have high catalytic rates, meaning that when the native enzymes were 
mixed with their donor substrate and/or the acceptor substrates, the glycosyl transfer 
or the hydrolysis always happened during the crystallisations, destabilising the 
proteins and, as a result, inhibiting the crystal formation. There has been no 
published structure of native GT6 with the intact donor substrate UDP-Gal or UDP-
GalNAc. There are three forms of BoGT6a E192Q in complex with UDP-GalNAc 
structures, including two orthorhombic forms and one monoclinic form.  
Both orthorhombic forms have 4 molecules in the asymmetric unit, but the substrates 
in their active site are different. Although UDP-GalNAc was present in the 
crystallisation solution, in the form I structure, only GalNAc was observed in the 
active site of all 4 molecules (Figure 54A). In contrast, in the form II structure, two 
molecules (chains A and C) contain intact UDP-GalNAc and the others (chains B 
and D) contain the hydrolysis products, UDP and α-GalNAc (noted as GalNAc) 
(Figure 54B and C). This shows that the BoGT6a E192Q mutant still retains 
sufficient hydrolysis activity to catalyse the reaction during the crystallisation. Form 
II crystals were obtained from the complex that had been incubated for 1 h, whereas 
the form I crystals that contain only GalNAc were grown from a preparation that had 
been incubated overnight, suggesting that the mutant GT had hydrolysed most of the 
substrate and the UDP product had dissociated from the protein molecules in the 
crystals. 
The monoclinic form structure (form III), was also prepared with protein that had 
been pre-incubated for only 1 h, but it is less ordered than the form II structure and 
so the crystal diffracted to a lower resolution. Interestingly, it consists of 16 
polypeptide chains in the asymmetric unit, which contain three different ligand 
configurations, designated as configuration A, B and C. Although the structure was 




solved at a low resolution (3.5 Å), the quality of the electron density map and clearly 
showed the electron densities of the ligands (Figure 54D, E and F).  
Configuration A, found in chains E, F, G, H, O and P, is an intact UDP-GalNAc 
bound in a compact conformation similar to chains A and C of orthorhombic form II. 
Configuration B, seen in chains A, B, C, D, I, J, K and L, includes UDP and α-
GalNAc. This is similar to the ligand conformation observed in chains B and D of 
the form II structure. The last configuration, C, found in chains M and N, also 
consists of two separate components, but the sugar moiety is close to the UDP and 
remains in a similar orientation and location to that in UDP-GalNAc. Due to the 
close distance between the sugar moiety and the residue Gln192, a link was created 
between them and the sugar moiety was set in β configuration (noted as NGA) 
(Figure 54F). 
 





Figure 54. Electron densities of ligands in 3 structures of BoGT6a E192Q in complex with the donor UDP-GalNAc. (A) shows a ligand in 
chain A (as representative) of the form I structure. (B) and (C) show ligands in chain A and in chain B (as representative) of the form II structure 
respectively. (D), (E), and (F) show ligands in chain E, chain A, and chain M (as representative) of the form III structure respectively. Proteins are 
showed in cartoon representation. Ligands are shown as stick in magenta. α-GalNAc is noted as GalNAc, UDP-GalNAc as UD2, and β-GalNAc as 
NGA. The 2Fo-Fc map is contoured at 1σ and coloured in blue. Residue Gln192 is noted, in 1 letter abbreviation, to show the bond. Picture created 
using Pymol. 




3.3.3.1 Symmetries in the structures of BoGT6a in complex with UDP-GalNAc 
After the three structures had been solved, the packing of the molecules in their 
asymmetric units attracted our attention, especially in the structure of BoGT6a 
E192Q•UDP-GalNAc in monoclinic form. In an attempt to understand the pattern of 
the packing style in the monoclinic complex structure, all the structures, including 
the BoGT6a•FAL and all mutant BoGT6a in complex with UDP-GalNAc, were 
compared to each other.  
The form I structure, BoGT6a E192Q•GalNAc, had 4 molecules per asymmetric 
unit, but at the first look, the packing was clearly different from that of the structure 
BoGT6a•FAL. Meanwhile the BoGT6a E192Q•UDP-GalNAc in orthorhombic form 
had a similar packing arrangement to that of BoGT6a•FAL (Figure 55).  
Attempting to superpose chain A of the BoGT6a E192Q•GalNAc structure with each 
chain of the BoGT6a•FAL structure illustrated that the positions of the chains in its 
asymmetric unit were different from those of the chains in the other structure. 
Nevertheless, when the symmetrical coordinates of the BoGT6a E192Q•GalNAc 
structure were shown, chain A of the BoGT6a E192Q•GalNAc structure superposed 
with chain D of BoGT6a E192Q•GalNAc structure, and its other chains superposed 
with the symmetrical coordinates (Figure 56B). The organisation of the chains of the 
BoGT6a E192Q•GalNAc structure was rearranged according to that of the 
BoGT6a•FAL structure (Figure 56C). This indicated that the relationship between 
the new positions of chains A, B and C and their old positions was pseudo 
translation. The new structure of BoGT6a E192Q•GalNAc also contains 4 molecules 
per asymmetric unit, with the position of the β-GalNAc similar to the position of 
FAL in the BoGT6a•FAL structure. 





Figure 55. Comparison of the arrangement of molecules in the asymmetric unit of the 
BoGT6a E192Q•UDP-GalNAc structure in form II and  that of the BoGT6a•FAL 
structure. (A) 4 molecules in the asymmetric unit of the BoGT6a E192Q•UDP-GalNAc 
form II structure. (B) 4 molecules in asymmetric unit of the BoGT6a•FAL structure. (C) a 
superposition of chain A of the BoGT6a E192Q•UDP-GalNAc form II structure onto chain 
A of the BoGT6a•FAL structure. Proteins are shown in cartoon representation where chain 
A is coloured in green, chain B in cyan, chain C in yellow, and chain D in magenta. The 
substrates are shown as orange sticks. Picture created using Pymol. 
  





Figure 56. Comparison of the arrangement in the asymmetric unit of the BoGT6a 
E192Q•GalNAc structure and that of the BoGT6a•FAL structure. (A) 4 molecules of 
BoGT6a E192Q•GalNAc in the asymmetric unit with the presence of their symmetric 




coordinates. The proteins are shown as ribbon and coloured by chain in which chain A is in 
green, chain B in cyan, chain C in yellow, and chain D in magenta. Their symmetric 
coordinates are also shown as ribbon, but coloured in grey. (B) a superposition of chain A of 
the BoGT6a•FAL structure with chain D of the BoGT6a E192Q•GalNAc structure. The 
BoGT6a•FAL structure is shown in cartoon representation in which molecules are coloured 
by chain. (C) new arrangement of 4 molecules in the asymmetric unit of the BoGT6a 
E192Q•GalNAc structure. Picture created using Pymol. 
According to the relationships which were found amongst the form I structure, the 
form II structure and the acceptor bound structure, the same pseudo translation was 
also expected to happen with the molecules of the structure III. In fact, the 
comparison of the positions of molecules in the three structures showed that the 
arrangement of 16 molecules in the monoclinic form contained both packing styles 
from the other structures (Figure 57).  
 
Figure 57. Comparison of the arrangement of molecules in the asymmetric unit of all 
three mutant BoGT6a E192Q complex structures. All the protein are shown as ribbon. 




The BoGT6a•GalNAc structure is coloured in green, the BoGT6a•UDP-GalNAc form II 
structure in magenta, and the BoGT6a•UDP-GalNAc form III structure in cyan. Picture 
created using Pymol. 
The same process of superpositions and analysis of the symmetry coordinates was 
performed with the BoGT6a E192Q•UDP-GalNAc structure in monoclinic form. It 
was superposed with the BoGT6a E192Q•UDP-GalNAc structure in the 
orthorhombic form because they had the same various phenomena of substrates 
bound in the active sites of its molecules. The symmetry coordinates of chains A, C, 
G, I, M and P were used instead of the molecules at their current positions, resulting 
in a long chain with 16 molecules composed of 4 groups, in which each group 
contained 4 molecules including 2 molecules with form B ligands, 1 molecule with 
form A ligand, and 1 molecule with form C ligand (Figure 58).  
 
 





Figure 58. New arrangement of 16 molecules in asymmetric unit of the BoGT6a E192Q•GalNAc form III structure. The protein is shown as 
ribbon. Chains A, B, C, D, I, J, K and L which contain ligands in configuration B are coloured in green, chains E, F, G, H, O and P which contain 
ligands in configuration A in yellow, and chains M and N which contain ligands in configuration C in pink. Each chain is labelled with their name. 
Picture created using Pymol. 




In all three crystal forms, the packing of molecules appears to be similar to that 
observed in the structure of BoGT6a in a complex with FAL. In both the form I 
structure and the BoGT6a•FAL structure there are two 2-fold axes of rotation. This 
is because the ligands in the active sites in each structure are similar. However, there 
is only one 2-fold axis in the form II structure due to the difference of the ligands in 
the active sites. The rotation exchanges molecules in pairs; one molecule in the pair 
has UDP-GalNAc and the other has UDP and GalNAc (Figure 59). Like in the 
BoGT6a in complex with FAL, the active sites of chain A and chain C face those of 
chain D and chain B respectively. The molecule with UDP and GalNAc is more 
solvent accessible with an exposed active site, while the active site of the molecule 
with UDP-GalNAc is buried by the C-terminal region. 
Similar packing features are also observed in the monoclinic structure, but there is 
more elaborate packing which caused a high number of molecules in the asymmetric 
unit of this form because of the presence of the different structure (structure C). A 
self rotation function was performed using Molrep (Vagin and Teplyakov, 1997) for 
the form III structure with an integration radius of 3.61 Å. There are only peaks 
appearing at chi = 180
o







60). In the inspection chi = 180
o
, two strong peaks on the y axis at the origin indicate 
the crystallographic 2-fold axis along the z axis. There are two extra peaks on the x 
axis which are at 42.19
o
 apart from the z axis (Figure 60). This indicates a NCS with 
a 2 fold axis which is parallel to the (x, z) plane and 42.19
o
 different from the z axis 
of the unit cell (Figure 61).  
As superposition shows, the core group of the form III structure is 4 molecules in 
which a molecule with the ligand in structure A is grouped with a molecule with the 
ligand in structure B. There is, however, a new group of 4 molecules in which 1 pair 
is composed of a molecule with ligand in structure A and a molecule with ligand in 
structure B, and the other pair is composed of a molecule with ligand in structure C 
and a molecule with ligand in structure B. A pseudo translation along the x axis 
causes the number of molecules in the asymmetric unit to double from 8 to 16 
molecules (Figure 61). Among the 4 molecules of each group, molecules in a pair are 
mediated by contacts between residues Glu223-Lys233, Pro221-Gly227 and each 
pair interacts with the other pair through Asn127 and Leu219 (Figure 62).






Figure 59. Symmetry in the BoGT6a E192Q•UDP-GalNAc complex form II structure. (A) Top view shows the rotation operation applied to the 
structure. The 2-fold symmetry axis was marked by a red oval in the center. (B) shows the side view of the structure and the rotation axis. The 
protein is shown in cartoon representation where chain A is coloured in green, chain B in cyan, chain C in yellow and chain D in magenta. The 
residues Pro221 are shown as stick and coloured following the chain that they belong to. The ligands are shown as orange sticks. Picture created 
using Pymol. 





Figure 60. Self rotation function result for the BoGT6a E192Q•UDP-GalNAc form III 
structure. The chi angles are shown. There are two peaks at the origin clearly indicating the 
crystallographic 2-fold axis and two extra peaks around 42
o
 apart from the y axis indicating 
the non-crystallographic 2-fold axis. Picture created using Molrep (Vagin and Teplyakov, 
1997).  





Figure 61. Symmetry in the BoGT6a E192Q•UDP-GalNAc form III structure. The protein is shown in cartoon representation where molecules 
with ligands in configuration A are coloured in yellow, configuration B in green, and configuration C in magenta. The unit cell is shown in green. 
The x, y and z axes are shown as blue arrows and noted. The translation direction and the rotation axis are noted. The deviation angle between the z 
axis and the rotation axis of the NCS is noted. The picture created using Pymol. 





Figure 62. Arrangement and interactions among chains in the form III structure. The 
protein is showed as surface in grey and the hydrophobic core in orange. The inset shows a 
closer look in hydrophobic core in which hydrophobic residues are shown as stick and 
colored by chains. Picture created using Pymol. 
3.3.3.2 Interactions with ligands and conformational changes  
Like the acceptor bound structure, the overall structures of the complexes are similar 
to that of the apo protein, which follow the GT-A fold comprising two contiguous 
subdomains. The first is the N-subdomain (residues 1-94) that includes 4 parallel β-
strands and 3 surrounding α-helices. The other part is the C-subdomain (residues 95-
246) that includes a 3 stranded mixed β-sheet and a small 2 stranded β-sheet 
associated with two α-helices. 
The difference between these structures compared to the apo form and the acceptor 
bound form is the length of the C-terminal region, which is longer due to the 
increased order of this region when the enzyme interacts with the donor substrate 
(Figure 63). The restructuring of the C-terminus of the enzyme was also observed in 
the BoGT6a in complex with the acceptor substrate, which is considered as a 
“closed” form of the enzyme. In this form, the binding sites of both UDP-GalNAc 
and FAL are located in a pocket on the protein surface that is covered by “a lid” 
formed by the C-terminus. This form is in contrast to the “open” form of the 
BoGT6a apo structure in which the C-terminus is flexible and in an orientation 
pointing out of the active site (Figure 63). 





Figure 63. Conformational comparison of the overall structures of the BoGT6a apo 
form structure (in pink), the BoGT6a•FAL structure (in yellow) and the BoGT6a 
E192Q•UDP-GalNAc form III structure (in green). The proteins are shown in cartoon 
representation. UDP-GalNAc is shown as green sticks and FAL as yellow sticks. The 
conformational differences are marked and labelled. The end residue of each chain is noted 
in colour as its protein. Picture created using Pymol. 
The interaction with either substrate stabilises loop 1 (residues 126-150) that is 
unstructured in the apo form and induces the enzyme to undergo a conformational 
change to a less open form in which loop 2 (residues 180 – 192) also changes 
conformation compared to the apo form structure (Figure 63).  
Although the acceptor bound structure has a closed structure, the C-termininus 
beyond residue Lys231 is slightly flexible with only one of 4 molecules in the 
asymmetric unit showing clear electron density up to residue Tyr236. In the form I 
structure, this C-terminal region is more stable but as in the BoGT6a•FAL structure, 
the structure could not be traced beyond residue Tyr236. Superposing these two 




structures showed that the position of the GalNAc moiety is the same as that of the 
FAL moiety in the acceptor binding site, but there are fewer interactions between the 
GalNAc and the enzyme than between the FAL and the enzyme (Figure 64). A close 
look at the interactions between the enzyme and GalNAc shows that no residue 
beyond Lys231 interacts with the sugar moiety. This is in agreement with the idea 
discussed above that the C-terminal region is not involved in acceptor interaction, 
leading to its high flexibility when there is only GalNAc moiety remaining in the 
active site. 
 
Figure 64. Comparison of the active sites of the BoGT6a•FAL structure and the 
BoGT6a•GalNAc structure. (A) a superposition of 4 molecules in the asymmetry of the 




BoGT6a•GalNAc structure. The proteins are shown in cartoon representation where chain A 
is coloured in green, chain B in cyan, chain C in yellow and chain D in magenta. α-GalNAc 
moieties (noted as GalNAc) are shown as sticks and coloured according to the molecule they 
belong to. C-terminus (noted as C-term) and N-terminus are marked. (B) a superposition of 
the active sites of the BoGT6a•FAL structure and the BoGT6a•GalNAc structure shows 
GalNAc in the acceptor binding site. The proteins are shown in cartoon representation and 
coloured in yellow for the BoGT6a•FAL structure, and in green for the BoGT6a•GalNAc 
structure. FAL is shown as light orange sticks and GalNAc as magenta sticks. Residues in 
the acceptor binding site are shown as lines and coloured according to the structure they 
belong to. H-bond is shown as a blue dash line. Pictures created using Pymol. 
In the form II structure and the form III structure, interactions with the donor 
substrate, especially the interaction between Lys231 and the diphosphate moiety of 
the UDP-GalNAc or UDP, stabilise part of the C-terminus and the structures can be 
followed beyond residue Lys236. However there are some variations of the C-
terminal regions among different chains beyond this residue which are related to the 
different configurations of their ligands, suggesting that this region is flexible 
(Figure 65).  
The C-terminal region could be followed up to residue Leu241 (for the form II 
structure) or Lys245 (for the form III structure) in the molecules where the UDP-
GalNAc is intact or the sugar moiety has not been moved to the acceptor binding site 
(Figure 65). As in the form I structure, the C-terminus becomes less ordered when 
UDP-GalNAc has been hydrolysed and GalNAc has moved to the acceptor binding 
site, leading to an absence of electron density for the C-terminal 10 residues and 
hence the models were built only up to residue Tyr236. This indicates that the C 
terminal region mainly involves in donor binding activity of the enzyme. 





Figure 65. A superposition of three configurations of the BoGT6a E192Q•UDP-GalNAc 
form III structure. The protein is shown in ribbon representation where the configuration A 
(chain E as representative) is coloured in cyan, configuration B (chain A as representative) 
in yellow, and configuration C (chain M as representative) in purple. The UDP-GalNAc 
ligand from chain E is coloured in grey to show the relation between the C terminus and the 
donor substrate. The end residue of each chain is labelled. Picture created using Pymol. 
The surface diagrams of the three forms in the monoclinic structure show that C 
(chain M) is slightly more open than A (chain E) while B (chain A) is the most open 
form in which both the UDP and GalNAc ligands are exposed to solvent (Figure 66). 
 





Figure 66. Surface diagrams of three BoGT6a E192Q donor bound structures in monoclinic form. (A) configuration A (yellow), (B) configuration B 
(green), and (C) configuration C (magenta). The ligands are shown as grey sticks. Picture created using Pymol.  




Insight into the interactions between the enzyme and its donor substrates in the 
configuration A and configuration C of the form II structure shows that residues 
Lys231, His239 and Arg243 belonging to the C terminus directly interact with the 
UDP moiety of the donor substrate, UDP-GalNAc in the configuration A or the UDP 
in the configuration C (Figure 67A and C). These interactions induce the 
conformational change of the C terminal region and also stabilise it. This explains 
why the C terminus can be built almost completely (only Asn246 was not built) in 
these structures, but incompletely in the acceptor bound structure, the form I 
structure and in the configuration B of the form III structure. 
In the configuration A of the form III structure, the ε-amino group of Lys231 H-
bonds with O1A, O1B and O3A atoms and the NH2 of Arg243 interacts weakly with 
different oxygen atoms in different chains. Furthermore, the OH of Tyr13, and 
peptide N of Ala96 make H-bond interactions with the diphosphate (Figure 67A, 
Figure 68A). On the other hand, in the configuration C of the form III structure, the 
amino group of Lys231 interacts more strongly with O1A and also with O1B of the 
diphosphate and the NH2 of Arg243 is near to but not in H-bonding distance (3.66 
Å) of O2A. Ala96 interacts with O3B but there is a stacking interaction between 
Tyr13 and the substrate (Figure 67C, Figure 68C). The β-GalNAc C1 is in close 
contact with Gln192
 
NE2 (Figure 67C, Figure 68C). 
In the configuration B of the form III structure, whilst there are similar interactions 
between the protein and the uracil and ribose, the diphosphate has a variable 
orientation in different chains and the Lys231 NH2 and Tyr13 OH interact with 
different oxygens, although the Ala96 NH and Asn95 ND2 mainly interact with 
O3B. The GalNAc moiety interacts with Gln192 NE2 through O4’ and Arg73 NH2 
and Gly157 N through O3’ as well as Asn95 OD1 through N2’ (Figure 67B, Figure 
68B). Phe125 and Thr134, which are conserved in the acceptor binding sites of GT6 
family members, appear as interacting residues with the GalNAc moiety. These 
residues do not involve in the donor substrate binding stage (the configuration A and 
C). This indicates that GalNAc moiety was transferred from the donor binding site to 
the acceptor binding site. In other words, the configuration B of the form III structure 
contains the product of the hydrolysis of UDP-GalNAc. 










Figure 67. Interactions of BoGT6a E192Q with bound ligands in the form III structure. 
(A) with ligand in the configuration A, (B) with ligand in in the configuration B, and (C) 
with ligand in the configuration C. The ligands are shown as pink sticks and marked as UD2 
for UDP-GalNAc, UDP for UDP, GalNAc for α-GalNAc and NGA for β-GalNAc. The 
interacting residues are shown as line and labelled in 1 letter abbreviation. The protein is 
shown in a cartoon representation where LBR-A is coloured in green, LBR-B in cyan, LBR-
C in magenta, LBR-D in yellow, LBR-E in orange, LBR-F in hot pink, LBR-G in green 
cyan, LBR-H in purple blue, and LBR-I in brown. Picture created using Pymol. 
 





Figure 68. Ligplot of BoGT6a E192Q-ligand interactions with key residues in different complexes. (A) structure A, (B) structure B and (C) 
structure C. The ligands are shown in purple, interacting residues in orange and hydrophobic interacting residues in red colours. Hydrogen bonds are 
shown as green dashes. Image created using Ligplot (Wallace et al., 1995).  




A comparison of the interactions between the enzyme and its ligands in the form II 
and those in the form III structures shows that the interactions are similar between 
the two forms, apart from the lack of interactions between Arg243 and the phosphate 
group of the UDP-GalNAc in the form II structure (Figure 69). This is due to the 
lower quality of this structure, leading to insufficient electron density for residues 
beyond Leu241. As mentioned above, only the configuration A and B are observed 
in the form II structure. The configuration C in the form III structure is assumed to 
be an intermediate stage of the enzyme catalytic process; it exists only for a brief 
time, and so is difficult to detect. Hence, for further discussion, the form III structure 
is used as representative of the structure of BoGT6a E192Q in complex with the 
donor substrate. This is because it contains the most information about the catalytic 
process of the enzyme. 
 





Figure 69. Interactions of the BoGT6a E192Q with its ligands in the form II structure. 
(A) with ligand in the configuration A, and (B) with ligand in the configuration B. The 
ligands are shown as pink sticks and marked as UD2 for UDP-GalNAc, UDP for UDP and 
GalNAc for α-GalNAc. The interacting residues are shown as line and labelled in 1 letter 
abbreviation. The protein is shown in a cartoon representation where LBR-A is coloured in 
green, LBR-B in cyan, LBR-C in magenta, LBR-D in yellow, LBR-E in orange, LBR-F in 
hot pink, LBR-G in green cyan, LBR-H in purple blue, and LBR-I in brown. Picture created 
using Pymol. 
3.3.3.3 Proposed mechanism of the hydrolysis by BoGT6a 
Although the structure of a ternary complex of BoGT6a with both UDP-GalNAc and 
FAL has not been determined, an examination of the structures with individual 
substrates still provides some information about the enzyme catalytic mechanism.  
In the structure of BoGT6a apo form structure, the C terminus is orientated in a 
direction away from the active site of the enzyme (Figure 70A). This makes the 
active site exposed completely to the environment, known as an open conformation 




of the enzyme. Such an open state is available to accommodate both the acceptor 
substrate and the donor substrate (Figure 70B).  
 
Figure 70. Analysis of surfaces of the BoGT6a apo form. (A) the surface of the BoGT6a 
apo form (PDB 4AYL) shows an open active site with the flexible C-terminus as an open 
lid. The end of the C terminus is boxed. The protein is shown in cartoon representation. (B) 




the surface of the model of BoGT6a apo form with both FAL and UDP-GalNAc in the 
configuration A shows an open active site available for all the ligands. LBR-A is coloured in 
green, LBR-B in cyan, LBR-C in magenta, LBR-D in yellow, LBR-E in orange, LBR-F in 
hot pink, LBR-G in green cyan, and LBR-H in purple blue. Picture created using Pymol. 
However, the access way of the active site is restricted when the enzyme interacts 
with its ligands. A model of the structure of BoGT6a in complex with its acceptor 
substrate, FAL and the UDP-GalNAc shows that the active site is not accessible for 
the donor substrate UDP-GalNAc. However, the FAL binding site is accessible for 
FAL in the complex with UDP-GalNAc in the model of BoGT6a E192Q in complex 
with UDP-GalNAc (configuration A) and FAL. Previous ITC studies that show FAL 
binds weakly to free BoGT6a (Kd 1.2 mM) but more strongly to the UDP complex 
(Kd 76 μM); the change in free energy of binding (-1.64 kcal/mol) arises from a more 
favorable enthalpy of binding (δΔH of -1.9 kcal/mol) (Thiyagarajan et al., 2012). 
This finding suggests BoGT6a follows a Bi-Bi sequential kinetic mechanism in 
which the donor substrate binds to the enzyme before the acceptor substrate, which is 
found in many glycosyltransferase (Rini et al., 2009).  
 





Figure 71. Analysis of surfaces of the BoGT6a complex forms. (A) shows the surface of 
the BoGT6a•FAL modelled with UDP-GalNAc in the configuration A. The access of the 
donor binding site is restricted. (B) shows the surface of the BoGT6a E192Q•UDP-GalNAc 
in the configuration A modelled with FAL. The acceptor binding site is still accessible. (C) 
shows the surface of the BoGT6a E192Q•UDP-GalNAc in the configuration B modelled 
with FAL. The active site is accessible for both the donor substrate and the acceptor 
substrate. UDP-GalNAc, UDP and α-GalNAc are shown as yellow sticks and FAL as pink 
sticks. LBR-A is coloured in green, LBR-B in cyan, LBR-C in magenta, LBR-D in yellow, 




LBR-E in orange, LBR-F in hot pink, LBR-G in green cyan, LBR-H in purple blue and 
LBR-I in brown. Picture created using Pymol. 
In addition, the presence of three configurations of the ligands in the form III also 
provides a nice picture of the hydrolysis reaction catalysed by BoGT6a.  
The configuration A of the form III structure represents the UDP-GalNAc Michaelis 
complex with BoGT6a, but it should be noted that the E192Q mutation in the form 
of BoGT6a used in these structural studies involves a key residue in catalysis 
(Tumbale and Brew, 2009), that interacts with both the donor and acceptor 
substrates. Previous ITC studies have shown that this mutation has little net effect on 
the ΔG for UDP-GalNAc binding (both around -5.8 kcal/mol) but this reflects 
mutually compensating effects on the ΔH and TΔS of binding (changes from -23.5 to 
-16.4 kcal/mol and 17.7 to 10.6 kcal/mol, respectively) suggesting that the mutation 
may weaken non-covalent interactions and reduce substrate-induced conformational 
rearrangements (Thiyagarajan et al., 2012). This agrees with the lower catalytic rate 
of the mutant compared to that of the wild type. This configuration shows the first 
step of the hydrolysis reaction when the intact UDP-GalNAc binds to the enzyme. 
The configuration B of the BoGT6a E192Q form III structure shows an open active 
site which is accessible for both the acceptor and donor substrate, or in other words, 
is ready to release the product. This can be the last step when the hydrolysis reaction 
is complete. 
The presence of the configuration C structure, which presents a glycosyl enzyme 
with a covalent bond between the residue Glu192 and C1 of the GalNAc moiety of 
the UDP-GalNAc, can be considered as the intermediate stage of the enzyme 
catalytic process. This finding is structural evidence supporting the double 
displacement mechanism for BoGT6a catalytic activity. Following this mechanism 
the mutant BoGT6a E192Q still retains its activity because amine group of Gln can 
play a role as a catalytic nucleophile as hydroxyl group of Glu (Figure 72). However, 
as the amine group is not as strong a nucleophile as a hydroxyl group, the reaction 
between it and C1 happens slowly which causes a reduction of enzyme activity. 





Figure 72. Diagram explains how the BoGT6a Glu192Gln retains enzyme activity. NH2 group of Glu192 can partly play the role of OH group of Gln192 
by giving/donating H atom to C1 of GalNAc moiety and form covalent bond. Diagram created using ChemDraw. 




Nonetheless, it should be recognised that these are structures stabilised by being 
incorporated in different locations in the unusual monoclinic crystal lattice. Only 
structures A and B are present in molecules in the orthorhombic form. More 
structural and chemical studies are necessary to draw a conclusive evidence for 
BoGT6a catalytic mechanism. 
3.3.3.4 Structure-function relationships in metal-dependent and metal-
independent GT6 
In the mammalian GT6, the metal-binding DXD motif is at the junction of the two 
subdomains and interacts directly with the ribose moiety of the UDP moiety as well 
as mediating metal ion interactions with the phosphate group of the UDP (Boix et 
al., 2001, Patenaude et al., 2002). The DXD motif is a shared feature of all GT 
families with GT-A folds with the exception of the metal-independent GT14 family 
(Breton et al., 1998b, Breton and Imberty, 1999). However, in the bacterial enzymes, 
it is replaced by the NXN sequence except in GT6s from bacteriophage 
Parachlamydia acanthamoebae, and the cyanophage PSSM-2, which still retain the 
DXD motif and require metal ions for activity (Thiyagarajan et al., 2012, Brew et 
al., 2010). The new structures of BoGT6a E192Q in complex with the donor 
substrate show a small positional change in each residue of the NXN motif compared 
to that in each residue of the DXD motif (Figure 73). 
In complexes containing free UDP, two cationic residues close to the C-terminus of 
α3GT, Lys359 and Arg365, interact with the diphosphate but in the complex of the 
low activity mutant of α3GT (Glu317Gln) with the substrate UDP-gal, the side chain 
of Lys359 is disordered and only Arg365 interacts with the α-phosphate (Tumbale et 
al., 2008). The interaction with Arg365 is facilitated by structural changes in a loop 
containing Trp195, with which Arg365 forms a stacking interaction. In the structure 
of a complex of the inhibitory substrate analog, UDP-2F-gal, with the Arg365Lys 
mutant of α-3GT, the side chain of Lys359 points towards the β-phosphate of the 
inhibitor but the C-terminal 9 residues including Arg365 are disordered (Jamaluddin 
et al., 2007). It should be noted that these complexes contain catalytically impaired 
mutants of the enzyme and, in one case, an inhibitor rather than substrate and are 
imperfect models of the enzyme-substrate complex. Both Lys359 and Arg365 make 




contacts with UDP in its complex with α3GT (Jamaluddin et al., 2007, Tumbale et 
al., 2008) and conservative substitutions of Lys359 to Arg or Arg365 to Lys result in 
>30-fold reductions in kcat but have small (~2-fold) effects on the KM for UDP-gal 
(Jamaluddin et al., 2007); the Lys to Ala mutation produces a 350-fold reduction in 
kcat. Therefore Lys359 and Arg365 are important, although not essential, for activity 
and appear to have a principal role in transition state stabilisation, mediated through 
interactions with the UDP leaving group, as opposed to (ground-state) substrate 
binding.  
 
Figure 73. Structural comparison of the metal independent BoGT6a (with the NXN 
motif) and the metal dependent bovine α3GT (PDB 1K4V(Boix et al., 2001)) (with the 
DXD motif). The protein are shown in the cartoon representation and coloured in silver for 
the BoGT6a and in grey for the bovine α3GT. The inset shows the details of the NXN motif 
(in yellow) and the DXD motif (in green). The residues were shown as stick, the UDP-
GalNAc (noted as UD2) and UDP as lines and colour in magenta. Metal ion was shown as 
sphere in magenta. Picture created using Pymol. 
Lys231 of BoGT6a is homologous with Lys359 of α3GT, a residue that is conserved 
in all metal-dependent (DXD) and metal-independent (NXN) GT6. However the 




residue corresponding to Arg365 of α3GT is conserved in most other metal-
dependent GT6 but not in the bacterial enzymes. The present structural studies 
indicate that Arg243 of BoGT6a has a similar structural location to α3GT Arg365 
but appears to interact less specifically with the diphosphate moiety. Also, it is not 
within H-bonding distance of the diphosphate in structure C. Substitution of Lys231 
by Ala increased the KM about 2-fold but reduced kcat more than 200-fold whereas 
the double mutation of  Arg243 and Arg244 to Ala reduced kcat by a factor of 10 
(Tumbale and Brew, 2009). Thus, Lys231 has a greater stabilising effect on the 
transition state than ground state and appears to help to stabilise the UDP leaving 
group during catalysis, a role similar to that of the homologous Lys in α3GT that is 
consistent with the present structural studies.  
Other metal-independent members of the GT-A superfamily- The majority of Leloir 
GTs, enzymes that utilise sugar nucleotides as donor substrates, group into either of 
two large superfamilies that have GT-A and GT-B folds. The GT-B superfamily is 
metal-independent whereas most representatives of the GT-A fold superfamily that 
have been functionally characterised are metal-dependent and have DXD metal-
binding motifs (Lairson et al., 2008). The sialyltransferases, whose donor substrate is 
a nucleotide monophosphate sugar (CMP-sialic acid) are metal-independent and 
include proteins with GT-A and GT-B-like folds, but with distinct topologies; 
comparisons of structure-function relationships between sialyltransferases and other 
GTs are challenging because of their non-standard folds and the character of the 
donor substrate (Audry et al., 2011). Among the members of the “standard” GT-A 
group that have been functionally characterised, only the members of GT14 are 
metal-independent like BoGT6a. The GT14 and GT6 families differ in catalysing 
inverting and retaining reactions, respectively, but GT14 members also differ in 
having no conserved motif corresponding to DXD (or NXN). The crystallographic 
structures of one GT14, C2GnT-L, in the apo-form and in complexes with either 
acceptor substrate or UDP have been determined (Pak et al., 2006, Pak et al., 2011). 
The enzyme is a disulphide-bonded dimer and, in the complex with UDP, the two 
molecules of each dimer are in “open” and “closed” conformations. In the closed 
conformation, two basic residues close to the C-terminus of the protein, Arg378 and 
Lys401, interact with the β-phosphate of the UDP but these interactions are not 




present in the open conformer. Substitution of either Arg378 or Lys401 by Ala 
eliminates catalytic activity but the Arg378 mutation has relatively small effects on 
the binding of UDP or UDP-GalNAc whereas the Lys401 mutation eliminates 
binding. Based on these observations, these two cationic residues were proposed to 
fulfil the role of the metal ion in metal-dependent GT-A GTs. Although 
characterised enzymes of the GT14 family are metal-independent, in some, the 
activity is enhanced by divalent metals (Sun et al., 2007). Therefore they appear to 
have a metal-binding site and may have evolved from a metal-dependent ancestor. In 
contrast, the activity of BoGT6a decreases when increasing levels of Mn
2+ 
ion are 
added to the enzyme (Tumbale and Brew, 2009).  
3.4 Conclusions 
In summary, the structures of BoGT6a in complex with either its acceptor substrate 
or the donor substrate show that the enzyme active site is built by residues close to 
both the N- and C-terminal regions and show that the C-terminally truncated 
BoGT6a, including all the key residues, represents the minimum size of a functional 
GT6. 
Regardless of the modest resolutions, the presence of non-crystallographic symmetry 
provides us with structures that are snapshots of potential intermediates in the 
hydrolysis of UDP-GalNAc. The Gln192 mutation in BoGT6a greatly reduces but 
does not eliminate the glycosyltransferase and hydrolase activities. This is because 
the residue Gln with the amine group still can be a catalytic base residue although it 
is not as effective as the hydroxyl group of the residue Glu.  
In addition, the presence of the configuration C in the BoGT6a E192Q•UDP-
GalNAc form III structure suggests BoGT6a follows the double displacement 
mechanism to retain the α configuration of the GalNAc moiety from the donor 
substrate UDP-GalNAc. 
As discussed above, two C-terminal basic residues in BoGT6a interact with the 
donor substrate, but these interactions are similar to those in metal-dependent GT6. 
If we surmise that the GT-A superfamily evolved from a metal-dependent common 
ancestor it would seem that the GT6 and GT14 families have used different 




adaptations to become metal-independent. In the GT6 family we propose that the 
replacement of the DXD motif by NXN was a major factor in the transition between 
metal-dependence and metal-independence. This double substitution removes the 
requirement for a divalent metal ion to counter charge repulsion between the 
aspartates and diphosphate of the UDP. Therefore, in the metal-dependent GT6, the 
role of the metal ion in donor substrate binding in the ground state and stabilising the 
UDP leaving group in the transition state (Lairson et al., 2008) is effectively 
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4 Crystallisation of BoGT6a E192Q in complex with its acceptor (FAL) and 
donor (UDP-GalNAc) substrates 
4.1 Methods 
4.1.1 Expression of BoGT6a E192Q 
4.1.1.1 Preparation of BoGT6a E192Q expression cell stock 
BoGT6a E192Q cloned into the vector pET42(+) was kindly provided by our 
collaborator; Professor Keith Brew, Florida Atlantic University, USA. In order to 
generate sufficient copies of the plasmid for subsequent transformation into an 
expression strain, the recombinant plasmid, which was fixed on a filter paper, was 
dissolved in 10 µl of DNA/RNA free water and 5 µl of this solution was transformed 
into E. coli DH5α cells using the heat shock method. The recombinant E. coli DH5α 
was selected on Luria-Bertani (LB) agar media (Table 8) containing 50 µg/ml of 
Kanamycin. To confirm that the sequence was correct, plasmid, which was isolated 
from the recombinant E. coli DH5α using a Wizard Plus SV Minipreps DNA 
purification system (Promega), was sent to Eurofins for DNA sequencing with the 
universal T7 primer and T7 term primer.  
Table 8. Ingredients of media used in BoGT6a E192Q expression 
Media Ingredients (per litre) 
LB broth 
10 g Tryptone 
5 g Yeast extract 
10 g NaCl 
LB agar 
10 g Tryptone 
5 g Yeast extract 
10 g NaCl 
1.5 g Agar 




E. coli BL21 CodonPlus (DE3)-RIPL competent cells were transformed with the 
plasmid isolated from E. coli DH5α using the heat shock transformation method. The 
transformed cells were spread onto LB agar media containing 50 µg/ml of 
Kanamycin and incubated at 37 
o
C overnight. One single colony was transferred to 
10 ml of LB broth (Table 8) supplemented with 50 µg/ml of Kanamycin and the 
inoculation was incubated overnight at 37 
o
C with shaking at 250 rpm. Glycerol 
stocks were made by mixing 500 µl of the overnight cell culture with 500 µl of 20 
%(
v
/v) glycerol and stored at -80 
o
C for using in further BoGT6a E192Q protein 
expression. 
4.1.1.2 Expression of BoGT6a E192Q 
The frozen glycerol stock was used to inoculate 10 ml of LB broth containing 50 
µg/ml of Kanamycin in a 50 ml falcon tube. The culture was allowed to grow at 37 
o
C with shaking at 250 rpm overnight. The whole overnight culture was used to 
inoculate 1 L of LB containing 50 µg/ml Kanamycin and incubated at 37 
o
C with 
shaking at 250 rpm until the OD600 reached 0.8 – 1.0. The temperature was then 
changed to 24 
o
C for expression overnight. After 20 hours the expression cultures 
were harvested by centrifugation at 4000 rpm for 20 min at 4 
o
C using a Beckman 
Coulter Avanti J-25 Centrifuge. The cell pellet was used for purification. 
4.1.2 Purification of BoGT6a E192Q 
4.1.2.1 Preparation of purification sample 
The cell pellet was washed by resuspension in 50 ml of 25 %%(
w
/v)  sucrose, 20 mM 
Tris-HCl, pH 7.0, and then collected by centrifugation at 5000 rpm, 4 
o
C , for 40 min 
using a Thermo Scientific Heracus Megafuge 16R Centrifuge. The cell pellet was 
then resuspended in lysis buffer (Table 9) and the cells were lysed using the cell 
disrupter (Constant Systems) at 20 kpsi. The cell lysate was centrifuged at 25,000 
rpm for 40 min at 4 
o
C using a Beckman Coulter Avanti J-25 Centrifuge. The 
supernatant was then used in subsequent affinity purification steps (called starting 
protein sample). To analyse how much of the protein was in insoluble form, 0.05 g 
of cell pellet was mixed with 200 µl lysis buffer, and the supernatant (called cell 
pellet sample) was collected after centrifugation at 13, 000 rpm, 4 
o
C for 1 min using 




an Eppendorf Centrfuge 5415D. 16 µl of each sample were mixed with 4 µl of 5X 
SDS-PAGE loading dye. The mixtures were heated at 95 
o
C for 5 min and stored at 4 
o
C until they were analysed by Bis-tris SDS-PAGE.  
4.1.2.2 Purification of BoGT6a E192Q 
4.1.2.2.1 Affinity chromatography using Ni2+ column 
The cell lysate supernatant was applied to a 5 ml His-trap column (GE), which had 
previously been equilibrated with 50 column volumes (CV) of equilibration buffer 
(Table 9) at a flow rate of 3 ml/min. The column was then washed with 10 CV of 
washing buffer 1 (Table 9) to eliminate nucleic acid contaminants followed by 20 
CV of washing buffer 2 (Table 9) to remove impurities that were weakly to 
moderately bound to the column. Finally, the protein was eluted by application of the 
elution buffer (Table 9) and fractions were collected (1 ml/fraction).  
All eluted fractions were placed on ice. 100 µl of each the cell lysate supernatant, 
loading flow through, washing step 1 flow through, washing step 2 flow through and  
the elution fractions were kept for analysis by Bis-Tris SDS-PAGE and Western 
blot. 16 µl of each sample were mixed with 4 µl of 5X SDS-PAGE loading dye. The 
mixtures were heated at 95 
o
C for 5 min and loaded onto a Bis-Tris SDS-PAGE gel. 
15 % resolving, 4 % stacking Bis-Tris SDS-PAGE gel was run for all samples at 200 
V at room temperature until the dye front migrated to the edge of the gel. The gel 
was stained with brilliant blue R-250 stain for an hour and washed with destaining 
solution until the protein bands were clearly visible.  
For Western blot detection, all samples were prepared and loaded onto a Bis-Tris 
SDS-PAGE gel as the process of Bis-Tris SDS-PAGE. The gel was also run at 200 
V at room temperature until the dye front migrated to the edge of the gel. After that, 
the samples were transferred to a PVDF membrane (Millipore) using a transfer 
cassette (Biorad). The transfer was set up at 60 V in 1 hour. The membrane was then 
incubated in a blocking solution (5% milk powder in TBST (20 mM Tris-Cl pH 7.5, 
0.15 M NaCl and 0.1% Tween 20)) in 1 hour to prevent the interactions between the 
membrane and the antibody used for detection of the target protein. The membrane 
was washed three times for 10 min each with TBST solution before being incubated 




with a monoclonal anti-polyHistidine conjugated with a horseradish peroxidase 
(HRP) antibody (code A7058-1VL, Sigma) for 1 hour. The proteins were detected by 
incubating the membrane in 10 ml of a colourimetric detection solution (0.1% 3,3’-
diaminobenzidine tetrahydrochloride (DAB), 0.002% hydrogen peroxide in TBST) 
until the blots appeared. 
4.1.2.2.2 Size exclusion chromatography 
Size exclusion chromatography was performed to enhance the purity of the protein. 
Protein eluted from the His-trap column was concentrated by centrifugation at 4000 
rpm, 4 
o
C using Amicon Ultra-15 MW3000 spin concentrators (Millipore) to get 1 
ml of protein solution in the storage buffer. Concentrated protein was loaded onto a 
Superdex 200 16/60 column (GE) that had been equilibrated with 1.5 CV of storage 
buffer (Table 9). Peak fractions were collected and analysed by gel electrophoresis 
and Western blotting as described previously. 
Table 9. Ingredients of buffers used in purification of BoGT6a E192Q 
Buffer Ingredients 
Lysis buffer 20 mM Tris-HCl, 1 mM EDTA, pH 8.0 
Equilibration buffer 20 mM Tris-HCl, pH 8.0, 100 mM NaCl 
Washing buffer 1 
20 mM Tris-HCl, pH 7.0, 100 mM NaCl, 
5 mM Imidazole pH 8.0 
Washing buffer 2 
20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 
60 mM Imidazole pH 8.0 
Elution buffer 1 
20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 
and 500 mM Imidazole pH 8.0 
Storage buffer 
20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 
2 mM DTT 
 




Fractions containing BoGT6a E192Q were concentrated to a final concentration of 8 
mg/ml by centrifugation at 4000 rpm, 4 
o
C with Amicon Ultra-15 MW3000 spin 
concentrators (Millipore) for use in crystallisation. A sample of the purified protein 
was also transferred into water and the molecular weight analysed by electrospray 
mass spectrometry. 
4.1.3 Crystallisation of BoGT6a E192Q in complex with its ligands 
BoGT6a E192Q obtained from the purification was used directly for crystallisation. 
The complex of the enzyme and its donor, UDP-GalNAc, was set-up by adding 100 
mM UDP-GalNAc to the protein solution such that the final concentration was 10 
mM. The complex of the enzyme with both its donor and acceptor was formed by 
adding 100 mM FAL to the mixture of protein and UDP-GalNAc (10 mM) to a final 
concentration of 10 mM. In an attempt to trap the intermediate state, these 
complexes were crystallised immediately after setting up. All processes were 
performed at room temperature. 
Potential crystallisation conditions for the BoGT6a E192Q·UDP-GalNAc complex 
were screened using the Phoenix crystallisation robot. Two commercial 
crystallisation screens: Structure Screen 1 & 2 and Proplex (Molecular Dimensions 
Ltd), were set-up in 96-well Intelli-plate® (Art Robbins Instrument). 0.2 µl sitting 
drops were set with a 1:1 protein: reservoir ratio. All of the plates were incubated at 
16 
o
C. Based on the hits obtained from this crystallisation screening, optimisations 
were performed in 24-well plates by varying the precipitant concentration but 
maintaining a constant ratio of protein: reservoir solution and incubation 
temperature. 
Co-crystallisations of BoGT6a E192Q with both UDP-GalNAc and FAL were set up 
based on crystallisation hits for the BoGT6a E192Q·UDP-GalNAc complex in 24-
well plates.  The plates were incubated at 16 
o
C. BoGT6a E192Q·UDP-GalNAc 
complex crystals were also soaked with 100 mM FAL in an attempt to obtain 
crystals of BoGT6a in complex with both its donor and acceptor substrates. 





4.2.1 Expression and purification 
The plasmid pET42(+)-BoGT6a E192Q received from our collaborator was 
propagated in E. coli DH5α cells and verified by DNA sequencing. Since this is a 
long sequence (738 bps without His-tag), the sequencing was performed with both 
T7 primer and T7 term primer. The combined results displayed the sequence of the 
full-length of the enzyme with 738 bps and 57 bps of the His-tag. The sequencing 
results were translated to give the 265 residue protein sequence. The mutation 
E192Q (GAA to CAA) was confirmed along with the presence of 19 residues that 
form the His-tag at the N-terminus of the protein (Figure 74). The protein mass 
calculated by using ExPASy – Compute pI/Mw (Expert Protein Analysis System) 
tool (Gasteiger et al., 2003) is 31033 Da and its pI is 7.86.  
The expression protocol used for BoGT6a E192Q was adapted from the native 
BoGT6a expression protocol established by Tumbale et. al (Tumbale and Brew, 
2009). Although the transformed E. coli BL21 CodonPlus (DE3)-RIPL cells were 
expected to express BoGT6a E192Q in soluble form by leaky expression, gel 
electrophoresis analysis showed that some protein was present in the cell pellet 
(Figure 76). However this was not a significant amount and so the insoluble protein 
was not used for purification, as this would have required modification of the 
purification protocol. 








Figure 74. DNA and amino acid sequences of BoGT6a E192Q. The sequence of the His-
tag was highlighted in orange and the E192Q mutant sequence was bold in red. 
DNA sequence 
atg ggc agc agc cat cat cat cat cat cac agc agc ggc ctg gtg ccg cgc ggc agc cat atg 
aga att ggt ata tta tat atc tgt act ggc aaa tat gac att ttt tgg aaa gac ttt tat cta agc gca 
gaa cgt tat ttt atg caa gac caa tct ttc att atc gag tat tat gta ttt act gat agt cct aaa cta 
tat gac gaa gaa aac aac aaa cat att cac cgg atc aaa caa aag aat tta gga tgg cct gac 
aac aca tta aaa cgt ttc cat ata ttc ctt cgt atc aag gaa cag tta gag cga gaa acc gac tat 
cta ttt ttc ttc aat gcc aat ctc tta ttc acc agt cct att ggc aaa gaa att cta cca cca tca gat 
agt aac gga tta cta gga act atg cac cct gga ttc tac aat aaa ccg aac tcc gaa ttt aca tac 
gag cga aga gat gct tct act gcc tat atc cca gag gga gaa ggt cga tat tat tac gct gga 
ggg ctt tca ggt gga tgt aca aag gcc tac ttg aaa ctc tgc aca aca att tgc tca tgg gtt gac 
aga gat gcc aca aac cat ata ata cca att tgg cac gac caa tct cta atc aat aaa tac ttt tta 
gat aat cca cca gct att aca ttg tcc cct gca tat cta tac cca gaa ggt tgg ctc ctt cct ttt gaa 
cca ata atc ctc att cga gac aaa aat aaa ccc caa tat ggc ggg cat gaa tta ttg cga aga aaa 
aac tga 
Protein sequence 
M G S S H H H H H H S S G L V P R G S H M R I G I L Y I C T G K Y D I F W 
K D F Y L S A E R Y F M Q D Q S F I I E Y Y V F T D S P K L Y D E E N N K 
H I H R I K Q K N L G W P D N T L K R F H I F L R I K E Q L E R E T D Y L 
F F F N A N L L F T S P I G K E I L P P S D S N G L L G T M H P G F Y N K P 
N S E F T Y E R R D A S T A Y I P E G E G R Y Y Y A G G L S G G C T K A 
Y L K L C T T I C S W V D R D A T N H I I P I W H D Q S L I N K Y F L D N 
P P A I T L S P A Y L Y P E G W L L P F E P I I L I R D K N K P Q Y G G H E 
L L R R K N Stop 
 




As a His-tag fused protein, BoGT6a E192Q was purified by the nickel affinity 
chromatography method using a 5 ml His-trap HP column (GE). The first trial 
purification was adapted from the purification protocol of native BoGT6a, in which 
contaminants were washed out through two wash-steps at 5 and 60 mM imidazole. 
The target protein was eluted at 500 mM imidazole (Tumbale and Brew, 2009). The 
chromatogram showed a high absorbance peak during the sample loading step (2200 
mAu), a small peak at the second washing step (600 mAu) and a high peak at the 
elution step (1000 mAu) (Figure 75). Although the flow through collected during 
sample loading and the washing fractions contain a high concentration of protein, 
western blot results indicated that there was no BoGT6A E192Q present in the 
washing fractions and only a small amount present in the flow through fraction 
(Figure 76).  
6 ml of the elution fraction at a concentration of 2 mg/ml was dialysed in order to 
transfer it into storage buffer and concentrated to 8 mg/ml. The final yield of 
BoGT6a E192Q was 12 mg of soluble protein per 1 L of cell culture. This is similar 
to the yield of native BoGT6a reported by Tumbale et. al (2009). Gel electrophoresis 
result showed 2 bands around 27 kDa in the elution fraction, but only one of these 
was present on the western blot (Figure 76). The lower molecular weight band on the 
protein gel was comparable to the theoretical molecular weight of the protein and 
was also reported in the purification of native BoGT6a (Tumbale and Brew, 2009). 
There was a smear associated with the higher band that may be contaminants from 
the cell culture. Thus further purification steps were required.  





Figure 75. Chromatography of the first trial affinity purification. (1) flowthrough fraction, (2) wash 1 step fraction, (3) wash 2 step fraction, and 
(4) elution fraction. The blue line indicates the UV intensity (mAu) and the pink line the conductivity of the solutions. 




Figure 76. Bis Tris SDS-PAGE analysis of first trial purification of BoGT6a E192Q. 
(A) shows the Bis Tris SDS-PAGE result and (B) the Western blot result. (M) 10 µl of 
Thermo Scientific PageRuler Plus Prestained protein ladder, (1) supernatant of cell lysate, 
(2) supernatant of the cell pellet after lysis, (3) flow through fraction, (4) wash 1 fraction, (5) 
wash 2 fraction, and (6) elution fraction. 20 µl of each sample was loaded. 
In an attempt to obtain a higher purity of BoGT6a E192Q, a lower elution gradient 
was applied with elution buffer 2, but the purity of the elution fraction was not 
improved. Size exclusion chromatography using Superdex 200 resin (GE) was thus 
used to separate the target protein from the impurities. There were three peaks 
appearing on the size exclusion chromatogram (Figure 77). A comparison of the 
retention time of those peaks and a standard graph shows that the first peak with a 
retention time about 85 ml corresponds to 44 kDa of protein weight.The second peak 
corresponds to 33 kDa of protein weight, which is the expected weight of the target 
protein. The last peak is too small comparing to the standard graph which can be the 
absorbance of imidazole in the buffer or contaminant from the cell culture. All of the 
fractions in each peak were pooled together and analysed using gel electrophoresis 
and Western blot.  
 





Figure 77. Chromatograph of the BoGT6a E192Q purification using size exclusion chromatography method. The collected fractions are 
marked in which 1 included C5-C8, 2 included C9-D5, and 3 included E1-E5. The inset is the standard graph in which the retention time of each 
peak is marked. The blue line indicates the UV intensity (mAu). 




On the gel electrophoresis result, peak 1 showed only one band near 27 KDa, the 
expected molecular weight of BoGT6a E192Q on the Bis Tris SDS-PAGE analysis. 
The peak 2 had two bands, with the major band also at the expected position for the 
protein. Peak 3 showed no bands (Figure 78). This was either because there was 
insufficient protein to be detected on the gel or the absorbance was from the 
imidazole in the sample and not from protein. This was confirmed by Western 
blotting (Figure 78). The fractions containing BoGT6a E192Q were pooled together 
and concentrated by centrifugation with Amicon Ultra-15 MW3000 (Millipore) to a 
final concentration of 8 mg/ml for use in crystallisation. 
 
Figure 78. Gel electrophoresis and Western blot results of analysing the BoGT6a 
E192Q purity after the size exclusion purification. (A) Gel electrophoresis result and (B) 
Western blot result. (1) 5 µl of the protein before applying to the Superdex 200 16/60 
column (GE), (2) C5-C8 fraction, (3) C9-D5 fraction, (4) E1-E5 fraction, and (M) 10 µl of 
Thermo Scientific PageRuler Plus Prestained protein ladder. 20 µl of each fraction was 
loaded on gel. 
The purified protein was analysed by MS and the result showed one peak with a 
mass of 31033.45 Da (Figure 79). The single strong peak from MS indicated that the 
protein solution was pure enough for crystallisation. Although the band of BoGT6a 
E192Q on the gel electrophoresis result appeared to be positioned around 27 kDa, 
the mass from MS corresponded to theoretical molecular weight of the protein, 




31034 Da, calculated by using ExPASy – Compute pI/Mw (Expert Protein Analysis 
System) tool (Gasteiger et al., 2003). The molecular weight of the protein was also 
in agreement with the DNA sequencing results that showed the presence of the long 
His-tag at the N-terminal region, and also corresponded to the form III structure of 
BoGT6a E192Q in complex with UDP-GalNAc in which first three His-tag residues 
were visible. With a successful expression and purification protocol established for 
BoGT6a E192Q the protein could be supplied consistently in the same condition and 
at sufficient purity for crystallisation. This facilitated the searching for crystallisation 
conditions for the BoGT6a E192Q complexes.  
 
Figure 79. The mass spectrometry result for BoGT6a E192Q. 
4.2.2 Crystallisation of BoGT6a E192Q in complex with its ligands 
BoGT6a E192Q in storage buffer was concentrated to 8 mg/ml by centrifugation at 
4000 rpm, 4 
o
C using an Amicon Ultra-15 MW3000 (Millipore). The concentrated 
protein solution was used to set-up two commercial crystallisation screens: Proplex 
and Structure Screen 1 & 2. However, only the Proplex screening gave hits (Figure 
80). Crystals appeared in wells D4, E11 and E12 after only two days, whilst in other 
wells it took two weeks for crystals to form. Conditions D4 and E12 were repeated 
on 24 well plates with the same protein concentration and incubation condition. Only 




small crystals appeared in the D4 condition while bigger crystals were obtained from 
the E12 condition, however, crystals from both conditions were too fragile to be 
mounted.  
The conditions were optimised by replacing (NH4)2SO4 with Li2SO4, and screening 
different PEG 8000 concentrations (20 % – 18 % – 15 %). The condition comprising 
0.1 M MES pH 6.5, 15 % (w/v) PEG 8000, and 0.2 M Li2SO4 gave bigger and better 
crystals. Crystals of BoGT6a E192Q•UDP-GalNAc from this condition were soaked 
with 10 mM FAL and left for 1 day at 16 
o
C in an attempt to obtain the ternary 
complex. This condition was also used for co-crystallisation of BoGT6a E192Q in 
complex with the acceptor, FAL, and the donor, UDP-GalNAc. This also yielded 
many bar-shaped crystals.  
Table 10. Conditions of “hits” for crystallisation of BoGT6a E192Q in complex with 
UDP-GalNAc using the ProPlex Screen HT-96 
Well 
Condition 
Salt Buffer Precipitant (w/v) 
B12 
0.1 M magnesium 
chloride 
0.1 M Na HEPES pH 7.0 15 % PEG 4000 
C11  0.1 M sodium cacodylate pH 6.5 25 % PEG 4000 
D3 
0.1 M potassium 
chloride 
0.1 M Na HEPES pH 7.0 
15 % PEG 5000 
MME 
D4 
0.2 M ammonium 
sulphate 
0.1 M Tris pH 7.5 
20 % PEG 5000 
MME 
E11  0.1 M sodium citrate pH 5.0 20 % PEG 8000 
E12 
0.2 M ammonium 
sulphate 
0.1 M MES pH 6.5 20 % PEG 8000 
 
Some of the crystals from these crystallisation experiments were analysed at 
Diamond Light Source station I04. Since PEG 8000 was used, the crystals were only 




soaked with the reservoir solution as a cryo-protectant before being cooling in liquid 
Nitrogen. The data collection process was not successful because there was ice 
covering some of the crystals and the maximum resolution of the diffraction data 
was only 4.5 Å (Figure 82). Although there were two datasets collected, these 
datasets are insufficient to determine the complex structure due to its low resolution 
(Table 11). 
Nevertheless, these results indicated that the crystals obtained were indeed protein 
crystals. This is a promising result because the cryo-protection process can be 
optimised. Due to time constraints, no further crystallisation optimisations were 
performed, but as this is the only crystallisation condition so far to have yielded 
reproducible crystals, its discovery is a potential step towards BoGT6a 
crystallisation.  
 
Figure 80. Crystals of BoGT6a E192Q in complex with UDP-GalNAc obtained from 
“hit” conditions. (A) from well B12, (B) from well C11, (C) from well D3, (D) from well 
D4, (E) from well E11 and (F) from well E12. 




Figure 81. Crystals of BoGT6a E192Q in complex with UDP-GalNAc (A, B C and D) or with both UDP-GalNAc and FAL (E, and F). (A) the 
D4 condition, (B) the E12 condition, (C) the E12 condition in which Li2SO4 was used instead of (NH4)2SO4, (D) and (E) the same condition as (C) 
before and after FAL was added respectively. (F) BoGT6a E192Q•UDP-GalNAc•FAL crystal in the condition as (C). 






Figure 82. Diffraction data from a BoGT6a E192Q in complex with UDP-GalNAc and FAL crystal obtained from the condition of 0.1 M 
MES pH 6.5, 15% (w/v) PEG 8000, and 0.2 M Li2SO4. 
 












Cell dimensions Rmerge 
Completeness 
(%) 
9 150 4.66 P21212 
a = 120.5 Å, b = 132.5 Å, c = 80.3 Å 
α = β = γ = 90.0 o 
0.095 99.6 
10 500 4.14 P2221 
a = 131.6 Å, b = 80.3 Å, c = 119.8 Å 













5 Conclusions and Future work 
The glycosyltransferase family 6 (GT6) consists of Histo-blood group A and B 
glycosyltransferases (GTA, GTB), α-galactosyltransferase (α3GT), Forssman 
glycolipid synthase (FS) and Isogloboside 3 synthase (iGb3S). This family is of 
medical importance because their products affect the human immune system; the 
most well-known examples of which are GTA and GTB, which determine our blood 
group types. The overall structures of these enzymes are well conserved but small 
changes in the structures are important for the observed differences in their catalytic 
activity. In that context, exploring their structures and an understanding on how they 
link to the catalytic mechanism are important. This will also help in engineering 
these enzymes to synthesise non-natural glycoconjugates. Bacteroides ovatus 
glycosyltransferase 6a (BoGT6a) is a unique member of the GT6 family because of 
its NXN motif in its sequence, which replaces the well-conserved DXD motif 
observed in all vertebrate GT6. In mammalian GT6, the DXD motif is involved in a 
metal-dependent catalytic mechanism. The substitution raises a question about the 
effect of NXN motif in BoGT6a catalytic activity. In fact, the enzyme does not 
require metal ion for its catalytic activity (Tumbale and Brew, 2009). However, the 
structure of BoGT6a apo form shows a remarkably high structural similarity to its 
mammalian homologues such as GTA, GTB and α3GT, apart from its shorter N-
terminal region (Thiyagarajan et al., 2012).  
To explore more about the enzyme catalytic mechanism, structural studies of the 
enzyme in complex with its donor substrate UDP-GalNAc and acceptor FAL were 
performed.  
The crystal structure of BoGT6a in complex with FAL was obtained at 3 Å in the 
space group P21. The structure contains 4 molecules in the asymmetric unit, each of 
which has one FAL moiety bound in the acceptor binding site. A comparison of the 
BoGT6a apo form structure and the BoGT6a•FAL shows the significant 
conformational changes of the enzyme associated with acceptor binding, including 
the internal loop (residues Tyr126 to Arg151) which is absent in the enzyme apo 
form structure due to its high flexibility, the LBR-F (residues Trp189 to Glu192) 
which is involved in the enzyme activity and the C terminus. The conformational 
change of the C terminus which is known as a closed conformation upon ligand 




binding and catalysis is also reported for most glycosyltransferase, including the 
other GT6 members (Lairson et al., 2008, Boix et al., 2001, Qasba et al., 2005, 
Patenaude et al., 2002). The acceptor binding site is highly conserved among GT6 
family consisting of Glu192, Trp189, Thr134, Tyr153 and His122 (BoGT6a 
numbering) regardless their metal dependence or metal independence property. This 
suggests that metal ion only involves in the donor binding activity. This is consistent 
with the proposed role of the metal ion role in glycosyltransferase catalytic activity 
which electrostatically stabilise the developing negative charge of the nucleoside 
diphosphate leaving group (Lairson et al., 2008). 
Belonging to the retaining glycosyltransferase group, the catalytic mechanism of 
BoGT6a has not been clearly understood. There are two proposed mechanisms for 
BoGT6a, the double displacement and internal return (SNi-like) mechanisms. The 
difference between the two mechanisms is the presence of an intermediate stage in 
which a covalent bond is formed between the catalytic residue of the enzyme and the 
sugar moiety from the donor substrate. The potential catalytic base residue of the 
BoGT6a is Glu192. This residue is highly conserved in GT6 family. Kinetic assay of 
the mutant Glu192Gln (E192Q) shows a significant reduction (about 30000 fold) in 
the glycosyltransferase activity of BoGT6a. Structural study of this mutant in 
complex with its donor UDP-GalNAc is thus necessary to elucidate the enzyme 
catalytic mechanism.  
There are three structures obtained for the BoGT6a E19Q•UDP-GalNAc complex. 
The form I structure was solved at 2.78 Å in the space group P212121. This structure 
contains 4 molecules in the asymmetric unit. Each molecule has only one α-GalNAc 
in their active site. The second structure, called the form II structure, was also solved 
in the space group P212121, but at a lower resolution (3.42 Å). This structure has 4 
molecules in the asymmetric unit and has two configurations of the bound ligands. 
The configuration A is an intact UDP-GalNAc and the configuration B is a separate 
UDP and α-GalNAc. The final structure, which consists of 16 molecules in the 
asymmetric, was solved at 3.50 Å in the space group P21. This structure not only has 
the two configurations of the ligands observed in the form II structure but also has 
the configuration C which consists of UDP and β-GalNAc. The interesting feature of 
this configuration is that the β-GalNAc is in a close contact with the residue Gln192. 




Such a close distance suggests a covalent bond formation between β-GalNAc and the 
Gln192. The configurations A, B and C are models for complexes in the hydrolysis 
reaction catalysed by BoGT6a, in which A is the substrate binding stage, C the short-
lived intermediate stage and B the product release stage.  
All three structures have provided the structural snapshots of BoGT6a catalysing 
UDP-GalNAc. The interactions between the enzyme and the donor substrate also 
gave an insight into the mechanistic role of the NXN motif cooperating with the 
residue Lys231 in the metal-independent activity of the BoGT6a. These structures 
together demonstrate how a significant divergence in catalytic properties can be 
accommodated by minor structural adjustments and explain the role of the NXN 
motif in BoGT6a metal independent catalytic activity. 
In the form III structure, a link between residue Gln192 and C1 of β-GalNAc was 
built, based on the electron density between them. This suggests that BoGT6a may 
follow a double displacement mechanism. However this remains ambiguous in the 
current modest resolution structures, hence a higher resolution structure of BoGT6a 
E192Q in complex with UDP-GalNAc is now required to provide more information. 
From such a high resolution structure we might hope to determine the configuration, 
α or β, and orientation of the sugar product, and positions of water molecules in the 
active site. 
Besides structural studies, more chemical evidence is required if we are to draw a 
conclusion regarding the enzyme mechanism. In the first instance, the existence of 
the link between residue Gln192 of the enzyme and C1 of β-GalNAc must be 
confirmed by other complementary methods, such as MS. MS experiments could be 
used to analyse the mixture of BoGT6a E192Q with the donor substrate, UDP-
GalNAc, and/or the acceptor substrate, FAL. The slow reaction rate of BoGT6a 
E192Q may help to trap the intermediate stage, which would be indicated by the 
presence of a peak with the weight equal to that of the glycosyl-enzyme complex. 
Another way to prove the enzyme mechanism might be by incorporating deuterium 
into the product. If the enzyme follows the double displacement mechanism, a 
deuterium atom from environmental D2O would replace the hydrogen of the amine 
group of Gln192. If this did not happen it would mean that the enzyme follows the 




SNi mechanism; the GalNAc moiety of UDP-GalNAc interacts directly with the D2O 
from the environment and the H atom of the Gln192 remains intact. 
In addition, obtaining the ternary structure may help us to understand more about the 
role of BoGT6a in catalysing the transfer of GalNAc moiety from UDP-GalNAc to 
FAL. In the future, crystallisation conditions for BoGT6a E192Q in complex with 
both the donor substrate, UDP-GalNAc, and the acceptor substrate, FAL, should be 
optimised to produce better quality crystals. The recent crystallisation result seems to 
provide a good basis for production of superior crystals, as well as for the 
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2.92  TRP 189[ O  ] P 
3.37  GLN 192[ OE1] P 
[ N2'] 3.13  3.73  ASN  95[ OD1] G, H, O 
[ N3 ] 
2.51  3.25  THR  10[ OG1] E, F, G, H, O 
2.32  3.39  THR  10[ O  ] E, F, G, H, P 
[ O1B] 
3.69  LYS 231[ NZ ] F 
3.90  ASN  95[ ND2] H 
[ O2B] 3.20  3.49  ARG 243[ NH2] E, G 
[ O1'] 3.70  ASN  95[ ND2] E 
[ O6'] 
3.71  HIS 190[ N  ] E 
3.70  GLN 192[ NE2] G 
[ O4'] 
3.44  3.86  GLN 192[ N  ] E, F, H, O 
2.97  GLN 192[ NE2] G 
[ O3'] 
2.83  3.62  GLY 157[ N  ] E, F, G, H, O, P 
2.68  3.59  ARG  73[ NH2] E, F, G, H, O, P 
[ O7'] 3.28  3.57  ASN  95[ ND2] E, F, P 
[ O3A] 
2.30  2.57  LYS 231[ NZ ] E, G, O 
3.33  3.45  ARG 243[ NH2] F, H, P 








2.55  2.94  TYR  13[ OH ] E, G 
2.54  2.80  LYS 231[ NZ ] F, H, O 
3.28  3.61  ASN  95[ ND2] F, H, P 
3.10  ARG 243[ NH2] G 
[ O2A] 
3.14  3.31  ARG 243[ NH2] F, H, P 
2.64  2.93  TYR  13[ OH ] F, H, P 
[ O3B] 
2.65  3.68  ALA  96[ N  ] E, F, G, H, O, P 
2.98  ASN  95[ ND2] O 
[ O2 ] 
 
3.23  THR  10[ OG1] E 
2.49  3.61  THR  10[ N  ] E, F, G, H, O, P 
[ O5B] 3.81   ASN  95[ ND2] H 
[ O4 ] 2.75  ASN  69[ ND2] H 
 






[ N3 ] 
3.54  3.85  ASN  69[ OD1] A, K 
2.40  3.30  THR  10[ OG1] A, B, C, D, I, J, M 
2.62  3.40  THR  10[ O  ] A, B, D, I, J, K, L, M 








2.23  3.42  TYR  13[ OH ] A, J, L 
2.60  2.75  LYS 231[ NZ ] M, N 
[ O2B] 
2.50  2.74  LYS 231[ NZ ] A, I 
2.67  3.00  TYR  13[ OH ] C, I 
[ O3B] 
2.97  TYR  13[ OH ] B 
3.29  TRP  66[ NE1] C 
2.47  LYS 231[ NZ ] J 
[ O1A] 
2.97  3.77  TYR  13[ OH ] A, K, N 
2.21  2.38  LYS 231[ NZ ] D, M, N 
[ O2A] 
2.33  2.44  LYS 231[ NZ ] B, I, L 
3.68  3.85  ARG 243[ NH2] M, N 
[ O3A] 
3.24  TYR  13[ OH ] B 
3.22  LYS 231[ NZ ] C 
[ O3'] 2.76  3.07  ALA  96[ N  ] A, B, C, D, I, J, L, M, N 
[ O2'] 
3.45  3.77  ALA  96[ N  ] A, C, L 
3.85  CYS   9[ N  ] M 
[ O2 ] 
2.83  3.41  THR  10[ N  ] 
A, B, C, D, I, J, K, L, M, 
N 
2.55  3.36  THR  10[ OG1] B, I, J, K 
[ O5'] 3.48  LYS 231[ NZ ] C 
[ O4 ] 2.55  3.37  ASN  69[ ND2] C, L, M 







[ O4'] 3.69  THR  70[ OG1] M 
α - GalNAc 
[ O1 ] 2.50  2.60  HIS 122[ NE2] A, K 
[ O  ] 3.62  GLN 192[ NE2] A 
[ O6 ] 
3.18  3.76  THR 134[ OG1] B, D 
2.58  GLN 192[ NE2] D 
2.80  TRP 189[ NE1] I 
[ O4 ] 
3.01  GLN 192[ NE2] B 
2.62  HIS 122[ NE2] I 
[ O3 ] 2.87  GLN 192[ NE2] C 
β - GalNAc 
[ C1 ] 1.30  1.31  GLN 192[ NE2] M, N 
[ O4 ] 3.38  3.69  ARG  73[ NH2] M, N 
[ O3 ] 2.60  2.81  ASN  95[ ND2] M, N 
[ O6 ] 3.59  ASP 191[ N  ] N 
[ O7 ] 2.46  ASN  95[ ND2] N 
 
